vTv Therapeutics Inc.
2020 Annual Report
Dear Fellow Shareholders,
I am pleased to report that 2020 was a successful year for vTv Therapeutics. In spite of the challenges for
the biotech industry, the nation, and the world at large created by COVID-19, we efficiently adapted our
business to push our novel development programs forward, including completion of a successful phase 2 study
for our leading drug candidate, TTP399.
As we turn our focus to 2021, several critical milestones appear on the horizon. First, initiating a pivotal
trial of TTP399 as an adjunct therapy for people with type 1 diabetes to reduce the incidence of hypoglycemia
will be a significant inflection point. The potential to reduce hypoglycemia while maintaining or improving
glycemic control in people reliant on insulin would be a significant advancement for the treatment of diabetes. In
addition, we hope that our on-going phase 1 multiple-ascending dose study of HPP737 will confirm its potential
as a next-generation PDE4 inhibitor, so that we can initiate a planned phase 2 study in psoriasis later this year.
PDE4 inhibition is a proven target for the treatment of psoriasis, with a significant player currently on the
market — though one with critical drawbacks. We believe this provides an opportunity for a better oral
treatment, which we think HPP737 might provide. Finally, though we are disappointed with the results of the
Elevage Study of azeliragon in Alzheimer’s disease, we believe that it would make a promising asset in the
hands of the right partner in other indications.
In addition to progress within our internally developed pipeline, our strategy of out-licensing assets to
partners with the ability to invest significant resources continues to bear fruit. Reneo Pharmaceuticals plans to
begin a Phase 2 clinical trial for the PPAR-δ drug candidate, REN001, in 2021 after having received orphan drug
designation from the FDA for primary mitochondrial myopathies. Newsoara Biopharma has advanced HPP737
into phase 2 with the initiation of a proof of concept study in chronic obstructive pulmonary disease (COPD) in
China, and will also initiate additional phase 2 studies in psoriasis and atopic dermatitis in 2021. In addition,
Huadong Medicine has begun a phase 2 study of our oral GLP-1r agonist for the treatment of type 2 diabetes.
Finally, we are excited about the new strategic partnership with Anteris Bio to develop our Nrf2 activator as a
treatment for renal diseases.
As always, we continue to be appreciative of the ongoing efforts of our employees, clinical investigators,
patients, caregivers and families especially in light of the challenges we all faced in 2020. We also thank you, our
investors, for your continued support.
Sincerely,
Steve Holcombe
President and CEO
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-37524
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
3980 Premier Dr, Suite 310
High Point, NC
(Address of principal executive offices)
47-3916571
(I.R.S. Employer
Identification No.)
27265
(Zip Code)
(336) 841-0300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each
Class
Class A Common Stock (Par Value $0.01)
Trading Symbol
VTVT
Name of each exchange on which
registered
NASDAQ Capital Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such
files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☐
Emerging growth company ☐
Accelerated filer
Smaller reporting company
☐
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm
that prepared or issued its audit report. ☐
Indicate by check mark if the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the registrant’s Common Stock held by non-affiliates on the last business day of the Registrant’s most recently
completed second quarter, June 30, 2020, was $29,590,387 (based on the closing sale price as reported on the NASDAQ).
Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of February 24, 2021.
Class of Stock
Class A common stock, par value $0.01 per share
Class B common stock, par value $0.01 per share
Shares Outstanding
57,550,710
23,094,221
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2021 Annual Meeting of Stockholders to be filed within 120 days after December 31,
2020 are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
vTv THERAPEUTICS INC. AND SUBSIDIARIES
INDEX TO FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020
PART I
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6. Selected Financial Data
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accountant Fees and Services
PART IV
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10-K Summary
PAGE
NUMBER
5
15
43
43
43
43
44
44
44
54
54
54
54
55
56
56
56
56
56
57
57
60
2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
As used in this Annual Report on Form 10-K, the “Company”, the “Registrant”, “we” or “us” refer to vTv Therapeutics Inc.,
“vTv LLC” refers to vTv Therapeutics LLC. The following discussion and analysis of our financial condition and results of operations
should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to
historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates,
assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that
could cause or contribute to these differences include those discussed below and elsewhere in this report under “Part I—Item 1A, Risk
Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business
strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug
development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical
facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,”
“plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements
represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we
assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Summary of Principal Risk Factors
Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may
adversely affect our business, financial condition, results of operations, cash flows, and prospects. These risks are discussed more fully
in “Part I – Item 1A, Risk Factors” below and include, but are not limited to, risks related to:
Our Financial Position and Need for Additional Capital
•
•
•
•
our ability to achieve or maintain profitability;
our ability to generate revenue in absence of any products approved for sale;
our need for additional capital to continue the development and commercialization of our drug candidates;
the impact of raising additional capital to our stockholders and the rights of our drug candidates.
The Development and Regulatory Approval of Our Drug Candidates
•
•
•
•
•
the potential failure of our clinical trials or our inability to receive regulatory approval for our drug candidates;
the identification of serious adverse or unacceptable side effects which are determined to be drug-related;
the impact of changes in law or regulatory policy on the approval of our drug candidates;
the impact of delays in the commencement, enrollment and completion of our clinical trials;
our ability to submit an NDA for the drug candidates we are developing;
Risks Relating to the Commercialization of Our Drug Candidates
•
•
•
•
•
•
•
•
the acceptance of drug candidates in the market, if approved by the appropriate regulatory agencies;
our ability to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our
drug candidates;
the impact of ongoing obligations and continued regulatory review for our drug candidates post-commercialization;
competition with other products;
the impact of healthcare cost containment initiatives and the growth of managed care;
our ability to obtain marketing approval for our drug candidates and obtain profitable pricing once approved;
the impact of healthcare laws and regulations on our relationships with healthcare professionals, principal investigators,
consultants, customers (actual and potential) and third-party payors;
our ability to obtain approval to commercialize products outside the United States;
Risks Relating to Our Dependence on Third Parties
3
•
•
•
•
our ability to establish and maintain collaborative relationships to further the development of our drug candidates;
the professional conduct of third parties we rely on to conduct, supervise and monitor certain of our clinical trials;
our dependence on limited sources of supply for the components used in TTP399 and our other drug candidates;
our reliance on third-party manufacturers to produce our drug candidates;
Risks Relating to Our Intellectual Property
•
•
•
•
•
•
•
our ability to continue to protect proprietary rights to our intellectual property;
the unauthorized disclosure of our trade secrets or other confidential information;
the impact of changes to the patent laws in the United States and other jurisdictions;
the impact of litigation for infringing intellectual property rights of third parties;
the impact of litigation to protect or enforce our patents or other intellectual property;
our ability to enforce our intellectual property rights throughout the world;
our ability to obtain patent term extensions for our drug candidates;
Risks Relating to Employee Matters and Managing Growth
•
•
•
the impact of expanding our operations and managing growth;
our ability to attract and retain key personnel;
the impact of our employees, independent contractors, principal investigators, CROs, consultants and collaborators in the
event that they engage in misconduct or other improper activities;
Other Risks Relating to Our Business
•
•
•
•
•
•
•
the impact of the widespread outbreak of an illness or any other communicable disease, or any other public health crisis;
the impact of COVID-19 on our clinical trials, the operations of our licensees and our financial results;
the impact of using our financial and human resources to pursue a particular research program or drug candidate and failing
to capitalize on programs or drug candidates that may be more profitable or for which there is a greater likelihood of
success;
the impact of product liability lawsuits;
the exposure to uninsured liabilities;
our ability to remain competitive given the rapidly changing market for our proposed drug candidates;
the impact of computer system failures, cyber-attacks or a deficiency in our cyber-security;
Risks Related to our Common Stock
•
•
•
•
•
•
•
•
•
•
the impact of MacAndrews’ substantial influence over our business;
the potential for conflicts of interest with our directors who have relationships with MacAndrews;
our ability to pay cash dividends;
the potential for securities class action litigation;
the impact of research and reports that equity research analysts publish about us and our business;
the impact of substantial sales of shares into the market at any time;
the dilution created by future sales and issuances of our Class A common stock or rights to purchase Class A common
stock;
our reliance upon our “smaller reporting company” status;
our exemption from certain corporate governance requirements since we are a “controlled company”;
the existence of provisions in our governing documents or state law which may delay or prevent our acquisition by a third
4
•
•
•
party;
our obligation to make payments under the Tax Receivable Agreement;
our ability to make distributions from vTv LLC to satisfy our obligations;
the benefits conferred upon M&F that will not benefit Class A common stockholders to the same extent as it will benefit
MacAndrews.
PART I
ITEM 1. BUSINESS
Overview
We are a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their
long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and
pre-clinical drug candidates for the treatment of a wide range of diseases. Our pipeline is led by our programs for the treatment of type 1
diabetes (TTP399) and for psoriasis (HPP737). We completed the Simplici-T1 Study, an adaptive Phase 1b/2 study supported by JDRF
International (“JDRF”), to explore the effects of TTP399 in patients with type 1 diabetes at the beginning of 2020. In February 2020, we
reported positive results from the Phase 2 - Part 2 confirming phase of this study which achieved its primary objective by demonstrating
statistically significant improvements in HbA1c (long-term blood sugar) for TTP399 compared to placebo. We are working on the
design for pivotal and registrational studies for TTP399, with input from the FDA. In addition to the pivotal studies of TTP399, we are
currently conducting a Phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the impact of TTP399 on
ketone body formation during a period of acute insulin withdrawal.
We are also conducting a multiple ascending dose Phase 1 study of HPP737, an orally administered phosphodiesterase type 4
(“PDE4”) inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part
of our psoriasis program. The goal of this study is to confirm the maximum tolerated dose with minimal or no gastrointestinal (“GI”)
intolerance in the form of nausea, vomiting or diarrhea. We expect to complete this study in the second quarter of 2021.
On December 15, 2020, the Company announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s
disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo. The Company is discontinuing its
development of azeliragon for Alzheimer’s disease, but is exploring the possibility of azeliragon as a drug candidate for other
indications, including the prevention of type 1 diabetes.
In addition to our internal development programs, we are furthering the clinical development of four other programs: a small
molecule GLP-1r agonist, the PDE4 inhibitor, HPP737, a PPAR-delta agonist, and an Nrf2 activator through partnerships with
pharmaceutical partners via licensing arrangements.
Impact of COVID-19
We have been actively monitoring the COVID-19 pandemic and its impact on our business, employees, patients, partners,
suppliers and vendors. Our financial results for the three and twelve months ended December 31, 2020 were not significantly impacted
by COVID-19. Though our financial results were not significantly impacted, COVID-19 precautions directly and indirectly impacted
the timelines for the clinical trials conducted during 2020 and may impact the timelines of the trials currently in process.
vTv has continued to make adjustments that allow us to maintain our business operations despite current circumstances, including
establishing remote working options for all employees. Given the current scope of the pandemic, we cannot predict the impact of the
progression of the COVID-19 outbreak on future clinical trial and financial results due to a variety of factors, including the continued
good health of our employees, the ability of our third party suppliers, vendors, manufacturers and partners to continue to operate and
provide services, the ability of our clinical trial sites to continue or resume operations, any further government and/or public actions
taken in response to the pandemic and the ultimate duration of the COVID-19 outbreak/pandemic.
5
Our Pipeline
The following table summarizes our current drug candidates and their respective stages of development:
* Chronic obstructive pulmonary disease
Our Strategy
Our goal is to advance the development of our differentiated pipeline of orally administered, small molecule drug candidates to
treat metabolic and inflammatory diseases to minimize their long-term complications and to improve the lives of patients. As key
components of our strategy, we are focused on:
•
•
•
•
Continuing to advance TTP399 as a potential treatment for type 1 diabetes. In February 2020, we announced positive
results from the Simplici-T1 Study, an adaptive Phase 2 clinical trial of TTP399, assessing the pharmacokinetics,
pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes. The study achieved its primary
objective by demonstrating statistically significant improvements in HbA1c (long-term blood sugar) for TTP399 compared
to placebo. We are working on the design for pivotal and registrational studies for TTP399, with input from the FDA. In
addition to the pivotal studies of TTP399, we are currently conducting a Phase 1 mechanistic study in patients with type 1
diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal.
Beginning to advance HPP737 as potential treatment of psoriasis. We are conducting a multiple ascending dose Phase 1
study of HPP737, an orally administered phosphodiesterase type 4 (“PDE4”) inhibitor, to assess the pharmacokinetics,
pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of our psoriasis program. The goal of
this study is to confirm the maximum tolerated dose with minimal or no GI intolerance in the form of nausea, vomiting, or
diarrhea. If successful, we plan to initiate a Phase 2 proof of concept study to assess the efficacy and safety of HPP737 as a
potential treatment for psoriasis.
Pursuing TTP273 as a treatment of cystic fibrosis-related diabetes. We are planning an adaptive Phase 1b/2 clinical trial
assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP273 and are seeking a funding partner to
enable the conduct of this clinical trial.
Seeking additional strategic collaborations and additional funding to support the continued development and
commercialization of our development programs. We will continue to seek additional funding to support the further
development of our drug candidates. Such support may come from strategic collaborations with non-profit research funding
organizations such as JDRF International or from collaboration agreements with other pharmaceutical companies.
6
•
Continuing to monitor and support existing partnerships for pipeline programs. Our partners developing our GLP-1r,
PPAR-δ, PDE4, and Nrf2 programs continue to advance these programs in their respective licensed territories. We continue
to support and monitor these partnerships. For example, following the successful completion of a Phase 1 study and the
receipt of orphan designation for the PPAR-δ drug candidate, Reneo Pharmaceuticals, Inc. recently completed a $95 million
Series B offering to initiate a global Phase 2 clinical trial in primary mitochondrial myopathies in early 2021.
Our Type 1 Diabetes Program –TTP399
Diabetes Overview
Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin (a hormone that enables people to
get energy from food). Type 1 diabetes results when the body’s immune system attacks and destroys the insulin-producing cells in the
pancreas called beta cells. While the causes of type 1 diabetes are not yet entirely understood, scientists believe that both genetic factors
and environmental triggers are involved. The onset of type 1 diabetes is not believed to be affected by diet or lifestyle.
Current Treatments for Type 1 Diabetes and Their Limitations
Patients with type 1 diabetes have difficulty achieving and maintaining consistent glycemic control, defined as HbA1c < 7% as
recommended by the American Diabetes Association (ADA). In order to maintain appropriate glycemic control, patients with type 1
diabetes are required to constantly monitor their blood glucose levels, closely manage their diet, and administer insulin via injection in
response. While technology has advanced to help people with type 1 diabetes manage the burden of this monitoring and insulin
administration process, including continuous glucose monitors and insulin pumps, patient outcomes have not improved: approximately
80% of people with type 1 diabetes fail to achieve the ADA’s recommended HbA1c levels. Failure to maintain glycemic control results
in dangerous excursions into hyperglycemia or hypoglycemia that are potentially fatal. In addition, the accumulated impact of these
glycemic excursions can raise a patient’s risk of potentially serious and life-threatening long-term complications, such as cardiovascular
disease, blindness, kidney failure, and nerve damage.
A number of existing treatment options for type 2 diabetes have been investigated to treat type 1 diabetes, generally without
success. While a pair of SGLT-1/2 and SGLT-2 inhibitors were recently approved in Europe and Japan with label restrictions to certain
sub-groups of people with type 1 diabetes, these therapies have not been approved in the U.S. due to safety risks primarily relating to
diabetic ketoacidosis (“DKA”). Alternative therapeutic modalities, including monoclonal antibodies, are under clinical investigation and
have demonstrated evidence of the potential to delay the onset of type 1 diabetes. Such alternatives have not completed clinical
development or received regulatory approval nor do they address the unmet need of existing patients with type 1 diabetes or those that
eventually become patients with type 1 diabetes following any therapeutic delay in disease onset.
With insulin and pramlintide injection as the only treatment options approved in the United States for type 1 diabetes, there is an
unmet medical need to provide people with type 1 diabetes additional, especially oral, treatment options that can help them to reduce
HbA1c, or the incidence of hypoglycemia (blood glucose levels below normal) or DKA.
The Role of Glucokinase Activation in Diabetes
Glucokinase (“GK”) is a key regulator of glucose homeostasis and acts as the physiological glucose sensor, changing its
conformation, activity, and/or intracellular location in parallel with changes in glucose concentrations. GK has two distinctive
characteristics that make it a good choice for blood glucose control. First, its expression is mostly limited to tissues that require glucose-
sensing (mainly liver and pancreatic β-cells). Second, GK acts as a biological sensor for changes in serum glucose levels and modulates
changes in liver glucose metabolism that in turn regulates the balance between hepatic glucose production and glucose consumption, and
modulates changes in insulin secretion by the β-cells. GK activation is attractive as a potential therapy for the treatment of type 1
diabetes and has a mechanism of action entirely distinct from currently marketed oral anti-diabetic drugs (“OAD”).
TTP399
TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (“GKA”) in development as a new
potential OAD for the treatment of type 1 diabetes. TTP399 has a novel mechanism of action: liver-selective activation of GK that seeks
to provide intensive glycemic control and a reduction in the risk of hypoglycemia. Our trials for TTP399 to date suggest that our liver-
selective approach to GK activation has the potential to avoid the tolerability issues associated with other GKAs, such as activation of
GK in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Based on
data from Phase 1 and 2 trials to date, we believe that TTP399, if approved, has the potential to be a first-in-class OAD due to its liver-
selectivity and novel mechanism of action. We have completed nine Phase 1 and two Phase 2 clinical trials of TTP399, one of which
was six months in duration. In our Phase 1 and 2 clinical trials, TTP399 was well tolerated with negligible incidence of hypoglycemia.
7
Positive Phase 2 Simplici-T1 Study
In February 2020, we announced positive results from the Simplici-T1 Study, an adaptive Phase 2 clinical trial of TTP399,
assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (“T1D”)
over a 12 week period. The study was designed to evaluate whether TTP399 is well tolerated and can improve daily glucose profiles and
HbA1c in people living with T1D when administered as an oral add-on to insulin therapy. The Simplici-T1 Study achieved its primary
objective by demonstrating statistically significant improvements in HbA1c for TTP399 compared to placebo.
TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both
treatment groups. The study had no report of diabetic ketoacidosis in either treatment group. There was no incidence of severe
hypoglycemia in the treated group and one incident in the placebo group. Patients taking TTP399 experienced fewer symptomatic
hypoglycemic episodes: two subjects taking TTP399 reported at least one event compared to eight subjects taking placebo.
Clinical Development Plan
In light of the positive results of our Simplici-T1 Study, we requested a Type C meeting with the FDA to discuss the trial design
and other requirements for the next stage of development for TTP399. The Company received written responses from the FDA in June
and September 2020. Based upon the responses provided, the Company plans to conduct a placebo-controlled six-month clinical trial in
approximately 400 subjects, followed by a second placebo-controlled six-month clinical trial to be initiated thereafter. The Company
would also include a six-month open label extension in the first clinical trial to provide patient data of the necessary duration to support
the safety and efficacy of TTP399. In its response, the FDA confirmed that the effect size of TTP399 on events of hypoglycemia as
demonstrated in the Phase 2 SimpliciT-1 Study are clinically meaningful and that a reduction in events of hypoglycemia would be an
acceptable clinical endpoint for evaluation of a therapy for the treatment of type 1 diabetes.
Finally, the Company is conducting a phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the
impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. The Company proposed the mechanistic study
to the FDA and the FDA recommended that the study be performed in support of the planned pivotal trials. The results of this
mechanistic study will provide additional evidence to support the effects of TTP399 on diabetic ketoacidosis (“DKA”) in patients with
type 1 diabetes. We expect to report top-line results in the second or third quarter of 2021.
Our Psoriasis Program – PDE4 Inhibitor
Psoriasis Overview
Psoriasis is a chronic autoimmune inflammatory disease in which the growth cycle of skin is accelerated due to an imbalance in
pro-inflammatory and anti-inflammatory cytokines. This results in the proliferation of skin cells and the development of raised, red,
silvery scale plaques (i.e. plaque psoriasis, psoriasis vulgaris) that has not only medical implications but an impact on a patient’s quality
of life. While the specific inciting events for this pro-inflammatory process are unknown psoriasis may be caused by autoimmunity and
genetic predisposition. Events such as trauma to the skin, stress, illness or infection that triggers the immune systems, obesity, and
weather have been identified as triggers for flare ups.
Current Treatment for Psoriasis and Their Limitations
Topical therapies including glucocorticoids and vitamin D analogs are the mainstay of treatment for mild psoriasis. The
continuous long-term use of glucocorticoids is limited by the risk of skin thinning / atrophy and the potential for systemic absorption.
Vitamin D analogs are often added to glucocorticoids to improve glucocorticoid efficacy while allowing for reduction in glucocorticoid
dose. Moderate to severe disease is treated with systemic therapies including oral PDE4 inhibition, immunosuppressants, retinoids, and
biologics (ex: anti-TNF agents, IL-17 inhibitors, IL-23 inhibitors). Biologics, while realizing high efficacy rates in treating psoriasis,
are associated with administration by injection, high cost, need for laboratory monitoring and increased risk of infection.
Inhibitors of PDE4 act by increasing intracellular concentrations of cyclic adenosine monophosphate (“cAMP”), which has a broad
range of anti-inflammatory effects. PDE4 activity is increased in the skin of patients with psoriasis leading to up-regulation of immune
modulatory, pro-inflammatory genes and cytokines including interleukin-17 (IL-17), interleukin-23 (IL-23), and tumor necrosis factor-
alpha (TNF-α). Treatments for psoriasis are aimed at reducing pro-inflammatory cytokine activity. The therapeutic potential of oral
PDE4 inhibitors has been limited by dose limiting AEs such as nausea, vomiting, diarrhea and headache.
HPP737
HPP737 is an orally administered, potent and selective, non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases
and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. HPP737 has
shown potent inhibition of IL-17a and TNF-α production in in vitro studies and activity in several animal models of inflammation.
HPP737 has completed Phase 1 single-ascending dose and initial multiple-ascending dose studies, in which it was well tolerated at all
doses tested in healthy volunteers. Clinical data generated to date supports achieving target engagement (reduction in ex vivo LPS
stimulated TNF-α) at HPP737 plasma concentrations predicted to be efficacious from preclinical models.
8
Clinical Development Plan
We are conducting a subsequent multiple ascending dose Phase 1 study of HPP737, an orally administered phosphodiesterase type
4 (“PDE4”) inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as
part of our psoriasis development program. The goal of this study is to continue multiple-dose escalation to define a maximum tolerated
dose characterized by minimal or no GI intolerance (i.e., nausea, vomiting or diarrhea). We expect to complete this study in the second
quarter of 2021.
Our Dementia Program – Azeliragon
Phase 2 Elevage Study in Patients with Mild-AD and Type 2 Diabetes
Based on a subgroup analysis from the previously conducted Phase 3 STEADFAST Study, we conducted a Phase 2 study to
evaluate azeliragon as a potential treatment of mild-AD in patients with type 2 diabetes (the “Elevage Study”). The Elevage Study did
not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease
Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.
Future Development of Azeliragon
Upon the failure of the Elevage Study, we have discontinued the development of azeliragon for the treatment of Alzheimer’s
disease. However, we are evaluating the potential for its use in other indications. We currently have an ongoing pre-clinical
collaboration with the University of Queensland Australia and Yale University to evaluate the use of azeliragon for the prevention of
type 1 diabetes in animal models. We may also pursue other strategic opportunities for the further development of azeliragon, when and
if they arise.
Our Cystic Fibrosis Related Diabetes Program – GLP-1r Agonist
Cystic Fibrosis Related Diabetes Overview
Cystic fibrosis related diabetes (“CFRD”) shares some features with both type 1 and type 2 diabetes but is distinct, and is likewise
categorized as diabetes due to other causes, specifically a disease of the exocrine pancreas by the American Diabetes Association. In
people with cystic fibrosis (“CF”), the thick, sticky mucus that is characteristic of the disease causes scarring of the pancreas. This
scarring prevents the pancreas from producing normal amounts of insulin. The damaged pancreas also responds to insulin signaling in a
delayed manner. The delay and blunting of the insulin response in patients with CFRD results in post-prandial hyperglycemia.
The Role of GLP-1r Activation in Cystic Fibrosis Related Diabetes
GLP-1, an incretin hormone that is released by the gut in response to nutrients, lowers postprandial glucose by promoting insulin
secretion. Abnormally low postprandial stimulation of incretins has been described in CF patients and improvement in postprandial
hyperglycemia has been demonstrated following prandial administration of GLP-1 agonists or DPP-4 inhibitors. Nevertheless, the use
of existing GLP-1 mimetics that are available for the treatment of type 2 diabetes to treat CFRD is limited by the GI side effects and
undesired weight loss associated with these agents.
TTP273
TTP273 is an orally available, small molecule GLP-1 receptor agonist which has been demonstrated to reduce postprandial
glucose excursion in response to an oral glucose test or mixed meal tolerance test in both pre-clinical and clinical studies. We believe
that TTP273 could be used to treat postprandial hyperglycemia in CFRD patients and CF patients with abnormal post-prandial glucose
excursions without inducing hypoglycemia or GI side effects. An oral therapy such as TTP273 is needed because the current method of
treatment of CFRD is injected insulin, which comes with associated risks of hypoglycemia and poses additional burdens on
patients. Other available oral therapies for type 2 diabetes are not recommended for the treatment of CFRD due to side effects such as
hypoglycemia, weight loss, or nausea. In particular, the GLP-1 mimetics currently in the market have been demonstrated to result in
increased GI side effects and undesired weight loss, both of which are major drawbacks for patients with CFRD.
We have completed two Phase 1 clinical trials and one Phase 2 clinical trial of TTP273. Additionally, we have completed nine
Phase 1 clinical trials and one Phase 2 clinical trial of TTP054, a predecessor orally administered GLP-1r agonist. In our Phase 1 and
Phase 2 clinical trials, TTP273 has been demonstrated to be well-tolerated with lower incidences of GI side effects, such as nausea and
vomiting, than placebo with minimal weight loss, especially in non-obese patients.
We are currently planning an adaptive Phase 1b/2 clinical trial assessing the pharmacokinetics, pharmacodynamics, safety and
tolerability of TTP273, but the final design may be adjusted based on the feedback received, if any, from the FDA and are seeking a
funding partner to enable the conduct of this clinical trial.
9
Our Nrf2/Bach1 Modulator Program
The Role of Nrf2/Bach1 Modulators
Chronic, unresolved inflammation, oxidative stress, and resulting fibrosis are key features of many diseases. Inflammation is an
integral component of the normal immune response that occurs when cells encounter harmful stimuli, such as invading pathogens,
damaged cells, or irritants. During inflammation, cells activate inflammatory processes and complexes that increase the production of
cytokines, which are proteins that recruit and activate immune cells.
Inflammation and mitochondrial metabolism are closely associated. The mitochondria are often called the “powerhouses” of the
cell as they produce the energy that the cell needs to function. This energy is produced by converting fatty acids and glucose into
adenosine triphosphate (ATP) by a process called oxidative phosphorylation. During inflammation, mitochondrial metabolism is
temporarily reprogrammed to suppress oxidative phosphorylation. Instead of primarily making ATP, the mitochondria divert fatty acids
and glucose to increase the production of proinflammatory mediators. During this reprogramming, the mitochondria release chemically-
reactive molecules called reactive oxygen species (ROS) that can directly attack pathogens and amplify the production of cytokines.
In a normal immune response, the resolution of inflammation begins after the harmful stimuli have been eliminated. Nrf2 is a
protein that plays a key role in the resolution of inflammation by regulating the expression of specific genes involved in mitochondrial
metabolism, redox balance, and cytokine production. When activated, Nrf2 promotes the resolution of inflammation by normalizing
mitochondrial metabolism, restoring redox balance, and suppressing cytokine production.
In many chronic and genetic diseases, Nrf2 activity is suppressed, and the resolution of inflammation fails to occur or is
inadequate, leading to persistent mitochondrial dysfunction, excess production of ROS, and production of cytokines. These processes
cause chronic inflammation, which can ultimately lead to tissue damage and loss of organ function.
To date, therapeutic agents seeking to active Nrf2, such as such as Bardoxolone or Tecfidera, have relied on reactive, electrophilic
biological targets that may present safety and tolerability issues. Non-electrophilic activation of the Nrf2 pathway via targeting the
Bach1 transcriptional repressor provides an alternative mechanism by which to increase the activation of Nrf2 to reduce the oxidative
stress and inflammation associated with many acute and chronic diseases.
Bach1 is a transcriptional repressor that controls the expression of certain genes involved in the body’s antioxidant response
processes. Genetic knock-out models of Bach1 have shown increased expression of multiple antioxidant proteins such as heme
oxygenase-1 (HMOX1), leading to a significant level of cellular, tissue and organ protection in a wide variety of mouse models. Hemin
and the hemin mimetic cobalt protoporphyrin IX (“CoPP”) are Bach1 ligands that have served as useful tool compounds to investigate
the role of Bach1 inhibition in a variety of disease settings. Both molecules have been shown to have beneficial effects on oxidative
stress and inflammatory-mediated pathologies in a number of animal models. Further, the ubiquity of the response suggests that the
observed tissue protective effects are not related to the underlying causes of a particular disease, but instead are an intrinsic outcome of
Bach1 modulation along with Nrf2 activation.
HPP3033
Our candidate, HPP3033, represents a novel, non-electrophilic therapeutic approach to activating the Nrf2 pathway that has the
potential to be used in the treatment of chronic diseases associated with oxidative stress. We are currently evaluating HPP3033 and other
Nrf2 activator compounds in various preclinical studies.
Partnered Development Programs
PPAR-δ and Reneo Pharmaceuticals, Inc.
On December 21, 2017, we entered into a License Agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License
Agreement”), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize our peroxisome
proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or
diagnostic application in humans.
Under the terms of the Reneo License Agreement, Reneo paid us an initial license fee of $3.0 million. We are eligible to receive
additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In addition, Reneo is
obligated to pay us royalty payments at mid-single to low-double digit rates, based on tiers of annual net sales of licensed
products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of
expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a
country or a specified number of years after the first commercial sale of a licensed product in a country. In addition, we have received
common stock and certain participation rights representing a minority interest in Reneo’s outstanding equity.
Under the terms of the Reneo License Agreement, Reneo will be responsible for the worldwide development and
commercialization of the licensed products, at its cost, and is required to use commercially reasonable efforts with respect to such
development and commercialization efforts.
10
The Reneo License Agreement, unless terminated earlier, will continue until expiration of all royalty obligations of Reneo to
us. Either party may terminate the Reneo License Agreement for the other party’s uncured material breach. Reneo may terminate the
Reneo License Agreement at will upon prior written notice. Upon expiration (but not earlier termination) of the Reneo License
Agreement, the licenses granted to Reneo will survive on a royalty-free basis in perpetuity.
GLP-1r and Huadong
On December 21, 2017, we entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
(“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop
and commercialize our glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic
uses in humans or animals, in China and certain other Pacific Rim territories, including Australia and South Korea (collectively, the
“Huadong License Territory”). Additionally, under the Huadong License Agreement, we obtained a non-exclusive, sublicensable,
royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to our GLP-1r program for
therapeutic uses in humans or animals outside of the Huadong License Territory.
Under the terms of the Huadong License Agreement, Huadong has paid us an initial license fee of $8.0 million, and we are eligible
to receive potential development and regulatory milestone payments totaling up to $22.0 million, as amended in January 2021.
Additionally, we are eligible to receive additional potential regulatory milestone of $20.0 million if Huadong receives regulatory
approval for a central nervous system indication. Further, we are eligible for an additional $50.0 million in potential sales-based
milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products.
Under the original Huadong License Agreement, we had the obligation to conduct a Phase 2 multi-region clinical trial (the “Phase
2 MRCT”), should Huadong require us to do so. We were also responsible for contributing up to $3.0 million in connection with the
Phase 2 MRCT, if it occurs. However, the Huadong License Agreement was amended in January 2021 to remove these obligations.
Huadong will be responsible for the development and commercialization of the licensed products in the Huadong License
Territory, at its cost, and is required to use commercially reasonable efforts with respect to its development efforts. Further, Huadong is
required to use commercially reasonable efforts to develop and commercialize at least one GLP-1r compound in China.
The Huadong License Agreement, unless terminated earlier, will continue on a product-by-product and country-by-country basis
until expiration of the royalty obligations Huadong owes to us on such licensed product, which extend until the later of the expiration of
certain patent or data exclusivity rights covering such licensed product in such country or eight years after the first commercial sale of
such product in such country. Either party may terminate the Huadong License Agreement for the other party’s uncured material
breach.
PDE4 and Newsoara Biopharma
On May 31, 2018, we entered into a license agreement with Newsoara (the “Newsoara License Agreement”), under which
Newsoara obtained an exclusive and sublicensable license to develop and commercialize our phosphodiesterase type 4 inhibitors
(“PDE4”) program, including the compound HPP737, in China and other Pacific Rim territories (collectively, the “Newsoara License
Territory”). Additionally, under the Newsoara License Agreement, we obtained a non-exclusive, sublicensable, royalty-free license to
develop and commercialize certain Newsoara patent rights and know-how related to our PDE4 program for therapeutic uses in humans
outside of the Newsoara License Territory.
Under the terms of the Newsoara License Agreement, Newsoara paid us an upfront cash payment of $2.0 million. We are eligible
to receive additional potential development, regulatory and sales-based milestone payments totaling up to $58.5 million, as amended. In
addition, Newsoara is obligated to pay us royalty payments at high-single to low-double digit rates, based on tiers of annual net sales of
licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest
of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product
in a country or a specified number of years after the first commercial sale of a licensed product in a country.
Under the terms of the Newsoara License Agreement, Newsoara will be responsible for the development and commercialization of
the licensed products in the Newsoara License Territory, at its cost, and is required to use commercially reasonable efforts with respect
to such development and commercialization efforts.
The Newsoara License Agreement, unless terminated earlier, will continue until expiration of all royalty obligations of Newsoara
to us. Either party may terminate the Newsoara License Agreement for the other party’s uncured material breach. Newsoara may
terminate the Newsoara License Agreement at will upon prior written notice. Upon expiration (but not earlier termination) of the
Newsoara License Agreement the licenses granted to Newsoara will survive on a royalty-free basis in perpetuity.
11
Nrf2 and Anteris Bio
On December 11, 2020, we entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License
Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize vTv LLC’s
Nrf2 activator, HPP971.
Under the terms of the Anteris License Agreement, Anteris paid vTv LLC an initial license fee of $2.0 million. vTv LLC is
eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million.
Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such
royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a
licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years
after the first commercial sale of a licensed product in a country. In addition, vTv LLC received a minority ownership interest in
Anteris.
Under the terms of the Anteris License Agreement, Anteris will be responsible for the development and commercialization of the
licensed products, at its cost, and is required to use commercially reasonable efforts with respect to such development and
commercialization efforts.
The Anteris License Agreement, unless terminated earlier, will continue until expiration of all royalty obligations of Anteris to
vTv LLC. Either party may terminate the Anteris License Agreement for the other party’s uncured material breach. Anteris may
terminate the Anteris License Agreement at will upon prior written notice. Either party may terminate the Anteris License Agreement
for the other party’s insolvency.
Inbound Partnerships
JDRF Agreement
In August 2017, we entered into a research, development and commercialization agreement with JDRF International (“JDRF”)
(the “JDRF Agreement”) to support the funding of the Simplici-T1 Study, an adaptive Phase 1b/2 study to explore the effects of TTP399
in type 1 diabetes. In February 2020, we reported positive results from the Phase 2 confirming portion of the Simplici-T1 Study. See
“Our Type 1 Diabetes Program –TTP399 – Positive Phase 2 Simplici-T1 Study” above for further details. According to the terms of the
JDRF Agreement, JDRF provided research funding of $3.0 million based on the achievement of research and development milestones,
with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, we have the
obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment
for type 1 diabetes.
Novo Nordisk
In February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo
License Agreement”) whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual
property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment,
control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, we obtained certain worldwide
rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. This agreement was
amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the
terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling
up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment
of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an
additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on
tiered sales of commercialized licensed products.
Third-Party Suppliers and Manufacturers
We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to
continue to rely, on third parties to manufacture clinical supplies of our drug candidates and for our other research and discovery
programs. We do not have multiple sources of supply for the components used in our drug candidates.
Intellectual Property
Patents
The IP portfolio for azeliragon includes issued patents in the U.S. directed to azeliragon as a composition of matter and methods
of use to treat various indications. The issued U.S. patent covering azeliragon as a composition of matter will expire no earlier than
2024 but may expire as late as 2029, if we obtain and apply the maximum possible extension under the Drug Price Competition and
12
Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”). The IP portfolio for azeliragon also includes patent families covering
polymorphs, salt forms, metabolites, degradation products and a synthetic precursor of azeliragon, methods of treatment using select
dosage regimens of azeliragon, and methods of treating select patient populations. These additional patent families have expiration dates
ranging from 2028 through potentially 2039. The issued U.S. patent covering the polymorph of azeliragon used in clinical development
will expire no earlier than 2028 but may expire as late as 2033, if we obtain and apply the maximum possible extension under the Hatch-
Waxman Act which can only be applied to a single patent following approval.
The IP portfolio for TTP399 includes issued patents in over 35 countries and territories, including the U.S., Europe, Japan,
Canada, Australia, and China, directed to TTP399 as a composition of matter. The issued U.S. patent covering TTP399 as a composition
of matter will expire no earlier than 2025 but may expire as late as 2030, if we obtain and apply the maximum possible extension under
the Hatch-Waxman Act following approval. Patents covering TTP399 as a composition of matter outside the United States will expire
no earlier than 2025 and may expire much later as a result of patent term extensions based on patent office delays, regulatory delays, or a
combination thereof. The IP portfolio for TTP399 also includes patent families covering crystal forms, salt forms, and solid
formulations of TTP399 as well as combinations of TTP399 with metformin, DPP-4 inhibitors, or GLP-1r agonists .The IP portfolio also
includes a patent family covering methods of treating type 1 diabetics using TTP399 in combination with insulin. These additional
patent families have expiration dates ranging from 2031 through potentially 2040.
The IP portfolio for HPP737 includes issued patents in the U.S. generically covering HPP737 as a composition of matter and
methods of use to treat various indications. The issued U.S. patent generically covering HPP737 as a composition of matter will expire
no earlier than 2029 but may expire as late as 2034, if we obtain and apply the maximum possible extension under the Hatch-Waxman
Act following approval. The IP portfolio for HPP737 also includes a patent family covering the specific structure of HPP737 and
another patent family covering a crystalline form of HPP737. Any patents issuing from these two patent families will expire in 2040.
The IP portfolio for the GLP-1r program includes issued patents in over 35 countries and regions, including the U.S., Europe,
Japan, Canada, Australia, and China, directed to TTP273 as a composition of matter. The issued U.S. patent covering TTP273 as a
composition of matter will expire no earlier than 2030, but may expire as late as 2035, if we obtain and apply the maximum possible
extension under the Hatch-Waxman Act following approval. Patents covering TTP273 as a composition of matter outside the United
States will expire no earlier than 2030 and may expire much later as a result of patent term extensions based on patent office delays,
regulatory delays, or a combination thereof. The IP portfolio for TTP273 also includes patent families covering crystalline, non-
crystalline, and salt forms of TTP273, synthetic precursors to, and method of manufacture of TTP273, as well as combinations of
TTP273 and metformin, and dosage regimens of TTP273. These additional patent families have expiration dates ranging from 2032
through potentially 2040.
The IP portfolio for the Nrf2/Bach1 program includes issued patents in over 25 countries and regions, including the U.S., Europe,
Japan, Canada, Australia, and China, directed to HPP971 and HPP3033 as compositions of matter. The issued U.S. patent covering
HPP971 and HPP3033 as compositions of matter will expire no earlier than 2032, but may expire as late as 2037, if we obtain and apply
the maximum possible extension under the Hatch-Waxman Act following approval. Patents covering HPP971 and HPP3033 as a
composition of matter outside the United States will expire no earlier than 2031 and may expire much later as a result of patent term
extensions based on patent office delays, regulatory delays, or a combination thereof. The IP portfolio for the Nrf2/Bach1 program also
includes patent families covering backup compounds, methods of use in combination with other Nrf2 activator compounds such as
dimethyl fumarate and bardoxolone, and methods to treat sickle cell diseases, osteoporosis, and refractive ocular disorders. These
additional patent families have expiration dates ranging from 2034 through potentially 2041.
Trade Secrets
In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We seek to
protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment
agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to
protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that
are developed by employees or through a relationship with a third party. We also seek to preserve the integrity and confidentiality of our
data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information
technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be
breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become publicly known
or be independently discovered by competitors. To the extent that our contractors use or incorporate intellectual property owned by
others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
Competition
The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our potential competitors include
large pharmaceutical and biotechnology companies, specialty pharmaceutical companies and generic drug companies. We believe the
key competitive factors that will affect the development and commercial success of our drug candidates are efficacy, safety and
13
tolerability profile, mechanism of action, control and predictability, convenience of dosing, price and reimbursement, and availability of
comparable alternative therapies.
Many of the companies against which we may compete have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain
FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the
success of all of our programs are likely to be their efficacy, safety, convenience, and availability of reimbursement.
Potential Competing Products – Type 1 Diabetes
If approved, we expect that our type 1 diabetes investigational drug candidate will compete with other oral non-insulin agents that
are currently being developed or which have limited approval in certain jurisdictions. These include SGLT-1/2 inhibitors, such as
sotagliflozin, being developed by Lexicon and SGLT-2 inhibitors such as AstraZeneca’s dapagliflozin, both of which are approved for
limited use in the European Union and Japan as well as Eli Lilly/Boehringer Ingelheim’s empagliflozin, which is not currently approved
for the treatment of type 1 diabetes. None of these treatments are approved for use in type 1 diabetes in the United States.
Potential Competing Products – Psoriasis
If approved, we expect that our psoriasis candidate will compete with Otezla (apremilast), the only PDE4 inhibitor currently
approved to treat psoriasis and marketed by Amgen Inc., topical PDE4 inhibitor drug candidates currently in development, if approved,
including roflumilast being developed by Arcutis Biotherapeutics, anti-TNF biologics approved to treat psoriasis, including Enbrel
(etanercept), Remicade (infliximab), and Humira (adalimumab), and anti-TNF biosimilars currently in development.
We believe that our investigational drug candidates may offer key potential advantages over these competitive products that could
enable our drug candidates, if approved, to capture meaningful market share from our competitors.
Collaboration Revenue and Customers
The majority of our collaboration revenue for the years ended December 31, 2020, 2019 and 2018 is related to our licenses of
certain compounds in the pre-clinical stage or clinical stage, including the Anteris License Agreement, Huadong License Agreement, the
Reneo License Agreement and the Newsoara License Agreement. Revenue recognized in these periods relates to initial consideration
received in the form of upfront payments and equity interests, research activities performed by our personnel, and the achievement of
development milestones.
Government Regulation and Product Approvals
Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union (“EU”), extensively regulate, among other things, the research, development, testing, manufacture,
pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for
obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable
statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. For a full
discussion of the regulatory framework for the approval and regulation of investigational drug candidates, and applicable domestic and
foreign healthcare law, please see “Part 1 – Item 1 – Business - Government Regulation and Product Approvals” in our Annual Report
on Form 10-K filed on February 21, 2020.
Human Capital
As of December 31, 2020, we had 25 employees, of which at least 13 hold graduate degrees (including 9 doctorate degrees) and
13 are engaged in full-time research and development activities. None of our employees are represented by a labor union, and we
14
consider our employee relations to be good. We continually evaluate our business needs and opportunities and balance in house
expertise and capacity with external expertise and capacity. Currently, we rely on third-party contract research organizations and
contract manufacturers for the conduct of our studies.
Our Corporate Information
We were incorporated under the laws of the State of Delaware in 2015. Our principal executive offices are located at 3980 Premier
Drive, Suite 310, High Point, NC 27265, and our telephone number is (336) 841-0300. We also maintain a corporate website,
www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate
governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on
the SEC’s website http://www.sec.gov. The contents of our website are not made a part of this Annual Report on Form 10-K.
ITEM 1A. RISK FACTORS
Risks Relating to Our Financial Position and Need for Additional Capital
We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future. We
may never achieve or maintain profitability.
We are a clinical-stage pharmaceutical company with limited operating history. We have never been profitable and do not expect
to be profitable in the foreseeable future. We have incurred net losses in each year since beginning to develop our drug candidates,
including net losses of approximately $8.5 million, $17.9 million and $8.7 million for the years ended December 31, 2020, 2019 and
2018, respectively. As of December 31, 2020, we had a total accumulated deficit of approximately $290.0 million. In addition, we have
not commercialized any products and have never generated any revenue from the commercialization of any product. We have devoted
most of our financial resources to research and development, including our preclinical development activities and clinical trials. We
expect to incur significant additional operating losses for the next several years, at least, as we conduct our research and development
activities, advance drug candidates through clinical development, complete clinical trials, seek regulatory approval and, if we receive
FDA approval, commercialize our products. Furthermore, the costs of advancing drugs into each succeeding clinical phase tend to
increase substantially over time. The total costs to advance any of our drug candidates to marketing approval in even a single jurisdiction
would be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are
unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from
the commercialization of products or achieve or maintain profitability. We expect to continue to incur significant additional expenses as
we continue the development of TTP399, advance our other drug candidates and expand our research and development programs.
Furthermore, our ability to successfully develop, commercialize and license our products and generate product revenue is subject to
substantial additional risks and uncertainties, as described under “—Risks Relating to the Discovery, Development and Regulatory
Approval of Our Drug Candidates” and “—Risks Relating to the Commercialization of Our Drug Candidates.” As a result, we expect to
continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and
will continue to have, an adverse effect on our stockholders’ equity and working capital. The amount of our future net losses will
depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. In addition, we may not be able to
enter into any collaborations that will generate significant cash. If we are unable to develop and commercialize one or more of our drug
candidates either alone or with collaborators, or if revenues from any drug candidate that receives marketing approval are insufficient,
we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we are
unable to achieve and then maintain profitability, the value of our equity securities will be materially and adversely affected.
Currently, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As
a result, our ability to generate revenue from products, curtail our losses and reach profitability is unproven, and we may never
generate substantial product revenue.
We have no products approved for commercialization and have never generated any revenue from the commercialization of any
product. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to
successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of
our product candidates. We do not anticipate generating revenue from product sales for several years. Our ability to generate future
revenue from product sales depends heavily on our success in many areas, including but not limited to:
•
•
obtaining regulatory and marketing approvals for product candidates for which we complete clinical studies;
completing research and nonclinical and clinical development of our product candidates;
•
establishing collaborations for the development of certain of our drug candidates;
15
•
•
•
•
•
•
•
•
establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount
and quality, products and services to support clinical development and the market demand for our product candidates, if approved;
launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with
a collaborator or distributor;
obtaining market acceptance of our product candidates as viable treatment options;
obtaining favorable formulary placement with government and third-party payors that allows for favorable reimbursement;
addressing any competing technological and market developments;
negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
maintaining, protecting and expanding our portfolio of intellectual property rights; and
attracting, hiring and retaining qualified personnel.
Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant
costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are
required by the FDA or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate.
Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain
additional funding to continue operations.
We will need additional capital to complete the development and commercialization of TTP399 and our other drug candidates, and
there is a substantial doubt about our ability to continue as a going concern. If we are unable to raise sufficient capital for these
purposes, we would be forced to delay, reduce or eliminate our product development programs.
Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect to
continue to incur significant research and development expenses in connection with our ongoing activities, particularly as we undertake
additional clinical trials of TTP399 and our other drug candidates and continue to work on our other research programs. Our current
capital will not be sufficient for us to complete the development of our drug candidates. As such, we will need to raise additional capital
to fund the ongoing and planned trials for our drug candidates and prior to the commercialization of any of our drug candidates. We are
seeking possible additional partnering opportunities and grants for our GKA, GLP-1r and other drug candidates which we believe may
provide additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We also continue to
evaluate other financing strategies to fund our ongoing trials. Such financing strategies include direct equity investments and future
public offerings of our common stock. The timing and availability of such financing are not yet known.
If the FDA or other regulators require that we perform additional studies beyond those we currently expect, or if there are any
delays in completing our clinical trials or the development of any of our drug candidates, our expenses could increase beyond what we
currently anticipate and the timing of any potential product approval may be delayed. We have no commitments or arrangements for any
additional financing to fund our research and development programs other than the funds available to us under our Controlled Equity
OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “ATM Offering”) and our
purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”). Under both of these
arrangements, the Company has the right to sell shares of the Company’s Class A Common Stock, subject to certain limitations and
conditions as set forth in the related agreements. As of February 24, 2021, there remains $5.5 million of availability under the ATM
offering. While the LPC Purchase Agreement allows for sales of up to $47.0 million, we only have 441,726 remaining shares registered
under this agreement as of February 24, 2020. Though we can register additional shares for sale under this agreement, such sales may be
limited by the conditions set forth in the LPC Purchase Agreement. We also will need to raise substantial additional capital in the future
to conduct further clinical trials of TTP399 and to continue developing our other drug candidates. Because successful development of
our drug candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and
commercialize and license our products under development.
Until such time that we can generate substantial revenue from product sales, we expect to finance our operating activities through
a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances
and licensing arrangements. We may seek to access the public or private capital markets whenever conditions are favorable, even if we
do not have an immediate need for additional capital at that time. If worldwide economic conditions and the international equity and
credit markets deteriorate and return to depressed states, it will be more difficult for us to obtain additional equity or credit financing,
when needed.
Our recurring losses, accumulated deficit and our current levels of cash and cash equivalents raise substantial doubt about our
ability to continue as a going concern as of the date of this report. If we are unable to continue as a going concern, we may have to
16
liquidate our assets and it is likely that investors will lose all or a significant part of their investments. If we seek additional financing to
fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors
or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all, and such
additional funding may cause substantial dilution to our existing investors. Further, if adequate funds are not available, we may be
required to delay, reduce the scope of or eliminate one or more of our research or development programs.
•
•
•
•
•
•
•
•
•
•
•
•
•
Our future capital requirements will depend on many factors, including:
the progress, costs, results and timing of our planned registrational trial(s) for TTP399 as a potential treatment of type 1 diabetes
and our multiple ascending dose phase 1 study of HPP737 in healthy volunteers as part of our psoriasis program;
the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;
the ability of our drug candidates to progress through clinical development successfully;
our need to expand our research and development activities;
the costs associated with securing, establishing and maintaining commercialization capabilities;
the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;
our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any
payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and
enforcement of any patents or other intellectual property rights;
our need and ability to hire additional management and scientific and medical personnel;
the effect of competing technological and market developments;
our need to implement additional internal systems and infrastructure, including financial and reporting systems;
the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other
arrangements into which we may enter in the future; and
the amount of any payments we are required to make to M&F TTP Holdings Two LLC in the future under the Tax Receivable
Agreement.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our
technologies or drug candidates.
Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity
offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing
arrangements. We do not currently have any committed external source of funds other than those available to us under the ATM
Offering and LPC Purchase Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, the interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences
that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with
third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant
rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.
We have a limited operating history, and we expect a number of factors to cause our operating results to fluctuate on a quarterly and
annual basis, which may make it difficult to predict our future performance.
We are a clinical stage pharmaceutical company with a limited operating history. Our operations to date have been primarily
limited to developing our technology and undertaking preclinical studies and clinical trials of TTP399 and our other drug candidates. We
have not yet obtained regulatory approvals for any of our drug candidates. Consequently, any statements about our future success or
viability are not based on any substantial operating history or commercialized products. Our financial condition and operating results
have varied significantly in the past and will continue to fluctuate from quarter-to-quarter or year-to-year due to a variety of factors,
17
many of which are beyond our control. As a result, we may never successfully develop and commercialize a product, which could lead
to a material adverse effect on the value of any investment in our securities.
Risks Relating to the Development, Regulatory Approval, and Commercialization of Our Drug Candidates
Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and failure can occur at any stage of
clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any drug candidate
we advance through various stages of clinical trials or development may not have favorable results in later stages of clinical trials or
development or receive regulatory approval.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any
stage of clinical development. Clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require
us, to conduct additional clinical or preclinical trials. In addition, data obtained from trials are susceptible to varying interpretations, and
regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. For example, the
Phase 2 Elevage Study in mild Alzheimer’s disease and type 2 diabetes did not meet its primary endpoints. Success in preclinical testing
and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to
demonstrate the efficacy and safety of a drug candidate. Frequently, drug candidates that have shown promising results in early clinical
trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine
whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical
trial is well advanced. While members of our management team have experience in designing clinical trials, our company has limited
experience in designing clinical trials, and we may be unable to design and execute a clinical trial to support regulatory approval.
Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts. For example,
if the results of our future clinical trials of our drug candidates do not achieve the primary efficacy endpoints or demonstrate safety, the
prospects for approval of these candidates would be materially and adversely affected. If our drug candidates are found to be unsafe or
lack efficacy, we will not be able to obtain regulatory approval for them and our business would be materially harmed.
We cannot be certain that any of our drug candidates will receive regulatory approval, and without regulatory approval we will not
be able to market our drug candidates and generate revenue from products. Any delay in the regulatory review or approval of our
drug candidates will materially and adversely affect our business.
Our ability to generate revenue related to product sales, which we do not expect will occur for at least the next several years, if
ever, will depend on the successful development and regulatory approval of our drug candidates. For example, the Phase 2 Elevage
Study in mild Alzheimer’s disease and type 2 diabetes did not meet its primary endpoints. Our clinical development programs for our
drug candidates may not lead to regulatory approval from the FDA and similar foreign regulatory agencies. This failure to obtain
regulatory approvals would prevent our drug candidates from being marketed and would prevent us from generating revenue from our
drug candidates, which would have a material and adverse effect on our business.
All of our drug candidates require regulatory review and approval prior to commercialization, and generally, only a small
percentage of pharmaceutical products under development are ultimately approved for commercial sale. Moreover, any delays in the
regulatory review or approval of our drug candidates would delay market launch, increase our cash requirements and result in additional
operating losses.
The process of obtaining FDA and other required regulatory approvals, including foreign approvals, often takes many years and
can vary substantially based upon the type, complexity and novelty of the products involved. Furthermore, this approval process is
extremely complex, expensive and uncertain, and failure to comply with applicable regulatory requirements can, among other things,
result in the suspension of regulatory approval as well as possible civil and criminal sanctions. We may be unable to submit any new
drug application (“NDA”), in the United States or any marketing approval application in foreign jurisdictions for any of our products. If
we submit an NDA including any amended NDA or supplemental NDA, to the FDA seeking marketing approval for any of our drug
candidates, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any of these
submissions will be accepted for filing and reviewed by the FDA, or that the marketing approval application submissions to any other
regulatory authorities will be accepted for filing and review by those authorities. We cannot be certain that we will be able to respond to
any regulatory requests during the review period in a timely manner, or at all, without delaying potential regulatory action. We also
cannot be certain that any of our drug candidates will receive favorable recommendations from any FDA advisory committee or foreign
regulatory bodies or be approved for marketing by the FDA or foreign regulatory authorities. In addition, delays in approvals or
rejections of marketing applications may be based upon many factors, including regulatory requests for additional analyses, reports, data
and studies, regulatory questions regarding data and results, changes in regulatory policy during the period of product development and
the emergence of new information regarding our drug candidates.
18
Data obtained from preclinical studies and clinical trials are subject to different interpretations, which could delay, limit or prevent
regulatory review or approval of any of our drug candidates. Furthermore, regulatory attitudes towards the data and results required to
demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information,
including on other products, policy changes and agency funding, staffing and leadership. We do not know whether future changes to the
regulatory environment will be favorable or unfavorable to our business prospects.
In addition, the environment in which our regulatory submissions may be reviewed changes over time. For example, average
review times at the FDA for NDAs have fluctuated over the last ten years, and we cannot predict the review time for any of our
submissions with any regulatory authorities. Review times can be affected by a variety of factors, including budget and funding levels
and statutory, regulatory and policy as well as personnel changes at the FDA. Moreover, in light of widely publicized events concerning
the safety risk of certain drug products, regulatory authorities, members of the U.S. Government Accountability Office, medical
professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the
withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of REMS, measures
that may, for instance, place restrictions on the distribution of new drug products. The increased attention to drug safety issues may
result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to
safety, which may make the FDA or other regulatory authorities more likely to delay or terminate clinical trials before completion, or
require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or
may result in approval for a more limited indication than originally sought.
In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
the course of a drug candidate’s clinical development and may vary among jurisdictions, and approval in one jurisdiction does not
guarantee approval in any other jurisdiction. Our drug candidates could fail to receive regulatory approval for many reasons, including
the following:
•
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
•
•
•
•
•
•
•
•
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate
is safe and effective for its proposed indication;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
authorities for approval;
we may be unable to demonstrate that a drug candidate’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or
clinical trials;
the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of an NDA or other
submission or to obtain regulatory approval in the United States or elsewhere;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies;
the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing
with partners; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
rendering our clinical data insufficient for approval.
This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain
regulatory approval to market our drug candidates, which would significantly harm our business, results of operations and prospects.
In addition, even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more
limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling
claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could
materially harm the commercial prospects for our drug candidates.
The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials
may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.
We currently have no drugs approved for sale and we cannot guarantee that we will ever have marketable drugs. Clinical failure
can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any collaborators
19
may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate
with substantial evidence through well-controlled clinical trials that our drug candidates are safe and effective for use in a diverse
population before we can seek regulatory approvals for their commercial sale. Success in early-stage clinical trials does not mean that
future larger registrational clinical trials will be successful because drug candidates in later-stage clinical trials may fail to demonstrate
sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through early-
stage clinical trials. Drug candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks
in subsequent registrational clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be
predictive of the success of later-stage clinical trials, and interim results of a clinical trial are not necessarily indicative of final results.
Changes in law could have a negative impact on the approval of our drug candidates.
The FDA has established regulations, guidelines and policies to govern the drug development and approval process, as have
foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations or
policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such
amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost,
timing and completion of the clinical trials for our drug candidates. In addition, the FDA’s policies may change and additional
government regulations may be issued that could prevent, limit or delay regulatory approval of our drug candidates, or impose more
stringent product labeling and post-marketing testing and other requirements. If we are slow or unable to adapt to any such changes,
our business, prospects and ability to achieve or sustain profitability would be adversely affected.
Delays in the commencement, enrollment and completion of our clinical trials could result in increased costs to us and delay or limit
our ability to obtain regulatory approval for our drug candidates.
Delays in the commencement, enrollment and completion of clinical trials could increase our product development costs or limit
the regulatory approval of our drug candidates. We do not know whether current or future clinical trials of our drug candidates will begin
on time or at all or will be completed on schedule or at all. The commencement, enrollment and completion of our clinical trials can be
delayed for a variety of reasons, including:
•
inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites;
•
•
•
•
•
•
•
regulatory objections to commencing a clinical trial;
inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial
programs, including some that may be for the same indication as our drug candidates;
withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to
participate in our clinical trials;
inability to obtain institutional review board (“IRB”), approval to conduct a clinical trial;
difficulty recruiting and enrolling subjects to participate in clinical trials for a variety of reasons, including willingness of subjects
to undergo required study procedures, meeting the enrollment criteria for our study and competition from other clinical trial
programs for the same indication as our drug candidates;
inability to recruit and retain subjects in clinical trials due to the treatment protocol, personal issues, side effects from the therapy
or lack of efficacy; and
difficulty in importing and exporting clinical trial materials and study samples.
Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of
the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial,
competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to
other available therapies, including any new drugs that may be approved for the indications we are investigating. Furthermore, we rely
on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing
their committed activities, we have limited influence over their actual performance.
20
We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such
trials are being conducted, by the DSMB for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a
suspension or termination due to a number of factors, including:
•
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
•
•
•
•
•
•
failure to pass inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;
failure of any contract manufacturing organizations (“CMOs”), that we use to comply with current Good Manufacturing Practices
(“cGMPs”);
unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;
failure to demonstrate benefit from using the drug;
changes in the regulatory requirement and guidance; or
lack of adequate funding to continue the clinical trial due to unforeseen costs resulting from enrollment delays, requirements to
conduct additional trials and studies, increased expenses associated with the services of our CROs and other third parties or other
reasons.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and
receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these
relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a
conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated
at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or
rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of one or more of our
product candidates.
If we experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects
of our drug candidates will be harmed, and our ability to generate product revenues from any of these drug candidates will be delayed. In
addition, any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval
process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business,
financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates.
We have never submitted an NDA before and may be unable to do so for TTP399 and our other drug candidates we are developing.
The submission of a successful NDA is a complicated process. As a team, we have limited experience in preparing, submitting and
prosecuting regulatory filings, and have not submitted an NDA before. Consequently, we may be unable to successfully and efficiently
execute and complete clinical trials in a way that leads to an NDA submission and approval of any of our drug candidates. We may
require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of the drug
candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials would prevent or delay
commercialization of the drug candidates we are developing.
Our drug candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval,
or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their
sales.
Serious adverse events or undesirable side effects from any of our drug candidates could arise either during clinical development
or, if approved, after the approved product has been marketed. The results of future clinical trials may show that our drug candidates
cause serious adverse events or undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure
to obtain, marketing approval from the FDA and other regulatory authorities or could result in a more restrictive label if our drug
candidates are approved.
Further, we, and our clinical trial investigators, currently determine if serious adverse or unacceptable side effects are drug-related.
The FDA or non-U.S. regulatory authorities may disagree with our or our clinical trial investigators’ interpretation of data from clinical
trials and the conclusion by us or our clinical trial investigators that a serious adverse effect or unacceptable side effect was not drug-
related. The FDA or non-U.S. regulatory authorities may require more information, including additional preclinical or clinical data to
support approval, which may cause us to incur additional expenses, delay or prevent the approval of one of our drug candidates, and/or
delay or cause us to change our commercialization plans, or we may decide to abandon the development or commercialization of the
drug candidate altogether.
21
If any of our drug candidates cause serious adverse events or undesirable side effects either during clinical development, or after
marketing approval, if obtained:
•
regulatory authorities, IRBs, or the DSMB may impose a clinical hold, or we may decide on our own to suspend or terminate a
study, which could result in substantial delays and adversely impact our ability to continue development of the product;
•
•
•
•
•
•
•
•
•
regulatory authorities may require the addition of labeling statements, specific warnings, contraindications or field alerts to study
subjects, investigators, physicians or pharmacies;
we may be required to change the product design or the way the product is administered, conduct additional clinical trials or
change the labeling of the product;
we may be required to implement a REMS, which could result in substantial cost increases or signification limitations on
distribution or have a negative impact on our ability to successfully commercialize the product;
we may be required to limit the patients who can receive the product;
we may be subject to limitations on how we promote the product;
sales of the product may decrease significantly;
regulatory authorities may require us to take our approved product off the market;
we may be subject to litigation or product liability claims; and
our reputation may suffer.
Any of these events could prevent us from obtaining approval or achieving or maintaining market acceptance of the affected
product, if approved, or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from
generating significant revenues from the sale of our products.
If any of our drug candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that
are generated from their sales will be limited.
The commercial success of our drug candidates, if approved, will depend upon the acceptance of these products among physicians,
healthcare payors, patients and others in the medical community. The degree of market acceptance of our drug candidates will depend on
a number of factors, including:
•
•
changes in the standard of care or the availability of alternative therapies for the targeted indications for any of our drug
candidates;
limitations or warnings contained in a product’s FDA-approved labeling;
•
•
•
•
•
•
•
•
•
•
•
•
limitations in the approved indications for our drug candidates;
demonstrated clinical safety and efficacy compared to other products;
lack of significant adverse side effects;
education, sales, marketing and distribution support;
availability and degree of coverage and reimbursement from third-party payors;
timing of market introduction and perceived effectiveness of competitive products;
cost-effectiveness;
availability of alternative therapies at similar or lower cost, including generics, biosimilar and over-the-counter products;
adverse publicity about our drug candidates or favorable publicity about competitive products;
convenience and ease of administration of our products;
potential product liability claims; and
government-imposed pricing restrictions.
If our drug candidates are approved, but do not achieve an adequate level of acceptance by physicians, healthcare payors, patients
and others in the medical community, sufficient revenue may not be generated from these products, and we may not become or remain
22
profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our drug candidates may
require significant resources and may not be successful.
If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and
market our drug candidates, we may not be successful in commercializing our drug candidates if and when they are approved.
We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical drugs. To
achieve commercial success for any approved drug for which sales and marketing is not the responsibility of any strategic collaborator
that we may have in the future, we must either develop a sales and marketing organization or outsource these functions to other third
parties. In the future, we may choose to build a sales and marketing infrastructure to market our drug candidates, if and when they are
approved, or enter into collaborations with respect to the sale and marketing of our drug candidate.
There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third
parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay
any commercial launch of a drug candidate. If the commercial launch of a drug candidate for which we recruit a sales force and establish
marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and
marketing personnel.
Factors that may inhibit our efforts to commercialize our drugs on our own include:
•
•
our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any
future drugs;
•
•
•
the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative
to companies with more extensive drug lines;
unforeseen costs and expenses associated with creating an independent sales and marketing organization; and
inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.
Entering into arrangements with third parties to perform sales and marketing services may result in lower revenues from the sale
of drug or the profitability of these revenues to us than if we were to market and sell any drugs that we develop ourselves. In addition,
we may not be successful in entering into arrangements with third parties to sell and market our drug candidates or may be unable to do
so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the
necessary resources and attention to sell and market our drugs effectively. If we do not establish sales and marketing capabilities
successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates.
Even if our drug candidates receive regulatory approval, we will still be subject to ongoing obligations and continued regulatory
review, which may result in significant additional expense, and we may still face future development and regulatory difficulties.
Even if regulatory approval is obtained for any of our drug candidates, regulatory authorities may still impose significant
restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies.
Given the number of high profile adverse safety events with certain drug products, regulatory authorities may require, as a condition of
approval, costly REMS, which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling,
expedited reporting of certain adverse events, pre-approval of promotional materials and restrictions on direct-to-consumer advertising.
For example, any labeling approved for any of our drug candidates may include a restriction on the term of its use, or it may not include
one or more of our intended indications or patient populations. Furthermore, any new legislation addressing drug safety issues could
result in delays or increased costs during the period of product development, clinical trials and regulatory review and approval, as well as
increased costs to assure compliance with any new post-approval regulatory requirements.
Our drug candidates will also be subject to ongoing regulatory requirements for the labeling, packaging, storage, advertising,
promotion, record-keeping and submission of safety and other post-market information. In addition, sellers of approved products,
manufacturers and manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality
control and manufacturing procedures conform to cGMP. As such, we and our CMOs are subject to continual review and periodic
inspections to assess compliance with cGMP and the terms and conditions of approvals. Accordingly, we and others with whom we
work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and
quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply
with certain requirements concerning advertising and promotion for our products. Promotional communications with respect to
23
prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product’s approved label. As such, we may not promote our products for indications or uses for which they do not have approval.
If a regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency, or
problems with the facility where the product is manufactured, or objects to the promotion, marketing or labeling of a product, it may
impose restrictions on that product or us, including requiring withdrawal of the product from the market. If our drug candidates fail to
comply with applicable regulatory requirements, a regulatory agency may:
•
issue warning letters or untitled letters;
•
•
•
•
•
•
•
•
mandate modifications to promotional materials or require us to disseminate corrective information to healthcare practitioners or
other parties;
require us to enter into a consent decree or permanent injunction, which can include imposition of various fines, reimbursements
for inspection costs, required due dates for specific actions and penalties for noncompliance;
impose other civil or criminal penalties;
suspend or withdraw regulatory approval;
suspend any ongoing clinical trials;
refuse to approve pending applications or supplements to approved applications filed by us;
impose restrictions on operations, including costly new manufacturing requirements; or
seize or detain products or require a product recall.
The FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have
obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.
We expect that our existing and future drug candidates will face competition, and most of our competitors have significantly greater
resources than we do.
The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our potential competitors include
large pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic or biosimilar drug companies,
universities and other research institutions. Our drug candidates, if successfully developed and approved, will compete in crowded and
competitive markets. In order to compete with approved products, our drug candidates will need to demonstrate compelling advantages.
We believe the key competitive factors that will affect the development and commercial success of our drug candidates are efficacy,
safety and tolerability profile, mechanism of action, control and predictability, convenience of dosing and price and reimbursement.
Oral non-insulin agents that are currently being developed to treat type 1 diabetes that may compete with TTP399 include SGLT-
1/2 inhibitors, such as sotagliflozin, being developed by Lexicon and SGLT-2 inhibitors such as AstraZeneca’s dapagliflozin and Eli
Lilly/Boehringer Ingelheim’s empagliflozin. Some of these SGLT-1 and SGLT-2 inhibitors have been approved for certain sub-groups
of type 1 diabetics in Europe and Japan, but these therapies have not yet been approved for use in the U.S. due to safety risks including
those pertaining to diabetic ketoacidosis.
•
•
•
•
•
•
•
•
Many of our potential competitors have substantially greater:
resources, including capital, personnel and technology;
research and development capability;
clinical trial expertise;
regulatory expertise;
intellectual property rights, including patent rights;
expertise in obtaining, maintaining, defending and enforcing intellectual property rights, including patent rights;
manufacturing and distribution expertise; and
sales and marketing expertise.
24
In addition, academic and government institutions are increasingly likely to enter into exclusive licensing agreements with
commercial enterprises, including our competitors, to market commercial products based on technology developed at such institutions.
Many of these competitors have significant products approved or in development that could be competitive with our products.
Accordingly, our competitors may be more successful than us in obtaining regulatory approval for drugs and achieving widespread
market acceptance. Our competitors’ drugs may be more effective, less costly, or more effectively marketed and sold, than any drug
candidate we may commercialize and may render our drug candidates obsolete or non-competitive before we can recover the expenses
of their development and commercialization. We anticipate that we will face intense and increasing competition as new drugs enter the
market and advanced technologies become available. Finally, the development of new treatment methods for the diseases we are
targeting could render our drug candidates non-competitive or obsolete.
Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval
of our other drug candidates and affect the prices we, or they, may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates,
restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell any products for
which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be
adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any
future collaborators, may receive for any approved products.
The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United
States, and members of Congress and the Administration have stated that they will address such costs through new legislative and
administrative measures. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States.
In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval
for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that
compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or
limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be
impaired. In the European Union, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the
European Union or member state level may result in significant additional requirements or obstacles that may increase our operating
costs.
Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and
promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
drug candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA’s approval process may
significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent drug labeling and
post-marketing testing and other requirements.
Our current and future relationships with healthcare professionals, principal investigators, consultants, customers (actual and
potential) and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare
laws and regulations.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the
recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements
with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors may expose us
to broadly applicable fraud and abuse and other healthcare laws, including, without limitation:
•
the Food, Drug and Cosmetic Act (“FDCA”) is the statute that provides the FDA with authority to oversee the safety and approval
of pharmaceutical products. The FDCA vests authority with FDA to conduct inspections of sponsors conducting pharmaceutical
development, such as vTv, to protect the rights, safety and welfare of clinical trial subjects, ensure the accuracy and reliability of
clinical trial data, and verify compliance with FDA regulations. The FDCA sets forth the standards for approval of new and
generic drugs, as well as setting forth the prohibition on marketing investigational products that have not been approved by the
FDA as safe and effective. The government (FDA and SEC) use the FDCA to ensure that companies do not mislead the medical,
patient or investor communities about investigational products prior to their approval. To that end, the FDCA prohibits “off-label
promotion” of any investigational or approved product for any uses, doses or populations, except that set forth in the full
prescribing information approved by the FDA. While physicians can prescribe a product for any dose, purpose or population in
25
•
•
•
•
•
•
•
•
their medical judgment, manufacturers can only market products for their FDA-approved dose, purpose and population. There are
significant civil and criminal penalties that attach to violations of the FDCA, including strict liability misdemeanors for
responsible corporate officers, even if such officers were not involved in or aware of the underlying wrongdoing;
the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which
payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person
or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In
addition, the Affordable Care Act provided that the government may assert that a claim including items or services resulting from
a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties,
including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to
be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or
fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
the Foreign Corrupt Practices Act that prohibits payments to foreign public officials relating to official acts. In addition to its
prohibition on bribery of foreign government officials, the Act requires companies to maintain accurate records and have vigorous
internal controls. The DOJ and SEC have made FCPA enforcement a high priority. In addition, other anti-corruption laws such as
the UK Bribery Act are even broader than the FCPA in that they apply to bribes offered to any person, not just government
officials. There are significant criminal and civil penalties and fines that attach to violations of the FCPA;
the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined
to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an
item or service that was not provided as claimed or is false or fraudulent;
HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a
scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless
of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by
any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for,
healthcare benefits, items or services relating to healthcare matters. A person or entity does not need to have actual knowledge of
the statute or specific intent to violate it to have committed a violation;
HIPAA, as amended by HITECH, and their respective implementing regulations, which impose obligations on covered entities,
including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that
create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect
to safeguarding the privacy, security and transmission of individually identifiable health information;
the federal Physician Payments Sunshine Act and its implementing regulations, which imposed annual reporting requirements for
certain manufacturers of drugs, devices, biologicals and medical supplies for payments and “transfers of value” provided to
physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family
members; and
analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including
private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict
payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state
and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from
each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and
regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business activities, including
our relationships with physician consultants, some of whom may prescribe our product candidates, if approved, in the future, may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our
operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be
subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion
26
from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our
operations, which could significantly harm our business.
If we try to obtain approval to commercialize any products outside the United States, many of the same risks that apply to obtaining
approvals in the United States will likely apply to such a process, and even if we obtain approval to commercialize any such products
outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
If we try to obtain approval to commercialize any of our products outside the United States, many of the same risks with respect to
obtaining such approvals in the United States will apply to that process. If any of our drug candidates are approved for
commercialization outside of the United States, we intend to enter into agreements with third parties to market them on a worldwide
basis or in more limited geographical regions. In that event, we expect that we will be subject to additional risks related to entering into
international business relationships, including:
•
•
reduced protection for intellectual property rights, including trade secret and patent rights;
different regulatory requirements for drug approvals;
•
•
•
•
•
•
•
•
•
existing tariffs, trade barriers and regulatory requirements and expected or unexpected changes;
economic weakness, including inflation, or political instability in foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign taxes, including withholding of payroll taxes;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations
incident to doing business in another country;
workforce uncertainty in countries where labor unrest is more or less common than in the United States;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes,
hurricanes, floods and fires; and
difficulty in importing and exporting clinical trial materials and study samples.
Risks Relating to Our Dependence on Third Parties
We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop
and commercialize our drug candidates successfully, if at all.
We intend to seek collaborative relationships for the development and/or commercialization of our drug candidates, including
TTP399. Failure to obtain a collaborative relationship for these candidates, particularly in the European Union and for other markets
requiring extensive sales efforts, may significantly impair the potential for our drug candidates. We also will need to enter into
collaborative relationships to provide funding to support our other research and development programs. The process of establishing and
maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:
•
a collaboration partner may shift its priorities and resources away from our drug candidates due to a change in business strategies,
or a merger, acquisition, sale or downsizing;
•
•
•
•
•
•
a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results,
manufacturing issues, a change in business strategy, a change of control or other reasons;
a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration;
a collaboration partner may not devote sufficient capital or resources towards our drug candidates;
a collaboration partner may change the success criteria for a drug candidate thereby delaying or ceasing development of such
candidate;
a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones
tied to such activities, thereby impacting our ability to fund our own activities;
a collaboration partner could develop a product that competes, either directly or indirectly, with our drug candidate;
27
•
•
•
•
•
a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the
marketing, distribution or sale of a product;
a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to
meet demand requirements;
a partner may exercise a contractual right to terminate a strategic alliance;
a dispute may arise between us and a partner concerning the research, development or commercialization of a drug candidate
resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or
arbitration which may divert management attention and resources; and
a partner may use our products or technology in such a way as to invite litigation from a third party.
Any collaborative partners we enter into agreements with in the future may shift their priorities and resources away from our drug
candidates or seek to renegotiate or terminate their relationships with us. If any collaborator fails to fulfill its responsibilities in a timely
manner, or at all, our research, clinical development, manufacturing or commercialization efforts related to that collaboration could be
delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been
the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to
successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of
our drug candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital.
We rely on third parties to conduct, supervise and monitor certain of our clinical trials, and if those third parties perform in an
unsatisfactory manner, it may harm our business.
We rely on contract research organizations (“CROs”) and clinical trial sites to ensure the proper and timely conduct of certain of
our clinical trials. While we have agreements governing their activities, and continue to monitor their compliance with those agreements
as well as federal standards and regulations, we have limited influence over their actual performance. We will control only certain
aspects of our CROs’ activities. Nevertheless, we will be responsible for ensuring that our clinical trials are conducted in accordance
with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory
responsibilities.
We and our CROs are required to comply with the FDA’s good clinical practices requirements (“GCPs”) for conducting,
recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of clinical trial participants are protected. The FDA enforces these GCPs through periodic inspections of
trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data
generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before
approving any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with GCPs. In
addition, our clinical trials conducted by third parties will require a sufficiently large number of test subjects to evaluate the safety and
effectiveness of a drug candidate. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of
patients, our clinical trials may be delayed or we may be required to repeat such clinical trials, which would delay the regulatory
approval process.
Our CROs are not our employees, and although we monitor their activities related to our trials, we are not able to control whether
or not they devote sufficient time and resources to our clinical trials. If our CROs do not successfully carry out their contractual duties or
obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our drug candidates. As
a result, our financial results and the commercial prospects for such drug candidates would be harmed, our costs could increase, and our
ability to generate revenues could be delayed.
We also rely on other third parties to store and distribute drug products for our clinical trials. Any performance failure on the part
of our distributors could delay clinical development or marketing approval of our drug candidates or commercialization of our products,
if approved, producing additional losses and depriving us of potential product revenue.
We do not have multiple sources of supply for the components used in TTP399 and our other drug candidates. If we were to lose a
supplier, it could have a material adverse effect on our ability to complete the development of TTP399 or our other drug candidates.
If we obtain regulatory approval for TTP399 or our other drug candidates, we would need to expand the supply of their components
in order to commercialize them.
We do not have multiple sources of supply for the components used in our drug candidates. We also do not have long-term supply
agreements with any of our suppliers. If for any reason we are unable to obtain drug substance or drug product from the manufacturers
28
we select, we would have to seek to obtain these from other manufacturers. We may not be able to establish additional sources of supply
for our drug candidates, or may be unable to do so on acceptable terms. Such suppliers are subject to regulatory requirements, covering
manufacturing, testing, quality control and record keeping relating to our drug candidates and subject to ongoing inspections by the
regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions.
The number of suppliers of the raw material components of our drug candidates is limited. In the event it is necessary or desirable
to acquire supplies from an alternative supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It could
also require significant time and expense to redesign our manufacturing processes to work with another company.
As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to
commercialization. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An
alternative vendor would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA
or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for
commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and
commercial timelines.
If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on
our ability to complete the development of our drug candidates or, if we obtain regulatory approval for our drug candidates, to
commercialize them.
We intend to rely on third-party manufacturers to produce our drug candidates. If we experience problems with any of these
suppliers, the manufacturing of our drug candidates or products could be delayed.
We do not have the capability to manufacture our drug candidates and do not intend to develop that capability. In order to continue
to develop our drug candidates, apply for regulatory approvals and ultimately commercialize products, we need to develop, contract for
or otherwise arrange for the necessary manufacturing capabilities. The facilities used by our CMOs to manufacture our drug candidates
must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control
the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory
requirements, known as cGMPs, for manufacture of both active drug substances and finished drug products. If our CMOs cannot
successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA or others, they will
not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, although we monitor our
suppliers and their compliance with our contractual terms and federal laws and regulations, we do not control the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign
regulatory authority does not approve these facilities for the manufacture of our drug candidates or if it withdraws any such approval in
the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our drug candidates, if approved.
In addition, there are a limited number of manufacturers that operate under the FDA’s cGMP regulations capable of manufacturing
our drug candidates. As a result, we may have difficulty finding manufacturers for our drug candidates with adequate capacity for our
needs. If we are unable to arrange for third-party manufacturing of our drug candidates on a timely basis, or to do so on commercially
reasonable terms, we may not be able to complete development of our drug candidates or market them.
Reliance on third-party manufacturers entails risks to which we might not be subject if we manufactured drug candidates
ourselves, including:
•
the limited number of manufacturers that could produce our drug candidates for us;
•
•
•
•
•
•
•
•
the inability to meet our product specifications and quality requirements consistently;
inability to access production facilities on a timely basis;
inability or delay in increasing manufacturing capacity;
manufacturing and product quality issues related to scale-up of manufacturing;
costs and validation of new equipment and facilities required for commercial level activity;
a failure to satisfy the FDA’s cGMP requirements and similar foreign standards on a consistent basis;
the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;
29
•
•
•
•
the reliance on a single source of supply which, if unavailable, would delay our ability to complete our clinical trials or to sell any
product for which we have received marketing approval;
the lack of qualified backup suppliers for supplies that are currently purchased from a single source supplier;
carrier disruptions or increased costs that are beyond our control; and
the failure to deliver products under specified storage conditions and in a timely manner.
Any of these risks could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our
products, cause us to incur higher costs and prevent us from commercializing our drug candidates successfully. Manufacturing of our
drug candidates and any approved products could be disrupted or halted if our third-party manufacturers do not comply with cGMP or
foreign manufacturing standards, even if the compliance failure does not relate to our drug candidates or approved products.
Furthermore, if any of our drug candidates are approved and our third-party manufacturers fail to deliver the required commercial
quantities of finished product on a timely basis and at commercially reasonable prices and we are unable to find one or more
replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and
on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years
to establish an alternative source of supply for our drug candidates and to have any such new source approved by the FDA or a foreign
regulator.
Risks Relating to Our Intellectual Property
It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.
Our commercial success will depend in part on our ability to:
apply for, obtain, maintain and enforce patents;
protect trade secrets and other confidential and proprietary information; and
operate without infringing upon the proprietary rights of others.
•
•
•
We will be able to protect our proprietary technology from unauthorized use by third parties only to the extent that such
proprietary rights are covered by regulatory exclusivity, valid and enforceable patents or are effectively maintained as trade secrets. Any
non-confidential disclosure to or misappropriation by third parties of our confidential or proprietary information could enable
competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.
The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or
future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable
cost or in a timely manner. It is also possible that we or our current licensors or licensees, or any future licensors or licensees, will fail to
identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to
obtain patent protection on them. Therefore, these and any of our patents and patent applications may not be prosecuted and enforced in
a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or
patent applications may exist, or may arise in the future, for example with respect to proper priority claims or inventorship. If we or our
current licensors or licensees, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual
property rights, such rights may be reduced or eliminated. Moreover, in some circumstances, we may not have the right to control the
preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license
to third parties. Therefore, such patents and patent applications may not be prosecuted and enforced in a manner consistent with the best
interests of our business. If our current licensors or licensees, or any future licensors or licensees, are not fully cooperative or disagree
with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are
material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and
unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may harm our business.
The patent applications that we own or license may fail to result in issued patents in the United States or in other countries. Even if
patents do issue on such patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in
such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the
United States Patent and Trademark Office (“USPTO”) Patent Trial and Appeals Board at any time within the one-year period following
that person’s receipt of an allegation of infringement of the patents. Patents granted by the European Patent Office may be similarly
opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions. In
the United States, Europe and other jurisdictions, third parties can raise questions of validity with a patent office even before a patent has
granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent
applications we hold or pursue with respect to our product candidates is successfully challenged, then our ability to commercialize such
30
product candidates could be negatively affected, and we may face unexpected competition that could harm our business. Further, if we
encounter delays in our clinical trials, the period of time during which we or our collaborators could market our product candidates
under patent protection would be reduced.
The degree of future protection of our proprietary rights is uncertain. Patent protection may be unavailable or severely limited in
some cases and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
•
we might not have been the first to invent or the first to file the inventions covered by each of our pending patent applications and
issued patents;
•
•
•
•
•
others may be able to make, use, sell, offer to sell or import products that are similar to our products or product candidates but that
are not covered by the claims of our patents; others may independently develop similar or alternative technologies or duplicate any
of our technologies;
the proprietary rights of others may have an adverse effect on our business;
any proprietary rights we do obtain may not encompass commercially viable products, may not provide us with any competitive
advantages or may be challenged by third parties;
any patents we obtain or our in-licensed issued patents may not be valid or enforceable; or
we may not develop additional technologies or products that are patentable or suitable to maintain as trade secrets.
If we or our current licensors or licensees, or any future licensors or licensees, fail to prosecute, maintain and enforce patent
protection for our product candidates, our ability to develop and commercialize our product candidates could be harmed and we might
not be able to prevent competitors from making, using and selling competing products. This failure to properly protect the intellectual
property rights relating to our product candidates could harm our business, financial condition and operating results. Moreover, our
competitors may independently develop equivalent knowledge, methods and know-how.
Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope
of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaborators were to initiate legal
proceedings against a third party to enforce a patent covering the product candidate, the defendant could assert an affirmative defense or
counterclaim that our patent is not infringed, invalid and/or unenforceable. In patent litigation in the United States, defendant defenses
and counterclaims alleging noninfringement, invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, definiteness and enablement.
Patents may be unenforceable if someone connected with prosecution of the patent withheld material information from the USPTO, or
made a misleading statement, during prosecution. The outcomes of proceedings involving assertions of invalidity and unenforceability
are unpredictable. It is possible that prior art of which we and the patent examiner were unaware during prosecution exists, which would
render our patents invalid. Moreover, it is also possible that prior art may exist that we are aware of, but that we do not believe are
relevant to our current or future patents, that could nevertheless be determined to render our patents invalid. If a defendant were to
prevail on a legal assertion of invalidity and/or unenforceability of our patents covering one of our product candidates, we would lose at
least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would harm our business.
Moreover, our competitors could counterclaim in any suit to enforce our patents that we infringe their intellectual property. Furthermore,
some of our competitors have substantially greater intellectual property portfolios, and resources, than we do.
Our ability to stop third parties from using our technology or making, using, selling, offering to sell or importing our products is
dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If any patent we
currently or in the future may own or license is deemed not infringed, invalid or unenforceable, it could impact our commercial success.
We cannot predict the breadth of claims that may be issued from any patent applications we currently or may in the future own or license
from third parties.
To the extent that consultants or key employees apply technological information independently developed by them or by others to
our product candidates, disputes may arise as to who has the proprietary rights to such information and product candidates, and certain
of such disputes may not be resolved in our favor. Consultants and key employees that work with our confidential and proprietary
technologies are required to assign all intellectual property rights in their inventions and discoveries created during the scope of their
work to our company. However, these consultants or key employees may terminate their relationship with us, and we cannot preclude
them indefinitely from dealing with our competitors.
If we are unable to prevent disclosure of our trade secrets or other confidential information to third parties, our competitive position
may be impaired.
We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or
obtainable. Our ability to stop third parties from obtaining the information or know-how necessary to make, use, sell, offer to sell or
import our products or practice our technology is dependent in part upon the extent to which we prevent disclosure of the trade secrets
31
that cover these activities. Trade secret rights can be lost through disclosure to third parties. Although we use reasonable efforts to
protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally
or willfully disclose our trade secrets to third parties, resulting in loss of trade secret protection. Moreover, our competitors may
independently develop equivalent knowledge, methods and know-how, which would not constitute a violation of our trade secret rights.
Enforcing a claim that a third party is engaged in the unlawful use of our trade secrets is expensive, difficult and time consuming, and
the outcome is unpredictable. In addition, recognition of rights in trade secrets and a willingness to enforce trade secrets differs in certain
jurisdictions.
Changes to the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby
impairing our ability to protect our products.
As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity and is therefore costly,
time consuming and inherently uncertain.
If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable
outcome in that litigation could harm our business.
Our commercial success depends significantly on our ability to operate without infringing, violating or misappropriating the
patents and other proprietary rights of third parties. Our own technologies may infringe, violate or misappropriate the patents or other
proprietary rights of third parties, or we may be subject to third-party claims of such infringement. Numerous U.S. and foreign issued
patents and pending patent applications owned by third parties, exist in the fields in which we are developing our product candidates.
Because some patent applications may be maintained in secrecy until the patents are issued, because publication of patent applications is
often delayed, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that we were
the first to invent the technology or that others have not filed patent applications for technology covered by our pending applications. We
may not be aware of patents that have already issued that a third party might assert are infringed by our product candidates. It is also
possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be
found to be infringed by our product candidates. Moreover, we may face Inter Partes Review (“IPR”) proceedings before the USPTO or
patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent
portfolio may thus have no deterrent effect. In the future, we may agree to indemnify our manufacturing partners against certain
intellectual property claims brought by third parties.
Intellectual property litigation involves many risks and uncertainties, and there is no assurance that we will prevail in any lawsuit
brought against us. Third parties making claims against us for infringement, violation or misappropriation of their intellectual property
rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and
commercialize our product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay
research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims,
regardless of their merit, would cause us to incur substantial expenses and, would be a substantial diversion of resources from our
business. In the event of a successful claim of any such infringement, violation or misappropriation, we may need to obtain licenses from
such third parties and we and our partners may be prevented from pursuing product development or commercialization and/or may be
required to pay damages. We cannot be certain that any licenses required under such patents or proprietary rights would be made
available to us, or that any offer to license would be made available to us on commercially reasonable terms. If we cannot obtain such
licenses, we and our collaborators may be restricted or prevented from manufacturing and selling products employing our technology.
These adverse results, if they occur, could adversely affect our business, results of operations and prospects, and the value of our shares.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
consuming and unsuccessful.
The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other
intellectual property rights. The defense and prosecution of contractual or intellectual property lawsuits, USPTO interference or
derivation proceedings, European Patent Office oppositions and related legal and administrative proceedings in the United States,
Europe and other countries, involve complex legal and factual questions. As a result, such proceedings may be costly and time-
consuming to pursue and their outcome is uncertain.
Litigation may be necessary to:
•
•
protect and enforce our patents and any future patents issuing on our patent applications;
enforce or clarify the terms of the licenses we have granted or been granted or may grant or be granted in the future;
32
•
•
protect and enforce trade secrets, know-how and other proprietary rights that we own or have licensed, or may license in the
future; or
determine the enforceability, scope and validity of the proprietary rights of third parties and defend against alleged patent
infringement.
Competitors may infringe our intellectual property. As a result, we may be required to file infringement claims to stop third-party
infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an
infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party
from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant
an injunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more
of our patents at risk of being invalidated, interpreted narrowly, or amended such that they do not cover our product candidates.
Moreover, such adverse determinations could put our patent applications at risk of not issuing, or issuing with limited and potentially
inadequate scope to cover our product candidates or to prevent others from marketing similar products.
IPR, interference, derivation or other proceedings brought at the USPTO, may be necessary to determine the priority or
patentability of inventions with respect to our patent applications or those of our licensors or potential collaborators. Litigation or
USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign
litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not
be able, alone or with our licensors or potential collaborators, to prevent misappropriation of our proprietary rights, particularly in
countries where the laws may not protect such rights as fully as in the United States.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other
proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation
or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the
results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive
these results to be negative, the market price for our common stock could be significantly harmed.
Some of our competitors may be able to sustain the costs of patent-related disputes, including patent litigation, more effectively
than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and
continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
We may not be able to enforce our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively
expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability
to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property
laws. Additionally, laws of some countries outside of the United States do not afford intellectual property protection to the same extent
as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual
property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the
enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or
the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws
under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have
not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where
we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete
with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and
divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property
rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in
which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be
inadequate.
If we do not obtain patent term extensions for our drug candidates, the length of our patent exclusivity will be shorter which may
harm our business materially.
Depending upon the timing, duration and specifics of any FDA marketing approval of our drug candidates, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of
1984 (“Hatch-Waxman Act”). The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent
term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total
33
of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension,
and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However,
we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory
review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to
satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may
obtain approval of competing products following the original expiration dates of our patents, and our business may be materially
harmed.
Risks Relating to Employee Matters and Managing Growth
We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing
growth.
As we advance our drug candidates through preclinical studies and clinical trials and develop new drug candidates, we may need
to increase our product development, scientific and administrative headcount to manage these programs. If we commercialize our
products, we may need to expand our staff further, particularly in sales and marketing. See “—Risks Relating to the Development,
Regulatory Approval, and Commercialization of Our Drug Candidates.” We do not presently have the capability to sell, distribute and
market our drug candidates. If we are unable to establish an effective sales force and marketing infrastructure, or enter into acceptable
third-party sales and marketing or licensing arrangements, we may not be able to commercialize our drug candidates successfully. In
addition, to meet our obligations as a public company, we will need to increase our general and administrative capabilities. Our
management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively
manage our operations, growth and various projects requires that we:
•
successfully attract and recruit new employees with the expertise and experience we will require;
•
•
•
manage our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;
develop a marketing, distribution and sales infrastructure if we seek to market our products directly, or successfully partner with a
third-party organization that will oversee those efforts; and
continue to improve our operational, manufacturing, financial and management controls, reporting systems and procedures.
If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely
affected.
We may not be able to manage our business effectively if we are unable to attract and retain key personnel.
We may not be able to attract or retain qualified management, finance, scientific and clinical personnel in the future due to the
intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and
retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the
achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.
Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the
development, regulatory, commercialization and business development expertise of our executive officers and key employees. If we lose
one or more of our executive officers or key personnel, our ability to implement our business strategy successfully could be seriously
harmed. Any of our executive officers or key employees may terminate their employment at any time. Replacing executive officers and
key employees may be difficult, will be costly and may take an extended period of time because of the limited number of individuals in
our industry with the mix of skills and experience required to develop, gain regulatory approval of and commercialize products
successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these
additional key personnel. Our failure to attract and retain key personnel could materially harm our business.
Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or
other improper activities, including noncompliance with legal, compliance or regulatory standards and requirements.
We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and
collaborators may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless
and/or negligent conduct or unauthorized activities that violate the regulations of the FDA and non-U.S. regulators, including those laws
requiring the reporting of true, complete and accurate information to the FDA and non-U.S. regulators, healthcare fraud and abuse laws
and regulations in the United States and abroad, or laws that require the reporting of true and accurate financial information and data. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended
34
to prevent fraud, misconduct, kickbacks, self-dealing, pre-market promotion, and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs
and other business arrangements. These activities also include the improper use or disclosure of information obtained in the course of
clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted new comprehensive
compliance policies, and revised our code of conduct, but it is not always possible to identify and deter employee or non-employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and
administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.
Other Risks Relating to Our Business
The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect
our business, results of operations and financial condition.
We could be negatively affected by the widespread outbreak of an illness or any other communicable disease, or any other public
health crisis that results in economic and trade disruptions, including the disruption of global supply chains. In March 2020, the World
Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted
global supply chains, and created significant volatility and disruption of financial markets. Due to the spread of COVID-19, many
countries around the world and jurisdictions in the United States have imposed quarantines and restrictions on travel and mass
gatherings to slow the spread of the virus. Further, “non-essential” businesses have been required to close operations or shift to a remote
working environment.
Due to the various restrictions put into effect by governments around the world, including the United States and Canada, health
professionals may reduce staffing and reduce or postpone meetings with clients in response to the spread of an infectious disease. Such
events may result in a period of business disruption, and in reduced operations, any of which could materially affect our business,
financial condition and results of operations.
Quarantines, stay-at-home orders and other limitations can disrupt our research and administrative functions, regardless of whether
we are actually forced to close our own facilities. Similar disruptions may also affect other organizations and persons that we collaborate
with or whose services we are dependent on. The need for our employees and business partners to work remotely also creates greater
potential for risks related to cybersecurity, confidentiality and data privacy.
With respect to the COVID-19 outbreak specifically, such outbreak could also potentially affect the operations of the FDA, EMA
or other health authorities, which could result in delays in meetings related to planned clinical trials. Further, it may also slow potential
enrollment of our ongoing clinical trials. The COVID-19 outbreak and mitigation measures also have had, and may continue to have, an
adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including
impairing our ability to raise capital when needed.
The extent to which the COVID-19 outbreak impacts our future business and operations will depend on developments that are
highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the
actions to contain its impact. As a result, there can be no assurance as to the manner and extent to which the COVID-19 outbreak (or
other large-scale disruption) could impact our operations, results and financial condition.
The recent outbreak of COVID-19 may materially and adversely affect our clinical trials, the operations of our licensees and our
financial results.
The extent to which COVID-19 may impact our clinical trials will depend on future developments, which are highly uncertain and
cannot be predicted with confidence, such as the duration of the outbreak, the severity of COVID-19, or the effectiveness of actions to
contain and treat for COVID-19. The continued spread of COVID-19 globally could adversely impact recruitment for our ongoing
clinical trials or our ability to recruit patients for future planned clinical trials. COVID-19 may also affect the employees and operations
of third-party contract research organizations located in affected geographies that we rely upon to carry out such enrollments and trials.
Further, it may delay the initiation of any additional clinical trials we are planning for which we require additional approval or are
seeking guidance from the FDA or other regulatory agencies. The negative impacts of COVID-19 in these instances may result in
delays to our operational plans, increases in our operating expenses, and may have a material adverse effect on our financial results.
35
Additionally, COVID-19 may hinder the ability of our license partners to continue the development of our licensed product
candidates. This may result in the delay or the inability of the partners to execute on their development plans which, in turn, may cause
delays in or the inability to achieve the clinical, regulatory and sales milestones which trigger payments to us under the terms of our
license agreements. This may have a material adverse effect on our financial results and operations as the related milestone payments
may not be received at the expected time, if at all.
We may use our financial and human resources to pursue a particular research program or drug candidate and fail to capitalize on
programs or drug candidates that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and human resources, we have here to date focused primarily on the regulatory approval of
azeliragon and TTP399. As a result, we may have foregone or delayed the pursuit of opportunities with other drug candidates or for
other indications that could later prove to have had greater commercial potential. Our future resource allocation decisions may cause us
to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on existing and future drug
candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial
potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through strategic
alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole
development and commercialization rights to such drug candidate, or we may allocate internal resources to a drug candidate in a
therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of any future products we develop.
We face an inherent risk of product liability as a result of the clinical testing of our drug candidates and will face an even greater
risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be
otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations
of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a
breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves
against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a
successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability
claims may result in:
•
decreased demand for any drug candidates or products we develop;
•
•
•
•
•
•
•
•
•
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants or delay or cancellation of clinical trials;
costs to defend the related litigation;
a diversion of management’s time and our resources;
substantial monetary awards to trial participants or patients;
regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue;
the inability or delay in our ability to commercialize any products we develop; and
a decline in our share price.
Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect
against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry
clinical trial liability insurance in the amount of $10.0 million in the aggregate. Although we maintain such insurance, any claim that
may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our
insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and
deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts
awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we
may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain
insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for
marketing for any drug product, we intend to expand our insurance coverage to include the sale of that product, however, we may be
unable to obtain this liability insurance on commercially reasonable terms.
36
Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant
uninsured liabilities.
We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain
include general liability, employment practices liability, property, auto, workers’ compensation, umbrella, clinical trial and directors’
and officers’ insurance. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage.
Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results
of operations.
The market for our proposed products is rapidly changing and competitive, and new drugs and new treatments that may be developed
by others could impair our ability to maintain and grow our businesses and remain competitive.
The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change. Developments by
others may render proposed products noncompetitive or obsolete, or we may be unable to keep pace with technological developments or
other market factors. Technological competition from pharmaceutical and biotechnology companies, universities, governmental entities
and others diversifying into the field is intense and is expected to increase.
As a company with nominal revenues engaged in the development of drug technologies, our resources are limited, and we may
experience technical challenges inherent in such technologies. Competitors have developed or are in the process of developing
technologies that are, or in the future may be, the basis for competition. Some of these technologies may have an entirely different
approach or means of accomplishing similar therapeutic effects compared to our proposed products. Our competitors may develop drugs
that are safer, more effective or less costly than our proposed products and, therefore, present a serious competitive threat to us.
The potential widespread acceptance of therapies that are alternatives to ours may limit market acceptance of our drug candidates,
even if commercialized. Some of our targeted diseases and conditions can also be treated by other medication. These treatments may be
widely accepted in medical communities and have a longer history of use or be offered at a more competitive price. The established use
of these competitive drugs may limit the potential for our technologies, formulations and products to receive widespread acceptance if
commercialized.
Therefore, changes in the market for our products and the availability of new or alternative treatments could have a material
adverse effect on our businesses, financial conditions and results of operations.
Our business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cyber-
security.
Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are
vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures,
cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization or persons with access to
systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion,
including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and
sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause
interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of
clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Also, confidential patient and other information may be compromised in
a cyber-attack or cyber-intrusion. To the extent that any disruption or security breach was to result in a loss of or damage to our data or
applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability,
damage to our reputation, and the further development of our drug candidates could be delayed.
Risks Related to our Common Stock
MacAndrews has substantial influence over our business, and their interests may differ from our interests or those of our other
stockholders.
MacAndrews holds, directly or indirectly, a majority of our combined voting power. Due to its ownership and rights under our
investor rights agreement, amended and restated certificate of incorporation and amended and restated bylaws, MacAndrews has the
power to control us and our subsidiaries, including the power to:
•
nominate a majority of our directors, elect a majority of our directors and appoint our executive officers, set our management
policies and exercise overall control over our company and subsidiaries;
•
determine the composition of the committees on our Board of Directors;
37
•
•
agree to sell or otherwise transfer a controlling stake in our company; and
determine the outcome of substantially all actions requiring stockholder approval, including transactions with related parties,
corporate reorganizations, acquisitions and dispositions of assets and dividends.
The interests of MacAndrews may differ from our interests or those of our other stockholders and the concentration of control in
MacAndrews will limit other stockholders’ ability to influence corporate matters. The concentration of ownership and voting power with
MacAndrews may also delay, defer or even prevent an acquisition by a third party or other change of control of our company and may
make some transactions more difficult or impossible without the support of MacAndrews, even if such events are in the best interests of
our other stockholders. The concentration of voting power with MacAndrews may have an adverse effect on the price of our Class A
common stock. Our company may take actions that our other stockholders do not view as beneficial, which may adversely affect our
results of operations and financial condition and cause the value of our Class A common stock to decline.
Our directors who have relationships with MacAndrews may have conflicts of interest with respect to matters involving our company.
One of our directors is affiliated with MacAndrews. This director will have fiduciary duties to us and in addition will have duties
to MacAndrews. In addition, our amended and restated certificate of incorporation provides that none of MacAndrews, any of our non-
employee directors who are employees, affiliates or consultants of MacAndrews or its affiliates (other than us or our subsidiaries) or any
of their respective affiliates will be liable to us or our stockholders for breach of any fiduciary duty by reason of the fact that any such
individual directs a corporate opportunity to MacAndrews or its affiliates instead of us, or does not communicate information regarding
a corporate opportunity to us that such person or affiliate has directed to MacAndrews or its affiliates. As a result, such circumstances
may entail real or apparent conflicts of interest with respect to matters affecting both us and MacAndrews, whose interests, in some
circumstances, may be adverse to ours. In addition, as a result of MacAndrews’ indirect ownership interest, conflicts of interest could
arise with respect to transactions involving business dealings between us and MacAndrews or their affiliates, including potential
business transactions, potential acquisitions of businesses or properties, the issuance of additional securities, the payment of dividends
by us and other matters.
We do not anticipate paying cash dividends on our Class A common stock, and accordingly, stockholders must rely on stock
appreciation for any return on their investment.
We have never declared or paid any cash dividend on our Class A common stock and do not anticipate paying cash dividends on
our Class A common stock in the future. As a result, the only return to stockholders will be appreciation in the price of our Class A
common stock, which may never occur. Investors seeking cash dividends should not invest in our Class A common stock.
Our share price may be volatile, which could subject us to securities class action litigation and result in substantial losses for our
stockholders.
The market price of shares of our Class A common stock could be subject to wide fluctuations in response to many risk factors
listed in this section, and others beyond our control, including:
•
results and timing of our clinical trials and receipt of data from the trials;
•
•
•
•
•
•
•
•
•
•
•
the availability of cash or financing to continue our clinical trials and other operations;
results of clinical trials of our competitors’ products;
failure or discontinuation of any of our research programs;
delays in the development or commercialization of our potential products;
regulatory actions with respect to our products or our competitors’ products;
actual or anticipated fluctuations in our financial condition and operating results;
actual or anticipated changes in our growth rate relative to our competitors;
actual or anticipated fluctuations in our competitors’ operating results or changes in their growth rate;
competition from existing products or new products that may emerge;
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital
commitments;
issuance of new or updated research or reports by securities analysts;
38
•
•
•
•
•
•
•
•
•
•
fluctuations in the valuation of companies perceived by investors to be comparable to us;
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
additions or departures of key management or scientific personnel;
disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain,
maintain, defend or enforce proprietary rights relating to our products and technologies;
announcement or expectation of additional financing efforts;
sales of our Class A common stock by us, our insiders or our other stockholders;
issues in manufacturing our potential products;
market acceptance of our potential products;
market conditions for biopharmaceutical stocks in general; and
general economic and market conditions.
Furthermore, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect
the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the
operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and
market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price
of shares of our Class A common stock. In addition, such fluctuations could subject us to securities class action litigation, which could
result in substantial costs and divert our management’s attention from other business concerns, which could potentially harm our
business. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price at which they
purchased their shares.
The trading market for our Class A common stock will be influenced by the research and reports that equity research analysts
publish about us and our business.
The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable
commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us
regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.
A substantial portion of our total outstanding shares may be sold into the market at any time. This could cause the market price of
our Class A common stock to drop significantly, even if our business is doing well.
The market price of our Class A common stock could decline as a result of sales of a large number of shares of our Class A
common stock or the perception that such sales could occur. These sales, or the possibility that these sales may occur, also might make it
more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.
As of December 31, 2020, MacAndrews and its affiliates hold 23,084,267 non-voting common units of vTv LLC (“vTv Units”)
and the same number of shares of vTv Therapeutics Inc. Class B common stock as well as an aggregate of 36,606,212 shares of our
Class A common stock. As a result, MacAndrews and its affiliates hold shares representing approximately 77.4% of the combined
voting power of our outstanding common stock. Pursuant to the terms of the Exchange Agreement among the Company, vTv LLC and
the holders of vTv Units party thereto (the “Exchange Agreement”), vTv Units (along with the corresponding number of shares of our
Class B common stock) will be exchangeable for (i) shares of our Class A common stock on a one-for-one basis or (ii) cash (based on
the market price of the shares of Class A common stock), at our option (as the managing member of vTv Therapeutics LLC). Shares of
our Class A common stock issuable upon an exchange of vTv Units as described above would be considered “restricted securities,” as
that term is defined in Rule 144 under the Securities Act, unless the exchange is registered under the Securities Act.
On August 13, 2015, we filed a registration statement under the Securities Act registering 3,250,000 shares of our Class A
common stock reserved for issuance under our 2015 Plan. On August 3, 2020, we filed a registration statement under the Securities Act
to register a further 3,750,000 shares of our Class A common stock reserved for issuance under our 2015 Plan, as amended.
We also have issued warrants to purchase 1,823,917 shares of our Class A common stock to MacAndrews. Further, as part of our
Loan Agreement, we issued warrants to purchase 190,586 shares of our Class A common stock to our lenders.
On February 27, 2018, we filed a shelf registration statement on Form S-3 through which we may offer and sell from time to time
shares of our Class A common stock with an aggregate initial offering price of up to $250,000,000. However, in no event will we sell
Class A common stock under this registration statement with a value exceeding more than one-third of the “public float” (the market
39
value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any
12-calendar month period so long as our public float remains below $75 million.
Further, we have entered into an investor rights agreement with an affiliate of MacAndrews providing certain governance and
registration rights. Pursuant to the investor rights agreement, we filed a shelf registration statement on Form S-3 in June 2019 to register
certain shares previously issued to MacAndrews.
Future sales and issuances of our Class A common stock or rights to purchase Class A common stock, including pursuant to our
equity incentive plans or the exercise of outstanding warrants, could result in additional dilution of the percentage ownership of our
stockholders and could cause our stock price to fall.
We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise
additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell Class A common stock,
convertible securities or other equity securities, including under the LPC Purchase Agreement, the ATM Offering, or pursuant to
warrants issued to M&F Group and our previous lenders, and such sales could result in substantial dilution to existing investors.
We incur significant costs and devote substantial management time as a result of operating as a public company and additional
resources would be required if we lose our “smaller reporting company” and “non-accelerated filer” status.
As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with
applicable provisions of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the Securities and Exchange
Commission, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company
responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial
reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and
are important to help prevent financial fraud.
However, we are currently a “smaller reporting company” and “non-accelerated filer” under the current SEC rules. As such we
take advantage of exemptions from certain reporting requirements including exemption from compliance with the auditor attestation
requirements of Section 404 of the Sarbanes Oxley Act and reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements. Should we lose these statuses, we may no longer be exempt from these requirements and expect
that compliance with the requirements will increase our legal and financial compliance costs and will make some activities more time
consuming and costly. In addition, our management and other personnel will need to divert attention from operational and other business
matters to devote substantial time to these public company requirements. In particular, we expect to incur significant expenses and
devote substantial management effort toward ensuring compliance with the requirements of Section 404(b) of the Sarbanes-Oxley Act.
In that regard, we currently do not have an internal audit function. We will continue to qualify as a smaller reporting company as long as
1) our public float is less than $250 million, or 2) we have less than $100 million in annual revenues and public float of less than $700
million. We cannot predict if investors will find our Class A common stock less attractive if we choose to rely on these exemptions.
However, for as long as we remain a “smaller reporting company” and “non-accelerated filer”, we intend to take advantage of
certain exemptions from various reporting requirements that are applicable to other public companies that do not qualify under these
categories including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. We intend to take advantage of these reporting exemptions as long as we remain
eligible to do so under the related rules.
We are exempt from certain corporate governance requirements since we are a “controlled company” within the meaning of the
NASDAQ rules, and as a result our stockholders will not have the protections afforded by these corporate governance requirements.
MacAndrews controls more than 50% of our combined voting power. As a result, we are considered a “controlled company” for
the purposes of NASDAQ rules and corporate governance standards, and therefore are permitted to elect not to comply with certain
NASDAQ corporate governance requirements, including those that would otherwise require our Board of Directors to have a majority of
independent directors and require that we either establish compensation and nominating and corporate governance committees, each
comprised entirely of independent directors, or otherwise ensure that the compensation of our executive officers and nominees for
directors are determined or recommended to the Board of Directors by the independent members of the Board of Directors. Accordingly,
holders of our Class A common stock do not have the same protections afforded to stockholders of companies that are subject to all of
the NASDAQ rules and corporate governance standards, and the ability of our independent directors to influence our business policies
and affairs may be reduced.
40
Provisions in our charter and bylaws and provisions of Delaware law may delay or prevent our acquisition by a third party, which
might diminish the value of our common stock.
Our amended and restated certificate of incorporation and amended and restated bylaws contain several provisions that may make
it more difficult or expensive for a third party to acquire control of us without the approval of the Board of Directors. These provisions
also may delay, prevent or deter a merger, acquisition, tender offer, proxy contest or other transaction that might otherwise result in our
stockholders receiving a premium over the market price for their common stock. The provisions include, among others:
•
a prohibition on actions by written consent of the stockholders;
•
•
•
•
authorized but unissued shares of common stock and preferred stock that will be available for future issuance;
the ability of our Board of Directors to increase the size of the Board of Directors and fill vacancies without a stockholder vote;
provisions that have the same effect as a modified version of Section 203 of the Delaware General Corporation Law, an
antitakeover law (as further described below); and
advance notice requirements for stockholder proposals and director nominations.
Section 203 of the Delaware General Corporation Law may affect the ability of an “interested stockholder” to engage in certain
business combinations, including mergers, consolidations or acquisitions of additional shares, for a period of three years following the
time that the stockholder becomes an “interested stockholder.” An “interested stockholder” is defined to include persons owning directly
or indirectly 15% or more of the outstanding voting stock of a corporation. We have elected in our amended and restated certificate of
incorporation not to be subject to Section 203 of the Delaware General Corporation Law. Nevertheless, the amended and restated
certificate of incorporation contains provisions that have the same effect as Section 203 of the Delaware General Corporation Law,
except that they provide that MacAndrews and its various successors and affiliates (and transferees of any of them) will not be deemed
to be “interested stockholders,” regardless of the percentage of our stock owned by them, and accordingly will not be subject to such
restrictions.
The provisions of our amended and restated certificate of incorporation and amended and restated bylaws, the significant common
stock ownership of MacAndrews and the ability of the Board of Directors to create and issue a new series of preferred stock or
implement a stockholder rights plan could discourage potential takeover attempts and reduce the price that investors might be willing to
pay for shares of our common stock in the future, which could reduce the market price of our common stock.
We will be required to pay M&F TTP Holdings Two LLC (“M&F”) for certain tax benefits we may claim. In certain circumstances,
payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the actual tax benefits we realize.
The only asset of the Company is its interest in vTv LLC. Class B common stock, together with the corresponding number of vTv
Units, may be exchanged for shares of our Class A common stock, or for cash, at our option (as the managing member of vTv LLC).
These exchanges of Class B common stock, together with the corresponding number of vTv LLC Units, may result in increases in the
tax basis of the assets of vTv LLC that otherwise would not have been available. Such increases in tax basis are likely to increase (for
tax purposes) depreciation and amortization deductions and therefore reduce the amount of income tax we would otherwise be required
to pay in the future and may also decrease gain (or increase loss) on future dispositions of certain assets to the extent the increased tax
basis is allocated to those assets. The IRS may challenge all or part of these tax basis increases and a court could sustain such a
challenge.
We have entered into a Tax Receivable Agreement with vTv Therapeutics Holdings (an entity which was dissolved in October
2015, but to which M&F became a successor) that will provide for the payment by us to M&F (or certain of its transferees or other
assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that we actually
realize (or, in some circumstances, we are deemed to realize) as a result of (a) the exchange of Class B common stock, together with the
corresponding number of vTv Units, for shares of our Class A common stock (or for cash), (b) tax benefits related to imputed interest
deemed to be paid by us as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax
Receivable Agreement. Although the actual increase in tax basis and the amount and timing of any payments under the Tax Receivable
Agreement will vary depending upon a number of factors, including the timing of exchanges, the price of shares of our Class A common
stock at the time of the exchange, the nature of the assets, the extent to which such exchanges are taxable, the tax rates then applicable,
and the amount and timing of our income, we expect that the payments that we may make to M&F could be substantial.
M&F generally will not reimburse us for any payments that may previously have been made under the Tax Receivable Agreement
even if the IRS subsequently disallows the tax basis increase or any other relevant tax item. Instead, any excess cash payments made by
us to M&F will be netted against any future cash payments that we might otherwise be required to make under the terms of the Tax
Receivable Agreement. However, we might not determine that we have effectively made an excess cash payment to M&F for a number
of years following the initial time of such payment. As a result, in certain circumstances we could make payments to M&F under the
Tax Receivable Agreement in excess of our cash tax savings. Our ability to achieve benefits from any tax basis increase and the
41
payments to be made under the Tax Receivable Agreement, will depend upon a number of factors, including the timing and amount of
our future income and the nature of our assets.
To the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, such payments will be
deferred and will accrue interest until paid. In addition, the Tax Receivable Agreement provides that, upon a merger, asset sale or other
form of business combination or certain other changes of control or if, at any time, we elect an early termination of the Tax Receivable
Agreement, our (or our successor’s) obligations under the Tax Receivable Agreement with respect to exchanged or acquired Class B
common stock, together with the corresponding number of vTv Units (whether exchanged or acquired before or after such change of
control or early termination), would be required to be paid significantly in advance of the actual realization, if any, of any future tax
benefits and would be based on certain assumptions, including that we would have sufficient taxable income to fully utilize the
deductions arising from the increased tax deductions and tax basis and other benefits related to entering into the Tax Receivable
Agreement, and, in the case of certain early termination elections, that any Class B common stock, together with the corresponding
number of vTv Units, that have not been exchanged will be deemed exchanged for the market value of the Class A common stock at the
time of termination. Consequently, it is possible that the actual cash tax savings realized by us may be significantly less than the
corresponding Tax Receivable Agreement payments.
The only asset of the Company is its interest in vTv LLC, and accordingly it will depend on distributions from vTv LLC to pay taxes
and expenses, including payments under the Tax Receivable Agreement. vTv LLC’s ability to make such distributions may be subject
to various limitations and restrictions.
The Company is a holding company, has no material assets other than its ownership of vTv Units and has no independent means
of generating revenue or cash flow. vTv LLC is treated as a partnership for U.S. federal income tax purposes and, as such, is not subject
to any entity-level U.S. federal income tax. Instead, taxable income will be allocated to holders of its common units, including us. As a
result, we will incur U.S. federal, state and local income taxes on our allocable share of any net taxable income of vTv LLC. Under the
terms of vTv LLC’s Amended and Restated LLC Agreement, vTv LLC will be obligated to make tax distributions to holders of its
common units, including us. In addition to tax expenses, we will also incur expenses related to our operations, including expenses under
the Tax Receivable Agreement, which could be significant. We intend, as its managing member, to cause vTv LLC to make distributions
in an amount sufficient to allow us to pay our taxes and operating expenses, including any payments due under the Tax Receivable
Agreement. However, vTv LLC’s ability to make such distributions may be subject to various limitations and restrictions including, but
not limited to, restrictions on distributions that would either violate any contract or agreement to which vTv LLC is then a party,
including the Loan Agreement or any other potential debt agreements, or any applicable law, or that would have the effect of rendering
vTv LLC insolvent. If vTv LLC does not distribute sufficient funds for us to pay our taxes or other liabilities, we may have to borrow
funds, which could adversely affect our liquidity and subject us to various restrictions imposed by any such lenders. To the extent that
we are unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue
interest until paid.
Our organizational structure confers certain benefits upon M&F and certain of its successors and assigns that will not benefit Class
A common stockholders to the same extent as it will benefit M&F.
Our organizational structure, including the fact that M&F owns more than 50% of the voting power of our outstanding voting
stock and owns part of its economic interest in our business through vTv LLC, confers certain benefits upon M&F that will not benefit
the holders of our Class A common stock to the same extent as it will benefit M&F. For example, the Tax Receivable Agreement will
provide for the payment by us to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in
U.S. federal, state and local income tax or franchise tax that we actually realize (or, in some circumstances, we are deemed to realize) as
a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of our Class A
common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by us as a result of the Tax Receivable
Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. Although we will retain 15% of
the amount of such tax benefits, it is possible that the interests of M&F may in some circumstances conflict with our interests and the
interests of our other stockholders. For example, M&F may have different tax positions from us, especially in light of the Tax
Receivable Agreement, that could influence their decisions regarding whether and when we should dispose of assets, whether and when
we should incur new or refinance existing indebtedness, and whether and when we should terminate the Tax Receivable Agreement and
accelerate our obligations thereunder. In addition, the determination of future tax reporting positions, the structuring of future
transactions and the handling of any future challenges by any taxing authority to our tax reporting positions may take into consideration
M&F’s tax or other considerations, which may differ from the considerations of us or our other stockholders. To the extent that M&F is
dissolved or liquidated, MacAndrews and/or its affiliates will succeed to the rights and obligations of M&F under the Tax Receivable
Agreement, and the same considerations described above apply to any such successor parties.
42
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
Our corporate headquarters is located in High Point, North Carolina, where we lease 12,786 square feet of office space in the
Premier Center office park. The initial term of the lease for this space continues through February 2025 and includes a one-time
termination option at the end of three years and an option to renew for an additional five years.
ITEM 3. LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings.
ITEM 4. MINE SAFETY DISCLOSURES
None.
43
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES
Market Information
Our Class A common stock is listed on the NASDAQ Capital Market under the symbol “VTVT”.
Dividend Policy
No cash dividends have ever been declared or paid on the common equity to date by the Company.
Holders
As of February 24, 2021, there were approximately 22 holders of record of our Class A common stock and 7 holders of record of
our Class B common stock. Because almost all of the shares of our Class A common stock are held by brokers, nominees and other
institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.
Securities Authorized for Issuance under Equity Compensation Plans
The following table summarizes information about our equity compensation plans as of December 31, 2020. The only awards that
have been granted under the plan below are in the form of option and restricted stock unit awards related to our Class A common stock:
Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights
(a)
Weighted-average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans (excluding
securities reflected in
column (a))
(c)
Plan Category
Equity compensation plans approved by
security holders
2015 Omnibus Equity Incentive Plan .................
4,489,191 $
4.39
2,475,809
Equity compensation plans not approved by
security holders .....................................................
Total ......................................................................
4,489,191
2,475,809
Issuer Purchases of Equity Securities
There have been no repurchases of the Company’s common stock during the fourth fiscal quarter of fiscal 2020.
ITEM 6. SELECTED FINANCIAL DATA
Not applicable to a smaller reporting company.
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes
included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based upon
current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans,
objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from
those anticipated in these forward-looking statements as a result of several factors, including those set forth in Part I, Item 1A, “Risk
Factors” in this Annual Report on Form 10-K. See the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-
Looking Statements.”
44
Company Overview
We are a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their
long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and
pre-clinical drug candidates for the treatment of a wide range of diseases.
Our pipeline is led by our programs for the treatment of type 1 diabetes (TTP399) and for psoriasis (HPP737). We completed
the Simplici-T1 Study, an adaptive Phase 1b/2 study supported by JDRF International (“JDRF”), to explore the effects of TTP399 in
patients with type 1 diabetes at the beginning of 2020. In February 2020, we reported positive results from the Phase 2 - Part 2
confirming phase of this study which achieved its primary objective by demonstrating statistically significant improvements in HbA1c
(long-term blood sugar) for TTP399 compared to placebo. We are working on the design for pivotal and registrational studies for
TTP399, with input from the FDA. In addition to the pivotal studies of TTP399, we are conducting a phase 1 mechanistic study in
patients with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal.
In addition, we are conducting a multiple ascending dose phase 1 study of HPP737, an orally administered phosphodiesterase
type 4 (“PDE4”) inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers
as part of our psoriasis program. The goal of this study is to confirm the maximum tolerated dose with minimal or no gastrointestinal
intolerance in the form of nausea, vomiting, or diarrhea. We expect to complete this study in the second quarter of 2021.
On December 15, 2020, the Company announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s
disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.
We are planning an adaptive Phase 1b/2 clinical trial assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of
TTP273, an orally administered non-peptidic agonist that targets the glucagon-like peptide 1 receptor (“GLP-1r”), in patients with cystic
fibrosis related diabetes and are seeking a funding partner to enable the conduct of this clinical trial.
In addition to our internal development programs, we are furthering the clinical development of four other programs, a small
molecule GLP-1r agonist, a PDE4 inhibitor, a PPAR-delta agonist, and an Nrf2 activator through partnerships with pharmaceutical
partners via licensing arrangements. In December 2017, we entered into a License Agreement with Hangzhou Zhongmei Huadong
Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and
sublicensable license to develop and commercialize our glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the
compound TTP273, in China and certain other Pacific Rim territories, including Australia and South Korea. We also entered into a
License Agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”) in December 2017, under which
Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize our peroxisome proliferation activated
receptor delta agonist program, including the compound HPP593. In May 2018, we entered into a License Agreement with Newsoara
Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”), under which Newsoara obtained an exclusive and
sublicensable license to develop and commercialize our phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound
HPP737, in China and other Pacific Rim territories. In December 2020, we entered into a License Agreement with Anteris Bio, Inc.
(“Anteris”) (the “Anteris License Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to
develop and commercialize vTv LLC’s Nrf2 activator, HPP971. For more information regarding the Huadong License Agreement,
Reneo License Agreement and the Newsoara License Agreement, see Part 1 – Item 1 – “Business – Partnered Development Programs”
of this Annual Report.
vTv Therapeutics Inc. (the “Company”, the “Registrant”, “we” or “us”) is a holding company, and its principal asset is a
controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary. The Company has
determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary
beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv
Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include
those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s
results under the VIE accounting model in its Consolidated Financial Statements.
To date, we have devoted substantially all of our resources to our research and development efforts relating to our investigational
drug candidates, including conducting clinical trials with our drug candidates, providing general and administrative support for these
operations and protecting our intellectual property. We do not have any products approved for sale and have not generated any revenue
from drug sales. From our inception through December 31, 2020, we (including our predecessor companies) have funded our operations
primarily through:
•
•
a series of private placements of preferred equity from 1999 through 2006 totaling $109.3 million;
the receipt of $23.4 million from completed research collaborations with Novo Nordisk, A/S Merck and Boehringer
Ingelheim from 2001 to 2006;
45
•
•
•
•
•
•
•
•
•
the receipt of $169.2 million of upfront, milestone and research fees during 2006 to 2010 under a license and research
agreement with Pfizer, Inc., which was terminated in 2011;
the receipt of $55.7 million of upfront, milestone and research expense reimbursements from 2010 to 2013 under a license
agreement for our GKA programs with an affiliate of Forest Laboratories, Inc., which was terminated in 2013;
various borrowings totaling $114.7 million from November 2011 through March 2014 from entities affiliated with
MacAndrews, which were converted to Series F and Series B preferred units of TTP and HPP, our predecessors;
borrowings of $46.6 million from April 2014 through June 2015 from entities affiliated with MacAndrews;
the completion of the IPO in August 2015, which raised proceeds of $104.4 million from the sale of our Class A common
stock, par value $0.01 per share (the “Class A Common Stock”), net of offering costs;
borrowings totaling $20.0 million from a venture loan and security agreement (the “Loan Agreement”) with Horizon
Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) in October 2016 and March 2017; and
letter agreements (the “Letter Agreements”) with M&F Group in December 2017, July 2018, December 2018, March 2019,
September 2019 and December 2019 under which we received a total of $59.0 million and through which we had the right
to sell to M&F Group shares of our Class A common stock at prices ranging from $1.33 to $4.38 per share, and M&F Group
had the right (exercisable up to three times) to require us to sell to it shares of Class A common stock at the same price
(subject to an aggregate dollar value maximum of Class A common stock that may be sold under each Letter Agreement,
whether at our option or M&F Group’s);
equity issuances of $13.0 million under the ATM Offering; and
equity issuances of $1.9 million under the LPC Purchase Agreement.
We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We
anticipate that our expenses will increase substantially as we:
•
•
•
•
•
continue the development of our lead drug candidates, TTP399 and HPP737;
seek to obtain regulatory approvals for our lead drug candidates;
prepare for the potential commercialization of our lead drug candidates;
expand our research and development activities and advance our clinical programs; and
maintain, expand and protect our intellectual property portfolio.
We do not expect to generate revenue from drug sales unless and until we successfully complete development and obtain
marketing approval for one or more of our drug candidates, which we expect will take a number of years and will be subject to
significant uncertainty. Accordingly, we will need to raise additional capital to fund continuing drug development prior to the
commercialization of any of our drug candidates, including to finance the planned registrational trial(s) of TTP399 in patients with type
1 diabetes as well as any future studies of HPP737 in patients with psoriasis. Until such time that we can generate substantial revenue
from product sales, we expect to finance our operating activities through a combination of equity offerings, debt financings, marketing
and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We are evaluating several
financing strategies to fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our
common stock. Nevertheless, we may be unable to raise additional funds or enter into such other arrangements when needed, on
favorable terms or at all, which would have a negative impact on our liquidity and financial condition and could force us to delay, reduce
the scope or eliminate one or more of our research and development programs or commercialization efforts. Failure to receive additional
funding could cause us to cease operations, in part or in full.
Financial Overview
Revenue
To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from up-front proceeds and
research fees under collaboration and license agreements.
In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from
the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from
quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of
payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the
46
development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and
our results of operations and financial position will be materially adversely affected.
Research and Development Expenses
Since our inception, we have focused our resources on our research and development activities, including conducting preclinical
studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We
recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of
external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations (“CRO(s)”), in
connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and
development costs consist primarily of salaries, benefits and related overhead expenses for personnel in research and development
functions and depreciation of leasehold improvements, laboratory equipment and computers. Since we typically use our employee and
infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.
From our inception through December 31, 2020, we have incurred approximately $591.0 million in research and development
expenses.
Our research and development expenses by project for the years ended December 31, 2020, 2019 and 2018 were as follows (in
thousands):
Direct research and development expense:
Azeliragon ............................................................ $
TTP399 .................................................................
HPP737 ................................................................
Other projects .......................................................
Indirect research and development expense ............
Total research and development expense ................ $
2020
Years Ended December 31,
2019
2018
6,103 $
917
493
683
2,819
11,015 $
7,233 $
2,762
56
578
4,490
15,119 $
13,507
879
46
649
7,954
23,035
We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the
development of TTP399 and HPP737 and further advance the development of our other drug candidates, subject to the availability of
additional funding.
The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably
estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our
clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may
commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:
•
•
•
•
•
•
•
the uncertainty of the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other
research and development activities;
the potential benefits of our candidates over other therapies;
our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or
may develop in the future;
future clinical trial results;
our ability to enroll patients in our clinical trials;
the timing and receipt of any regulatory approvals; and
the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of
doing so.
A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant
change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory
authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of
clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be
required to expend significant additional financial resources and time with respect to the development of that drug candidate.
47
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance,
corporate development, human resources and administrative support functions. Other significant general and administrative expenses
include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants,
occupancy costs and information systems.
Interest Expense, Net
Interest expense, net primarily consists of our cash and non-cash interest expense related to our Loan Agreement. Cash interest on
the Loan Agreement was recognized at a floating interest rate equal to 10.5% plus the amount by which the one-month London
Interbank Offer Rate (“LIBOR”) exceeds 0.5%. Non-cash interest expense represents the amortization of the costs incurred in
connection with the Loan Agreement, the allocated fair value of the warrants to purchase shares of our Class A Common Stock issued in
connection with the Loan Agreement (the “Warrants”) and the accretion of the final interest payment (which will be paid in cash upon
loan maturity), all of which are recognized in our Consolidated Statement of Operations using the effective interest method.
Other Income (Expense), Net
Other income (expense), net primarily consists of gains and losses related to the adjustment of the fair value of the warrants issued
to MacAndrews in connection with the Letter Agreements.
Results of Operations
In this section, we discuss the results of our operations for the year ended December 31, 2020 compared to the year ended
December 31, 2019. For a discussion of the year ended December 31, 2019 compared to the year ended December 31, 2018, please refer
to Part II, Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on
Form 10-K for the year ended December 31, 2019.
Comparison of the year ended December 31, 2020 and 2019
The following table sets forth certain information concerning our results of operations for the periods shown:
(dollars in thousands)
Statement of operations data:
Revenue ............................................................................... $
Operating expenses:
Research and development ................................................
General and administrative ................................................
Total operating expenses .................................................
Operating loss .......................................................................
Interest income .....................................................................
Interest expense ....................................................................
Other (expense) income, net .................................................
Loss before income taxes .....................................................
Income tax provision ............................................................
Net loss before noncontrolling interest .................................
Less: net loss attributable to noncontrolling interest ...........
Net loss attributable to vTv Therapeutics Inc. ...................... $
2020
Year Ended
2019
Change
6,414 $
2,764
$
3,650
11,015
7,251
18,266
(11,852)
12
(692)
(270)
(12,802)
—
(12,802)
(4,303)
(8,499) $
15,119
8,537
23,656
(20,892 )
53
(1,827 )
828
(21,838 )
100
(21,938 )
(8,894 )
(13,044 )
$
(4,104)
(1,286)
(5,390)
9,040
(41)
1,135
(1,098)
9,036
(100)
9,136
4,591
4,545
Revenues
Revenues were $6.4 million and $2.8 million for the years ended December 31, 2020 and 2019, respectively. The revenue
recognized in 2020 is primarily attributable to the upfront payment and fair value of the equity interest received by the Company in
connection with the Anteris License Agreement. The revenue earned during 2019 primarily relates to the recognition of amounts
deferred at the initiation of our license agreements which were related to the transfer of technology performance obligations. The
technology service period for our license agreement with Reneo ended in the second quarter of 2019. Further, in 2019 we recognized an
additional $1.0 million of revenue related to the satisfaction of a milestone within our license agreement with Newsoara.
48
Research and Development Expenses
Research and development expenses were $11.0 million and $15.1 million for the years ended December 31, 2020 and 2019,
respectively. The decrease in research and development expenses during this period of $4.1 million, or 27.1%, was primarily due to:
•
•
•
A decrease in clinical trial costs of $1.1 million for azeliragon from 2019. This decrease was mainly driven by a decrease in
spending for the Elevage study as it was in the start-up/enrollment stage in 2019 and patients completed the trial in 2020;
A decrease in clinical trial costs of $1.8 million for TTP399 from 2019, which was caused by a decrease in spending for the
SimpliciT-1 trial. This study completed in January 2020 and costs incurred in 2020 related to consulting and other costs
involved in planning for the next trial(s) as well as the incurrence of certain manufacturing costs to get drug product ready
for these trials; and
A decrease in other research and development costs of $1.7 million, which was primarily driven by decreases in
compensation costs of approximately $1.1 million due to the reversal of certain performance-based compensation accruals,
and lower cash and share-based compensation costs. Additionally, facility costs decreased approximately $0.2 million due
to the relocation and shut down of the company’s former laboratory space in late 2019. We also experienced decreases in
other costs related to the curtailment of expenses, particularly travel, because of COVID-19.
General and Administrative Expenses
General and administrative expenses were $7.3 million and $8.5 million for the years ended December 31, 2020 and 2019,
respectively. The decrease in general and administrative expenses during this period of $1.3 million, or 15.1%, was primarily due to
decreases of $1.3 million for compensation cost which was caused, in part, by the reversal of certain performance-based compensation
accruals which are no longer expected to be paid ($0.7 million) and lower share-based compensation expense ($0.3 million). Decreases
in facility costs attributable to the relocation of our corporate headquarters were offset by increases in costs for professional services.
Interest Expense, Net
Interest expense, net was $0.7 million and $1.8 million for the years ended December 31, 2020 and 2019, respectively. Interest
expense primarily relates to our Loan Agreement which bore interest at 10.5% plus the amount by which the one-month LIBOR exceeds
0.5%. The decrease in interest expense from 2019 to 2020 was driven by the continued repayment of principal amounts outstanding in
accordance with the terms of the Loan Agreement.
Liquidity and Capital Resources
Liquidity and Going Concern
As of December 31, 2020, we had an accumulated deficit of $290.0 million. Since our inception, we have experienced a
history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as
we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of
December 31, 2020, our currently available sources of liquidity include our unrestricted balance of cash and cash equivalents of $5.7
million. Based on our current operating plan, we believe that our current cash and cash equivalents, availability under the ATM
Offering and amounts raised under the LPC Purchase Agreement through February 24, 2021 will allow us to meet our liquidity
requirements through the end of the third quarter of 2021. These factors raise substantial doubt regarding our ability to continue as a
going concern. In addition to available cash and cash equivalents and available funds discussed above, we are seeking possible
additional partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide additional cash for
use in our operations and the continuation of the clinical trials for our drug candidates. We are evaluating several financing strategies to
fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The
timing and availability of such financing are not yet known.
Letter Agreements
Under the terms of the Letter Agreements entered into in prior years, the Company had the right to sell to M&F Group shares of its
Class A Common Stock at a specified price per share, and M&F Group had the right (exercisable up to three times) to require the
Company to sell to it shares of Class A Common Stock at the same price. As of December 31, 2020, an aggregate of $59.0 million
worth of Class A Common Stock had been sold under the Letter Agreements. In connection with the entrance into several of these
Letter Agreements, the Company issued to M&F Group a total of 1,823,917 warrants (the “Letter Agreement Warrants”) to purchase
additional shares of the Company’s Class A Common Stock.
49
Debt Transaction
In October 2016, we and vTv LLC entered into the Loan Agreement with Horizon Technology Finance Corporation and
Silicon Valley Bank, under which we borrowed $20.0 million. Each loan tranche bore interest at a floating rate equal to 10.5% plus the
amount by which the one-month LIBOR exceeds 0.5%. Additionally, each tranche included a final interest payments of $0.8 million
which was paid upon the maturity of the respective tranche. As of December 31, 2020, all amounts outstanding under the Loan
Agreement had been paid.
In connection with the Loan Agreement, we issued to the Lenders warrants to purchase shares of our Class A common stock
(the “Warrants”). On October 28, 2016, we issued Warrants to purchase 152,580 shares of our Class A common stock at a per share
exercise price of $6.39 per share, and on March 24, 2017, in connection with the funding of the second tranche, we issued Warrants to
purchase 38,006 shares of our Class A common stock at a per share exercise price of $5.92 per share. The Warrants will expire seven
years from their date of issuance.
Cash Flows
(dollars in thousands)
Net cash used in operating activities ...................................... $
Net cash provided by investing activities ..............................
Net cash provided by financing activities ..............................
Net increase in cash and cash equivalents ............................. $
(18,000 )
—
19,470
1,470
$
$
(23,018)
242
22,870
94
Year Ended
December 31,
2020
2019
Operating Activities
For the year ended December 31, 2020, our net cash used in operating activities decreased $5.0 million from the prior year. The
decrease in uses of cash was primarily driven by lower spending on our clinical trials during 2020 coupled with the impact of changes in
working capital.
Investing Activities
No cash was provided by or used in investing activities for the year ended December 31, 2020. During the year ended December
31, 2019, we disposed of lab equipment for which we received proceeds of approximately $0.3 million.
Financing Activities
For the year ended December 31, 2020, net cash provided by financing activities was $19.5 million compared to net cash provided
by financing activities of $22.9 million for the year ended December 31, 2019, resulting in a decrease of $3.4 million. This decrease was
reflective of lower proceeds from the sale of stock to support our ongoing operations and lower debt service requirements.
Future Funding Requirements
To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue
from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and
commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our
ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval
for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur
significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need
substantial additional funding in connection with our continuing operations.
50
Based on our current operating plan, we believe that our current cash and cash equivalents, availability under the ATM Offering
and amounts raised under the LPC Purchase Agreement through February 24, 2021 will allow us to meet our liquidity requirements
through the end of the third quarter of 2021. In addition to the available cash and cash equivalents and other sources of liquidity, we are
seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide
additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We are also evaluating
several financing strategies to fund the future clinical trials of TTP399 and HPP737, including direct equity investments and future
public offerings of our common stock. The timing and availability of such financing are not yet known. We have based our estimates on
assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of
the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to
estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug
candidates.
Our future capital requirements will depend on many factors, including:
•
The progress, costs, results and timing of our planned registrational trial(s) to evaluate TTP399 as a potential treatment of
type 1 diabetes and planned studies of HPP737 as a potential treatment of psoriasis;
•
•
•
•
•
•
•
•
•
•
•
•
•
the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the
basis for review and approval of our drug candidates;
the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;
the ability of our drug candidates to progress through clinical development successfully;
our need to expand our research and development activities;
the costs associated with securing, establishing and maintaining commercialization capabilities;
the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;
our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing
of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution,
defense and enforcement of any patents or other intellectual property rights;
our need and ability to hire additional management and scientific and medical personnel;
the effect of competing technological and market developments;
our need to implement additional internal systems and infrastructure, including financial and reporting systems;
the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or
other arrangements into which we may enter in the future; and
the amount of any payments we are required to make to M&F TTP Holdings Two LLC in the future under the Tax
Receivable Agreement.
Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a
combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances
and licensing arrangements. We do not currently have any committed external source of funds other than those available through the
ATM Offering and LPC Purchase Agreement. However, we are evaluating several financing strategies to fund the on-going and future
clinical trials of TTP399 and HPP737, including direct equity investments and future public offerings of our common stock. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights
of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing
arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug
candidates or grant licenses on terms that may not be favorable to us. If we are unable to obtain additional funding, we could be forced
to delay, reduce or eliminate our research and development programs or commercialization efforts, which could adversely affect our
business prospects.
51
Off-Balance Sheet Arrangements
As of December 31, 2020, we do not currently have outstanding any off-balance sheet arrangements as defined under SEC rules.
However, during the periods presented we had Letter Agreements under which we had received funding of $59.0 million and, in
exchange, had issued a total of 33,790,546 shares of our Class A Common Stock.
Discussion of Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial
statements, which we have prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The
preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues
and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on
historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies,” to
our audited financial statements, we believe that the following accounting policies related to revenue recognition, research and
development, income taxes, and share-based compensation are the most critical for fully understanding and evaluating our financial
condition and results of operations.
Basis of Presentation
The Company is a holding company, and its principal asset is a controlling equity interest in vTv LLC, the Company’s principal
operating subsidiary. The Company has determined that vTv LLC is a VIE for accounting purposes and that the Company is the primary
beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of the
Company is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that
most significantly impact vTv LLC’s economic performance. The Company has therefore consolidated vTv LLC’s results under the VIE
accounting model in its consolidated financial statements.
Revenue Recognition
The majority of our revenue results from its license and collaboration agreements associated with the development of
investigational drug products. We account for a contract when it has approval and commitment from both parties, the rights of the
parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.
For each contract meeting these criteria, we identify the performance obligations included within the contract. A performance obligation
is a promise in a contract to transfer a distinct good or service to the customer. We then recognize revenue under each contract as the
related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange
for the transferred assets or services. Development, regulatory and sales milestones included in our collaboration agreements are
considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction
price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s
transaction price is allocated to each performance obligation using our best estimate of the standalone selling price of each distinct good
or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach.
Revenue is recognized over the related period over which we expect the services to be provided using a proportional performance model
or a straight-line method of recognition if there is no discernable pattern over which the services will be provided.
See Note 2 “Summary of Significant Accounting Policies”, to the Consolidated Financial Statements in Item 15 of Part IV of this
Annual Report on Form 10-K for further information regarding the adoption of ASC Topic 606, “Revenue From Contracts With
Customers” and the related changes in the recognition of revenue that were adopted on January 1, 2018.
Research and Development
Major components of research and development costs include cash compensation, costs of preclinical studies, clinical trials and
related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and
compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf.
Costs incurred in research and development are expensed as incurred.
52
We record accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with
numerous contract research organizations. In the normal course of business, we contract with third parties to perform various clinical
study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and
variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the
achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of our accrual
policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such,
expense accruals related to clinical studies are recognized based on our estimate of the degree of completion of the event or events
specified in the specific clinical study.
We record nonrefundable advance payments we make for future research and development activities as prepaid expenses. Prepaid
expenses are recognized as expense in the statements of operations as we receive the related goods or services.
Income Taxes
In connection with the IPO, vTv Therapeutics Inc. was formed. From August 1, 2015, vTv Therapeutics Inc. has been subject to
corporate level income taxes. Prior to July 30, 2015, our predecessor entities were taxed as partnerships and all their income and
deductions flowed through and were subject to tax at the partner level.
vTv Therapeutics Inc. holds vTv Units and is required to recognize deferred tax assets and liabilities for the difference between the
financial reporting and tax basis of its investment in vTv LLC.
Our income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best
assessment of estimated future taxes to be paid. We are subject to income taxes in both the United States and various state jurisdictions.
Significant judgments and estimates are required in determining the consolidated income tax expense.
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events included in the financial statements. Under this method, we determine
deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by
using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.
We recognize deferred tax assets to the extent we believe these assets are more-likely-than-not to be realized. In making such a
determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary
differences, projected future taxable income, tax planning strategies and recent results of operations.
We record uncertain tax positions on the basis of a two-step process in which (1) we determine whether it is more-likely-than-not
that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the
more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized
upon ultimate settlement with the related tax authority.
Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in our Consolidated
Statement of Operations. We have not incurred any significant interest or penalties related to income taxes in any of the periods
presented.
Share-Based Compensation
Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and
compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is
estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to our
own shares, we estimate expected volatility based on the historical volatility of our own stock coupled with a portfolio of selected stocks
of companies believed to have market and economic characteristics similar to our own. The risk-free rate is based on the U.S. Treasury
yield curve in effect at the time of grant. Due to a lack of historical exercise data, we estimate the expected life of our outstanding stock
options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. The fair value of restricted stock units
(“RSU”) grants are based on the market value of our Class A Common Stock on the date of grant. We also estimate the amount of
share-based awards that are expected to be forfeited based on historical employee turnover rates.
53
Effect of Recent Accounting Pronouncements
See discussion of recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies”, to the
Consolidated Financial Statements in Item 15 of Part IV of this Annual Report on Form 10-K.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
Our Loan Agreement was fully repaid as of December 31, 2020. As a result, we no longer have any material interest rate exposure.
Market Risk
Our exposure to market risk is limited to our cash, cash equivalents and marketable securities, all of which have maturities of one
year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash
and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we
maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality.
The securities in our investment portfolio are not leveraged, are classified as available for sale and are, due to their short-term nature,
subject to minimal interest rate risk. Because of the short-term maturities of our investments, we do not believe that an increase in
market rates would have a material negative impact on the value of our investment portfolio.
Foreign Currency Risk
We do not have any material foreign currency exposure.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this Item is included in our Financial Statements and Supplementary Data listed in Item 15 of Part IV
of this Annual Report on Form 10-K.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management has
evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-
15(e) of the Securities Exchange Act of 1934) as of December 31, 2020. Based upon that evaluation, our Chief Executive Officer and
Chief Financial Officer concluded that, as of December 31, 2020, our disclosure controls and procedures were effective in causing
material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized and reported by
management on a timely basis and to ensure the quality and timeliness of our public disclosures with SEC disclosure obligations.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls
and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud,
if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be
faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people or by management override of controls.
The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there
can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control
may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may
deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may
not be detected.
54
Management’s Annual Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule
13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance
with generally accepted accounting principles. Our internal control over financial reporting includes those written policies and
procedures that:
•
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions
of assets;
•
•
•
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles;
provide reasonable assurance that receipts and expenditures are being made only in accordance with management and
director authorization; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
assets that could have a material effect on the consolidated financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. Management
based this assessment on criteria described in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Based on this assessment, management determined that as of December 31, 2020,
we maintained effective internal control over financial reporting.
Changes to Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 9B. OTHER INFORMATION
None.
55
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this item is incorporated by reference to our Proxy Statement for the 2021 Annual Meeting of Stockholders
to be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item is incorporated by reference to our Proxy Statement for the 2021 Annual Meeting of
Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
The information required by this item is incorporated by reference to our Proxy Statement for the 2021 Annual Meeting of
Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this item is incorporated by reference to our Proxy Statement for the 2021 Annual Meeting of
Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this item is incorporated by reference to our Proxy Statement for the 2021 Annual Meeting of
Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.
56
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements
The following documents are included on pages F-1 through F-30 attached hereto and are filed as part of this Annual Report on
Form 10-K.
Report of Independent Registered Public Accounting Firm ................................................................................................................. F-2
Consolidated Balance Sheets as of December 31, 2020 and 2019 ........................................................................................................ F-4
Consolidated Statements of Operations for the Years Ended December 31, 2020, 2019 and 2018 ...................................................... F-5
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the Years Ended
December 31, 2020, 2019 and 2018 ................................................................................................................................................. F-6
Consolidated Statements of Cash Flows for the Years Ended December 31, 2020, 2019 and 2018 .................................................... F-7
Notes to Consolidated Financial Statements ......................................................................................................................................... F-8
(a)(2) Financial Statement Schedules
Not applicable
(a)(3) List of Exhibits
Exhibit
Number
Description
3.1
3.2
4.1
4.2
4.3*
10.1
10.2
10.3
10.4
10.5
10.6
10.7
Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 to the Company’s Form
8-K, filed August 4, 2015 (File No. 001-37524)).
Amended and Restated By-laws (incorporated by reference from Exhibit 3.2 to the Company’s Form 8-K, filed August 4,
2015 (File No. 001-37524)).
Form of Warrant to Purchase Class A Common Stock (incorporated by reference from Exhibit 4.1 to the Company’s Form
10-K, filed February 24, 2017 (File No. 001-37524)).
Common Stock Purchase Warrant (incorporated by reference from Exhibit 4.2 to the Company’s Form 10-K, filed February
27, 2018 (File No. 001-37524)).
Description of Capital Stock.
Reimbursement of Fees and Expenses Letter Agreement, dated July 16, 2015, by and between vTv Therapeutics Inc. and
MacAndrews & Forbes Group, LLC (incorporated by reference from Exhibit 10.6 to Amendment No. 5 to the Company’s
Registration Statement on Form S-1, filed July 23, 2015 (File No. 333-204951)).
Reorganization Agreement, dated as of July 29, 2015, among vTv Therapeutics Inc., vTv Therapeutics LLC, vTvx Holdings
I LLC, vTvx Holdings II LLC and vTv Therapeutics Holdings LLC (incorporated by reference from Exhibit 10.1 to the
Company’s Form 8-K, filed August 4, 2015 (File No. 001-37524)).
Amended and Restated Limited Liability Company Agreement of vTv Therapeutics LLC, dated July 29, 2015 (incorporated
by reference from Exhibit 10.2 to the Company’s Form 8-K, filed August 4, 2015 (File No. 001-37524)).
Investor Rights Agreement, dated as of July 29, 2015, among vTv Therapeutics Inc., vTv Therapeutics Holdings LLC
and other stockholders party thereto from time to time (incorporated by reference from Exhibit 10.3 to the Company’s
Form 8-K, filed August 4, 2015 (File No. 001-37524)).
Exchange Agreement, dated as of July 29, 2015, among vTv Therapeutics LLC, vTv Therapeutics Inc. and vTv
Therapeutics Holdings LLC (incorporated by reference from Exhibit 10.4 to the Company’s Form 8-K, filed August 4, 2015
(File No. 001-37524)).
Tax Receivable Agreement, dated as of July 29, 2015, among vTv Therapeutics Inc. and the other persons named therein
(incorporated by reference from Exhibit 10.5 to the Company’s Form 8-K, filed August 4, 2015 (File No. 001-37524)).
Form of Indemnification Agreement (incorporated by reference from Exhibit 10.7 to Amendment No. 4 to the Company’s
Registration Statement on Form S-1, dated July 23, 2015 (File No. 333-204951)).
57
Exhibit
Number
10.8†
10.9†
10.10†
10.11†
10.12†
10.13††
10.14††
10.15
10.16††
10.17††
Description
Executive Chairman Agreement, dated as of July 16, 2015, by and between vTv Therapeutics Inc. and Jeff Kindler
(incorporated by reference from Exhibit 10.13 to Amendment No. 4 to the Company’s Registration Statement on Form S-1,
filed July 20, 2015 (File No. 333-204951)).
Employment Agreement, dated as of July 16, 2015, by and between vTv Therapeutics LLC and Stephen Holcombe, and for
certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit 10.14 to
Amendment No. 4 to the Company’s Registration Statement on Form S-1, filed July 20, 2015 (File No. 333-204951)).
Employment Agreement, dated as of July 16, 2015, by and between vTv Therapeutics LLC and Rudy Howard, and for
certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit 10.15 to
Amendment No. 4 to the Company’s Registration Statement on Form S-1, filed July 20, 2015 (File No. 333-204951)).
vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (incorporated by reference from Exhibit 10.6 to the Company’s
Form 8-K, filed August 4, 2015 (File No. 001-37524)).
vTv Therapeutics Inc. Form of Nonqualified Option Award Agreement (incorporated by reference from Exhibit 10.7 to the
Company’s Form 8-K, filed August 4, 2015 (File No. 001-37524)).
Agreement Concerning Glucokinase Activator Project, dated as of February 20, 2007, by and between Novo Nordisk A/S
and TransTech Pharma, Inc. (incorporated by reference from Exhibit 10.8 to Amendment No. 1 to the Company’s
Registration Statement on Form S-1, dated June 19, 2015 (File No. 333-204951)).
Venture Loan and Security Agreement dated as of October 28, 2016 by and among the Company, vTv Therapeutics LLC,
Horizon Technology Finance Corporation and Silicon Valley Bank (incorporated by reference from Exhibit 4.1 to the
Company’s Form 10-K, filed February 24, 2017 (File No. 001-37524)).
First Amendment of Venture Loan and Security Agreement and Consent, dated as of December 20, 2017, by and among the
Company, vTv Therapeutics LLC, Horizon Credit II LLC and Silicon Valley Bank (incorporated by reference from Exhibit
10.17 to the Company’s Form 10-K, filed February 27, 2018 (File No. 001-37524)).
License and Research Agreement, dated as of December 21, 2017, by and between Hangzhou Zhongmei Huadong
Pharmaceutical Co., Ltd. And vTv Therapeutics LLC (incorporated by reference from Exhibit 10.19 to the Company’s
Form 10-K, filed February 27, 2018 (File No. 001-37524)).
License and Research Agreement, dated as of December 21, 2017, by and between Reneo Pharmaceuticals, Inc. and vTv
Therapeutics LLC (incorporated by reference from Exhibit 10.20 to the Company’s Form 10-K, filed February 27, 2018
(File No. 001-37524)).
10.18††
License Agreement, dated as of May 31, 2018, by and between Newsoara Biopharma Co., Ltd. and vTv Therapeutics LLC
(incorporated by reference from Exhibit 10.1 to the Company’s Form 10-Q, filed August 3, 2018 (File No. 001-37524)).
10.19†
10.20†
10.21
10.22
10.23
10.24
Employment Agreement, dated as of March 7, 2019, by and between vTv Therapeutics LLC and Stephen L. Holcombe, and
for certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit 10.1 to the
Company’s Form 8-K, filed March 11, 2019 (File No. 001-37524)).
Employment Agreement, dated as of March 7, 2019, by and between vTv Therapeutics LLC and Rudy C. Howard, and for
certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit 10.2 to the
Company’s Form 8-K filed March 11, 2019 (File No. 001-37524)).
Form of Securities Purchase Agreement to Purchase Class A Common Stock, under the Company’s Form S-3 (incorporated
by reference from Exhibit 10.1 to the Company’s Form 8-K, filed March 20, 2019 (File No. 001-37524)).
Letter Agreement, dated as of March 18, 2019, by and between MacAndrews & Forbes Group LLC and vTv Therapeutics
Inc. (incorporated by reference from Exhibit 10.2 to the Company’s Form 8-K, filed March 20, 2019 (File No. 001-37524)).
Letter Agreement, dated as of September 26, 2019, by and between MacAndrews & Forbes Group LLC and vTv
Therapeutics Inc. (incorporated by reference from Exhibit 10.1 to the Company’s Form 10-Q, filed October 30, 2019 (File
No. 001-37524)).
Form of Securities Purchase Agreement to Purchase Class A Common Stock, under the September 26, 2019 Letter
Agreement, by and between MacAndrews & Forbes Group LLC and vTv Therapeutics Inc. (incorporated by reference from
Exhibit 10.2 to the Company’s Form 10-Q, filed October 30, 2019 (File No. 001-37524)).
58
Exhibit
Number
10.25
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33†
10.34†
Description
Letter Agreement, dated as of December 23, 2019, by and between MacAndrews & Forbes Group LLC and vTv
Therapeutics Inc. (incorporated by reference from Exhibit 10.25 to the Company’s Form 10-K, filed February 21, 2020 (File
No. 001-37524)).
Form of Securities Purchase Agreement to Purchase Class A Common Stock, under the December 23, 2019 Letter
Agreement, by and between MacAndrews & Forbes Group LLC and vTv Therapeutics Inc. (incorporated by reference from
Exhibit 10.26 to the Company’s Form 10-K, filed February 21, 2020 (File No. 001-37524)).
Controlled Equity OfferingSM Sales Agreement, dated as of April 24, 2020, by and between vTv Therapeutics Inc. and
Cantor Fitzgerald & Co. (incorporated by reference from Exhibit 1.1 to the Company’s Form 8-K, filed on April 24, 2020
(File No. 001-37524)).
Second Amendment of Venture Loan and Security Agreement and Consent, dated as of April 1, 2020, by and among the
Company, vTv Therapeutics LLC, Horizon Funding Trust 2019-1 and Silicon Valley Bank (incorporated by reference from
Exhibit 10.1 to the Company’s Form 10-Q, filed on August 3, 2020 (File No. 001-37524)).
Third Amendment of Venture Loan and Security Agreement and Consent, dated as of July 29, 2020, by and among the
Company, vTv Therapeutics LLC, Horizon Funding Trust 2019-1 and Silicon Valley Bank (incorporated by reference from
Exhibit 10.1 to the Company’s Form 10-Q, filed on May 7, 2020 (File No. 001-37524)).
First Amendment to vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (incorporated by reference from Exhibit
3.5 to the Company’s Form S-8, filed August 3, 2020 (File No. 333-240304)).
Purchase Agreement, dated November 24, 2020, by and between vTv Therapeutics Inc. and Lincoln Park Capital Fund,
LLC (incorporated by reference from Exhibit 10.1 to the Company’s Form 8-K, filed on November 24, 2020 (File No. 001-
37524)).
Registration Rights Agreement, dated November 24, 2020, by and between vTv Therapeutics Inc. and Lincoln Park Capital
Fund, LLC (incorporated by reference from Exhibit 10.2 to the Company’s Form 8-K, filed on November 24, 2020 (File
No. 001-37524)).
Employment Agreement, dated as of December 10, 2020, by and between vTv Therapeutics LLC and Stephen L.
Holcombe, and for certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit
10.1 to the Company’s Form 8-K, filed December 10, 2020 (File No. 001-37524)).
Employment Agreement, dated as of December 10, 2020, by and between vTv Therapeutics LLC and Rudy C. Howard, and
for certain limited purposes specified therein, vTv Therapeutics Inc. (incorporated by reference from Exhibit 10.2 to the
Company’s Form 8-K filed December 10, 2020 (File No. 001-37524)).
10.35*†† License Agreement, dated December 11, 2020, by and between Anteris Bio, Inc. and vTv Therapeutics LLC.
10.36*†† First Amendment to License Agreement, dated as of December 21, 2020 by and between Hangzhou Zhongmei Huadong
Pharmaceutical Co., Ltd. And vTv Therapeutics LLC.
10.37†
Executive Chairperson Agreement, dated as of December 30, 2020, by and between vTv Therapeutics Inc. and Robin E.
Abrams (incorporated by reference from Exhibit 10.1 to the Company’s Form 8-K filed December 30, 2020 (File No. 001-
37524)).
21.1*
23.1*
31.1*
31.2*
32.1*
32.2*
Subsidiaries of vTv Therapeutics Inc.
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange
Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as
amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
101.INS* XBRL Instance Document
59
Exhibit
Number
Description
101.SCH* XBRL Taxonomy Extension Schema
101.CAL* XBRL Taxonomy Extension Calculation Linkbase
101.DEF* XBRL Taxonomy Extension Definition Document
101.LAB* XBRL Taxonomy Extension Label Linkbase
101.PRE* XBRL Taxonomy Extension Presentation Linkbase
† Management contract or compensatory plan or arrangement
†† Confidential treatment received with respect to portions of this exhibit.
*
Filed herewith
ITEM 16. FORM 10-K SUMMARY
None.
60
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 24, 2021
VTV THERAPEUTICS INC.
(Registrant)
/s/ Stephen L. Holcombe
Stephen L. Holcombe
President and Chief Executive Officer
/s/ Rudy C. Howard
Rudy C. Howard
Chief Financial Officer
By:
By:
61
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on
behalf of the registrant and in the capacities and on the dates indicated.
/s/ Robin E. Abrams
Robin E. Abrams
Chairwoman
/s/ Stephen L. Holcombe
Stephen L. Holcombe
President and Chief Executive Officer
(Principal Executive Officer)
/s/ Rudy C. Howard
Rudy C. Howard
Chief Financial Officer
(Principal Financial and Accounting Officer)
/s/ John A. Fry
John A. Fry
/s/ Hersh Kozlov
Hersh Kozlov
/s/ Richard S. Nelson
Richard S. Nelson
/s/ Noel J. Spiegel
Noel J. Spiegel
/s/ Howard L. Weiner
Howard L. Weiner
Director
Director
Director
Director
Director
February 24, 2021
February 24, 2021
February 24, 2021
February 24, 2021
February 24, 2021
February 24, 2021
February 24, 2021
February 24, 2021
62
INDEX TO FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm........................................................................................................ F-2
Financial Statements:
Consolidated Balance Sheets as of December 31, 2020 and 2019 ........................................................................................... F-4
Consolidated Statements of Operations for the Years Ended December 31, 2020, 2019 and 2018 ......................................... F-5
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the Years
Ended December 31, 2020, 2019 and 2018 ......................................................................................................................... F-6
Consolidated Statements of Cash Flows for the Years Ended December 31, 2020, 2019 and 2018 ........................................ F-7
Notes to Consolidated Financial Statements .................................................................................................................................. F-8
The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the
“Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principal
operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Annual Report on Form 10-K to the
“Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries.
F-1
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of vTv Therapeutics Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of vTv Therapeutics Inc. (the Company) as of December 31, 2020 and
2019, the related consolidated statements of operations, changes in redeemable noncontrolling interest and stockholders’ deficit and
cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the
“consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the
financial position of the Company at December 31, 2020 and 2019, and the consolidated results of its operations and its cash flows for
each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.
The Company's Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
As discussed in Note 1 to the financial statements, the Company has not generated any product revenue, has not achieved profitable
operations, has insufficient liquidity to sustain operations and has stated that substantial doubt exists about the Company’s ability to
continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters
are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that
our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was
communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material
to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the
critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure
to which it relates.
Description of the
Matter
Accrued Development Costs
As discussed in Notes 2 and 7 to the consolidated financial statements, the Company has
recorded $2.6 million of accrued expenses at December 31, 2020, which includes costs for
clinical trial and contract manufacturing activities (together, clinical related activities) based
upon estimates of expenses incurred through the balance sheet date that have yet to be invoiced
by the contract research organizations (CROs), clinical study sites, contract manufacturing
organizations, or other vendors (together, clinical vendors). This accrual process involves
identifying services that have been performed and estimating the level of service performed
F-2
How We Addressed
the Matter in Our
Audit
and the associated cost when the Company has not yet been invoiced or otherwise notified of
actual cost incurred.
Auditing the Company’s accruals for clinical vendor costs associated with in-process clinical
related activities is judgmental because the timing and pattern of vendor invoicing may not
correspond to the level of services provided and the estimate can incorporate significant
assumptions such as expected patient enrollment, site activation, and estimated project
duration.
To evaluate the clinical vendors accrued costs, our audit procedures included, among others,
reading the Company’s contracts with clinical vendors (including pending change orders),
testing the completeness and accuracy of the underlying data used in the estimate of the level
of service provided including evaluating the significant assumptions as discussed above for
the applicable in process contracts with clinical vendors. To assess the significant
assumptions, we corroborated the progress of clinical related activities through inquiry with
the Company’s operations personnel that oversee the clinical trials contract manufacturing
activities and with information obtained directly from third party clinical vendors, as well as
tested invoices received from clinical vendors subsequent to the balance sheet date.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2000.
Raleigh, North Carolina
February 24, 2021
F-3
vTv Therapeutics Inc.
Consolidated Balance Sheets
(dollars in thousands, except per share and share data)
December 31,
2020
December 31,
2019
Assets
Current assets:
Cash and cash equivalents ................................................................................................... $
Accounts receivable, net ......................................................................................................
Prepaid expenses and other current assets ...........................................................................
Current deposits ...................................................................................................................
Total current assets ...................................................................................................................
Restricted cash and cash equivalents, long-term.......................................................................
Property and equipment, net .....................................................................................................
Operating lease right-of-use assets ...........................................................................................
Long-term investments .............................................................................................................
Long-term deposits ...................................................................................................................
Total assets ............................................................................................................................... $
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses ............................................................................. $
Current portion of operating lease liabilities .......................................................................
Current portion of contract liabilities ..................................................................................
Current portion of notes payable .........................................................................................
Total current liabilities ..............................................................................................................
Contract liabilities, net of current portion .................................................................................
Operating lease liabilities, net of current portion ......................................................................
Warrant liability, related party ..................................................................................................
Other liabilities .........................................................................................................................
Total liabilities ..........................................................................................................................
Commitments and contingencies ..............................................................................................
Redeemable noncontrolling interest .........................................................................................
Stockholders’ deficit:
Class A Common Stock, $0.01 par value; 100,000,000 shares authorized, 54,050,710
and 40,918,522 shares outstanding as of December 31, 2020 and December 31, 2019,
respectively.......................................................................................................................
Class B Common Stock, $0.01 par value; 100,000,000 shares authorized, and 23,094,221
outstanding as of December 31, 2020 and December 31, 2019.........................................
Additional paid-in capital ....................................................................................................
Accumulated deficit ............................................................................................................
Total stockholders’ deficit attributable to vTv Therapeutics Inc. .............................................
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit ........................ $
5,747 $
158
939
371
7,215
—
367
482
6,725
—
14,789 $
6,120 $
155
31
84
6,390
1,009
676
2,871
50
10,996
1,777
5
806
250
2,838
2,500
461
543
2,480
444
9,266
7,068
110
31
6,172
13,381
1,033
831
2,601
260
18,106
83,895
40,183
541
409
232
209,161
(290,036 )
(80,102 )
14,789 $
232
183,858
(233,522)
(49,023)
9,266
The accompanying notes are an integral part of the consolidated financial statements.
F-4
vTv Therapeutics Inc.
Consolidated Statements of Operations
(in thousands, except per share and share data)
Revenue ........................................................................................................... $
Operating expenses:
Research and development ...................................................................
General and administrative ...................................................................
Total operating expenses .................................................................
Operating loss ..................................................................................................
Other income (loss) ..........................................................................................
Other (expense) income – related party ...........................................................
Interest income.................................................................................................
Interest expense ...............................................................................................
Loss before income taxes and noncontrolling interest .....................................
Income tax provision .......................................................................................
Net loss before noncontrolling interest ............................................................
Less: net loss attributable to noncontrolling interest .......................................
Net loss attributable to vTv Therapeutics Inc. ................................................. $
Net loss attributable to vTv Therapeutics Inc. common shareholders ............. $
Net loss per share of vTv Therapeutics Inc. Class A Common Stock,
basic and diluted ...................................................................................... $
Weighted-average number of vTv Therapeutics Inc. Class A Common
Stock, basic and diluted ...........................................................................
2020
Years Ending December 31,
2019
2018
6,414
$
2,764
$
12,434
11,015
7,251
18,266
(11,852)
—
(270)
12
(692)
(12,802)
—
(12,802)
(4,303)
(8,499) $
(8,499) $
15,119
8,537
23,656
(20,892)
1
827
53
(1,827)
(21,838)
100
(21,938)
(8,894)
(13,044) $
(17,913) $
23,035
9,223
32,258
(19,824)
46
(638)
61
(3,290)
(23,645)
200
(23,845)
(15,934)
(7,911)
(8,650)
(0.18) $
(0.59) $
(0.69)
47,137,917
30,292,030
12,449,236
The accompanying notes are an integral part of the consolidated financial statements.
F-5
.
c
n
I
s
c
i
t
u
e
p
a
r
e
h
T
v
T
v
t
i
c
i
f
e
D
’
s
r
e
d
l
o
h
k
c
o
t
S
d
n
a
t
s
e
r
e
t
n
I
g
n
i
l
l
o
r
t
n
o
c
n
o
N
e
l
b
a
m
e
e
d
e
R
n
i
s
e
g
n
a
h
C
f
o
s
t
n
e
m
e
t
a
t
S
d
e
t
a
d
i
l
o
s
n
o
C
3
1
2
6
7
6
,
2
1
5
1
0
0
5
,
1
2
—
)
8
0
3
,
1
(
3
7
8
,
2
5
)
3
5
8
,
2
8
(
)
4
4
0
,
3
1
(
8
1
5
,
1
3
4
4
,
5
0
0
5
,
7
2
)
2
9
9
(
—
5
0
4
,
3
1
)
9
9
4
,
8
(
)
3
2
0
,
9
4
(
9
0
0
,
1
6
9
4
,
2
1
0
0
0
,
0
1
—
0
3
9
,
1
)
5
1
0
,
8
4
(
)
2
0
1
,
0
8
(
)
1
1
9
,
7
(
)
7
4
0
,
1
5
1
(
l
a
t
o
T
'
s
r
e
d
l
o
h
k
c
o
t
S
t
i
c
i
f
e
D
$
)
8
5
0
,
9
7
2
(
$
2
8
6
,
7
2
1
$
d
e
t
a
l
u
m
u
c
c
A
t
i
c
i
f
e
D
l
a
n
o
i
t
i
d
d
A
n
i
-
d
i
a
P
l
a
t
i
p
a
C
)
1
1
9
,
7
(
—
3
1
2
—
—
—
—
3
7
8
,
2
5
)
4
4
0
,
3
1
(
)
3
8
8
,
3
3
2
(
—
—
—
—
—
—
—
—
—
—
5
0
4
,
3
1
)
9
9
4
,
8
(
)
2
2
5
,
3
3
2
(
$
)
5
1
0
,
8
4
(
)
6
3
0
,
0
9
2
(
—
—
6
7
6
,
2
1
5
1
4
9
3
,
1
2
—
—
)
8
0
3
,
1
(
—
8
1
5
,
1
5
9
5
,
0
5
1
6
0
4
,
5
1
3
3
,
7
2
)
2
9
9
(
—
—
—
9
0
0
,
1
8
5
8
,
3
8
1
1
4
4
,
2
1
—
—
7
3
9
,
9
6
1
9
,
1
$
1
6
1
,
9
0
2
$
k
c
o
t
S
n
o
m
m
o
C
B
s
s
a
l
C
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
)
a
t
a
d
e
r
a
h
s
t
p
e
c
x
e
,
s
d
n
a
s
u
o
h
t
n
i
(
t
n
u
o
m
A
s
e
r
a
h
S
t
n
u
o
m
A
s
e
r
a
h
S
e
l
b
a
m
e
e
d
e
R
g
n
i
l
l
o
r
t
n
o
c
n
o
N
t
s
e
r
e
t
n
I
—
2
3
2
—
—
—
—
—
—
—
2
3
2
—
—
—
—
—
—
—
2
3
2
—
—
—
—
—
—
—
2
3
2
$
6
4
2
,
9
1
1
,
3
2
—
—
—
)
5
2
0
,
5
2
(
—
—
—
—
1
2
2
,
4
9
0
,
3
2
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1
2
2
,
4
9
0
,
3
2
$
1
2
2
,
4
9
0
,
3
2
7
9
—
—
—
—
6
0
1
—
—
—
3
0
2
—
—
7
3
9
6
1
—
—
—
9
0
4
—
—
5
5
3
6
4
1
—
—
1
4
5
$
4
5
2
,
3
9
6
,
9
—
—
—
5
2
0
,
5
2
9
1
1
,
7
1
6
,
0
1
—
7
6
6
,
1
1
—
—
—
5
6
0
,
7
4
3
,
0
2
4
6
3
,
6
3
6
,
3
7
2
4
,
3
2
9
,
6
1
—
6
6
6
,
1
1
—
—
—
2
2
5
,
8
1
9
,
0
4
1
4
9
,
0
8
4
,
5
0
0
0
,
0
5
2
,
6
7
6
6
,
1
1
0
8
5
,
9
8
3
,
1
)
4
3
9
,
5
1
(
0
4
4
,
1
3
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
$
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
7
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
—
—
)
1
5
1
(
—
—
—
)
3
7
8
,
2
5
(
)
4
9
8
,
8
(
2
8
4
,
2
6
—
—
—
—
—
—
—
—
—
—
)
5
0
4
,
3
1
(
)
3
0
3
,
4
(
3
8
1
,
0
4
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
e
g
n
a
h
c
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
r
o
f
k
c
o
t
S
n
o
m
m
o
C
B
s
s
a
l
C
f
o
e
g
n
a
h
c
x
E
g
n
i
t
n
u
o
c
c
a
f
o
t
c
e
f
f
e
e
v
i
t
a
l
u
m
u
C
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
n
e
m
e
e
r
g
A
r
e
t
t
e
L
e
h
t
r
e
d
n
u
y
t
r
a
p
d
e
t
a
l
e
r
a
o
t
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
s
s
a
l
C
e
s
a
h
c
r
u
p
o
t
s
t
n
a
r
r
a
w
d
n
a
t
n
e
m
e
e
r
g
A
r
e
t
t
e
L
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
y
t
r
a
p
d
e
t
a
l
e
r
-
k
c
o
t
S
n
o
m
m
o
C
A
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
V
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
t
s
e
r
e
t
n
i
g
n
i
l
l
o
r
t
n
o
c
n
o
n
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
8
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
f
o
e
u
l
a
v
n
o
i
t
p
m
e
d
e
r
n
i
e
g
n
a
h
C
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
g
n
i
r
e
f
f
o
t
c
e
r
i
d
d
e
r
e
t
s
i
g
e
r
r
e
d
n
u
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
n
e
m
e
e
r
g
A
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
y
t
r
a
p
d
e
t
a
l
e
r
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
V
o
t
s
t
n
a
r
r
a
w
d
n
a
t
n
e
m
e
e
r
g
A
r
e
t
t
e
L
f
o
e
c
n
a
u
s
s
I
-
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
e
s
a
h
c
r
u
p
r
e
t
t
e
L
e
h
t
r
e
d
n
u
y
t
r
a
p
d
e
t
a
l
e
r
a
o
t
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
g
n
i
r
e
f
f
o
M
T
A
r
e
d
n
u
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
t
s
e
r
e
t
n
i
g
n
i
l
l
o
r
t
n
o
c
n
o
n
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
9
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
f
o
e
u
l
a
v
n
o
i
t
p
m
e
d
e
r
n
i
e
g
n
a
h
C
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
n
e
m
e
e
r
g
A
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
t
n
e
m
e
e
r
g
A
C
P
L
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
V
r
e
d
n
u
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
f
o
e
u
l
a
v
n
o
i
t
p
m
e
d
e
r
n
i
e
g
n
a
h
C
r
e
t
t
e
L
e
h
t
r
e
d
n
u
y
t
r
a
p
d
e
t
a
l
e
r
a
o
t
k
c
o
t
S
n
o
m
m
o
C
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
—
$
0
1
7
,
0
5
0
,
4
5
5
1
0
,
8
4
5
9
8
,
3
8
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
t
s
e
r
e
t
n
i
g
n
i
l
l
o
r
t
n
o
c
n
o
n
$
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
0
2
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
.
s
t
n
e
m
e
t
a
t
s
l
a
i
c
n
a
n
i
f
d
e
t
a
d
i
l
o
s
n
o
c
e
h
t
f
o
t
r
a
p
l
a
r
g
e
t
n
i
n
a
e
r
a
s
e
t
o
n
g
n
i
y
n
a
p
m
o
c
c
a
e
h
T
6
-
F
vTv Therapeutics Inc.
Consolidated Statements of Cash Flows
(in thousands)
Cash flows from operating activities:
Net loss before noncontrolling interest ............................................................................................. $
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating
activities:
Loss (gain) on disposal of property and equipment, net ............................................................
Depreciation expense .................................................................................................................
Share-based compensation expense ...........................................................................................
Change in fair value of investments ...........................................................................................
Change in fair value of warrants, related party ..........................................................................
Amortization of debt discount ....................................................................................................
Changes in assets and liabilities:
Accounts receivable ...................................................................................................................
Prepaid expenses and other assets ..............................................................................................
Long-term deposits .....................................................................................................................
Accounts payable and accrued expenses ...................................................................................
Accreted interest on debt ............................................................................................................
Contract liabilities ......................................................................................................................
Other liabilities ...........................................................................................................................
Net cash used in operating activities .................................................................................................
Cash flows from investing activities:
Proceeds from sale of assets .......................................................................................................
Purchases of property and equipment ........................................................................................
Net cash provided by investing activities .........................................................................................
Cash flows from financing activities:
Proceeds from issuance of Class A Common Stock to a related party under the Letter
Agreements ..............................................................................................................................
Proceeds from issuance of Class A Common Stock, net of offering costs ...............................
Proceeds from debt issuance ......................................................................................................
Repayment of notes payable ......................................................................................................
Net cash provided by financing activities .........................................................................................
Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents ...........
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of year ..............
Total cash, cash equivalents and restricted cash and cash equivalents, end of year ........................ $
Supplemental cash flow information:
Cash paid for interest .................................................................................................................. $
Cash paid for income taxes ........................................................................................................ $
Non-cash activities:
Right-of-use assets obtained in exchange for lease obligations ................................................ $
Leasehold improvements obtained in exchange for lease obligations ...................................... $
Change in redemption value of noncontrolling interest............................................................. $
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC
member units for vTv Therapeutics Inc. Class A Common Stock .........................................
Issuance of Letter Agreements and warrants to purchase vTv Therapeutics Inc. Class A
Common Stock to a related party ...........................................................................................
$
$
Twelve Months Ended December 31,
2019
2018
2020
(12,802) $
(21,938) $
(23,845)
—
94
1,009
(4,245)
270
380
(153)
(254)
444
(997)
(1,512)
(24)
(210)
(18,000)
—
—
—
10,000
14,426
500
(5,456)
19,470
1,470
4,277
5,747 $
623 $
— $
— $
— $
48,015 $
—
—
$
$
(288)
39
1,518
—
(827)
532
(5)
732
(408)
(618)
—
(1,755)
—
(23,018)
312
(70)
242
27,500
5,443
500
(10,573)
22,870
94
4,183
4,277 $
1,295 $
100 $
548 $
384 $
(13,405) $
— $
992 $
(12)
218
2,676
—
638
1,014
8,000
(1,135)
2,256
(6,199)
—
(10,435)
(32)
(26,856)
12
(5)
7
21,500
—
500
(5,388)
16,612
(10,237)
14,420
4,183
2,276
1,000
—
—
(52,873)
151
1,308
The accompanying notes are an integral part of the consolidated financial statements.
F-7
vTv Therapeutics Inc.
Notes to Consolidated Financial Statements
(dollar amounts are in thousands, unless otherwise noted)
Note 1: Description of Business and Basis of Presentation
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”), was incorporated in the state of Delaware in April
2015. The Company is a clinical-stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term
complications through end-organ protection.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC
(“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the
discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv
Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that
the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all
of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics
Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its
Consolidated Financial Statements. Various holders own non-voting interests in vTv LLC, representing a 29.9% economic interest in
vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 70.1% of vTv LLC’s economic results, subject to increase in the
future, should vTv Therapeutics Inc. purchase additional nonvoting common units (“vTv Units”) of vTv LLC or should the holders of
vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B
Common Stock”)) for shares of Class A Common Stock (or cash) pursuant to the Exchange Agreement among the Company, vTv
LLC and the holders of vTv Units party thereto (the “Exchange Agreement”). vTv Therapeutics Inc. has provided financial and other
support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the IPO in 2015, its agreeing to be a co-borrower
under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon
Valley Bank (together, the “Lenders”) which was entered into in 2016, its entrance into the letter agreements with MacAndrews and
Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates
“MacAndrews”), in December 2017, July 2018, December 2018, March 2019, September 2019 and December 2019 (the “Letter
Agreements”), the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor
Fitzgerald”) (the “ATM Offering”), and the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC
Purchase Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv
Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management
is the management of vTv LLC. The creditors of vTv LLC do not have any recourse to the general credit of vTv Therapeutics Inc.
Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties
at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Going Concern and Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing
development of the Company’s drug candidates will require additional financing. From its inception through December 31, 2020, the
Company has funded its operations primarily through a combination of debt and equity financings, research collaboration agreements,
upfront and milestone payments for license agreements and private placements of preferred equity. As of December 31, 2020, the
Company had an accumulated deficit of $290.0 million and has generated net losses in each year of its existence. The Company’s
currently available sources of liquidity include the Company’s cash and cash equivalents balance as of December 31, 2020 of $5.7
million.
As of December 31, 2020, the Company also had the ability to sell an additional 3,941,726 shares of Class A Common Stock
under the LPC Purchase Agreement based on the number of shares initially registered. The extent to which the Company utilizes the
LPC Purchase Agreement as a source of funding will depend on a number of factors, including the prevailing market price of and the
volume of trading in the Company’s Class A Common Stock and the extent to which the Company is able to secure funds from other
sources. The number of shares that the Company may sell to Lincoln Park under the purchase agreement on any given day and during
the term of the agreement is limited. Additionally, the Company and Lincoln Park may not effect any sales of shares of our common
stock under the purchase agreement during the continuance of an event of default under the purchase agreement.
F-8
On January 14, 2021, the Company also expanded the availability under its ATM Offering, pursuant to which the Company may
offer and sell, from time to time, through Cantor, shares of its Class A common stock having an aggregate offering price of $5.5
million. Management believes these sources of liquidity will allow the Company to continue its operations and activities for a period
of less than twelve months from the issuance of these Consolidated Financial Statements.
Based on the Company’s current operating plan, management believes that the current cash and cash equivalents, availability
under the ATM Offering and amounts raised under the LPC Purchase Agreement through February 24, 2021 will allow the Company
to meet its liquidity requirements through the end of the third quarter of 2021. These conditions raise substantial doubt about the
Company’s ability to continue as a going concern. The Company is evaluating several financing strategies to fund its planned and
ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The timing and
availability of such financing are not yet known.
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which
contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The
Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and
classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a
going concern.
Note 2: Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of
America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards,
the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of its Class B Common Stock, the useful
lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on
historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making
judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit
with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.
Three customers represented 100% of the revenue earned during the years ended December 31, 2020 and 2018. Four customers
represented 100% of the revenue earned during the year ended December 31, 2019.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash
equivalents.
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents, long-term relates to the minimum balance that the Company was required to maintain in a
deposit account pledged to secure the Loan Agreement and was subject to an account control agreement pursuant to the Loan
Agreement, as amended. The Loan Agreement was amended to remove the minimum cash requirements during 2020 and with its full
repayment as of December 31, 2020, the account control agreement has been terminated.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated
Balance Sheets as of December 31, 2020 and 2019 that sum to the total of the same such amounts shown in the Consolidated
Statements of Cash Flows (in thousands):
F-9
Cash and cash equivalents ................................................................... $
Restricted cash and cash equivalents, long-term .................................
Total cash, cash equivalents and restricted cash and cash
equivalents shown in the consolidated statement of
cash flows ......................................................................................... $
2020
2019
5,747 $
—
1,777
2,500
5,747 $
4,277
Collaboration Revenue and Accounts Receivable
The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its
potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements.
Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and
establishes an allowance based on its history of collections and write-offs and the current status of all receivables.
Property and Equipment and other Long-lived Assets
The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that
extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a
straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements
are depreciated over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets,
the costs and related accumulated depreciation are removed from the accounts with the resulting gains or losses, if any, reflected in
results of operations.
The estimated useful lives of property and equipment are as follows:
Asset Category
Laboratory equipment ................................
Computers and hardware ...........................
Furniture and office equipment ..................
Software .....................................................
Leasehold improvements ........................... Shorter of useful life or remaining
Useful Life (in years)
7
3-5
3-7
3
term of lease
The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with
the relevant accounting guidance and recorded an impairment charge of $0.1 million during the year ended December 31, 2018. No
such charges were recognized during the years ended December 31, 2020 or 2019. There were no assets held for sale at December 31,
2020 or 2019.
Investments
The Company holds equity investments without readily determinable market values. The Company has elected to measure
these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly
transactions for the identical or similar investment.
Revenue Recognition
On January 1, 2018, the Company adopted ASC Topic 606, “Revenue From Contracts With Customers” (“ASC Topic 606”),
using the modified retrospective method applied to those contracts which were not completed as of the adoption date. Results for
reporting periods beginning after January 1, 2018 are presented under ASC Topic 606, while prior period amounts are not adjusted
and continue to be reported in accordance with the Company’s historic accounting under ASC Topic 605.
The Company recorded a net reduction to its opening accumulated deficit of $0.2 million as of January 1, 2018 due to the
cumulative impact of adopting ASC Topic 606. This impact related to the recognition of an asset for the incremental costs of
obtaining contracts.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development
of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the
rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of
F-10
consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included
within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The
Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in
exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s
collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is
included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance
obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the
standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price
is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the
services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernable
pattern over which the services will be provided.
Fair Value of Financial Instruments
The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a
recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial
measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable
inputs, when determining fair value. The three tiers are defined as follows:
•
•
•
Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active
markets;
Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in
the marketplace for identical or similar assets and liabilities; and
Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its
own assumptions.
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and
development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug
development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to
consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and
development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to
contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts
with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of
these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments
under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or
similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to
the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the
Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid
expenses. Prepaid expenses are recognized as expense in the Consolidated Statements of Operations as the Company receives the
related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research
and development expense.
Patent Costs
Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating
expenses on the Consolidated Statements of Operations.
F-11
Income Taxes
From its formation on August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30,
2015, the Company’s predecessor entities were taxed as partnerships and all their income and deductions flowed through and were
subject to tax at the partner level.
vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial
reporting and tax basis of its investment in vTv LLC.
The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect
management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States
and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the
Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of
assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a
change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.
The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In
making such a determination, the Company considers all available positive and negative evidence, including future reversals of
existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.
The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-
likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions
meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to
be realized upon ultimate settlement with the related tax authority.
Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s
Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in
any of the periods presented.
Noncontrolling Interest
The Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B Common stock at
the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption
value as of the balance sheet date. See discussion and additional detail of the redeemable noncontrolling interest at Note 13.
Segment and Geographic Information
Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs
expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker
(“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief
Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.
F-12
Leases
The Company determines if an arrangement is a lease at inception. Balances recognized related to operating leases are included
in operating lease right-of-use assets and operating lease liabilities in the Consolidated Balance Sheets. Operating lease right-of-use
assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at commencement date. Lease terms may include options to extend of terminate the lease if it is reasonably certain that the
Company will exercise the option. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the information available at the commencement date in determining the present value of future payments.
The operating lease right-of-use asset also includes any lease payments made and excludes lease incentives and initial direct costs
incurred. The Company has elected a practical expedient to not separate its lease and non-lease components and instead account for
them as a single lease component.
Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-
term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which
the obligation for those payments is incurred.
Share-Based Compensation
Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant,
and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option
awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with
respect to its own shares, the Company estimates expected volatility based on the historical volatility of its own stock as well as a
portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is
based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates
the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2.
The fair value of restricted stock units (“RSU”) grants are based on the market value of the Class A Common Stock on the date of
grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee
turnover rates.
Comprehensive Income
The Company does not have any components of other comprehensive income recorded within its Consolidated Financial
Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements.
Recently Issued Accounting Pronouncements
There have been no recently accounting pronouncements which are expected to have a material impact on the Company’s
financial statements.
Note 3: Collaboration Agreements
Reneo License Agreement
On December 21, 2017, the Company entered into the Reneo License Agreement, under which Reneo obtained an exclusive,
worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta
(PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans.
Under the terms of the Reneo License Agreement, Reneo paid the Company an upfront cash payment of $3.0 million. The Company is
eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In
addition, Reneo is obligated to pay the Company royalty payments at mid-single to low-double digit rates, based on tiers of annual net
sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis
until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a
licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. As
additional consideration, the Company has also received common stock and certain participation rights representing a minority equity
interest in Reneo.
Pursuant to the terms of the Reneo License Agreement, the Company is required to provide technology transfer services for a
defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations
at the inception of the Reneo License Agreement. The significant obligations were determined to be the license and the technology
transfer services. The Company has determined that the license and technology transfer services represent a single performance
obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this
F-13
combined performance obligation. The remaining milestone payments that the Company is eligible to receive have not been included
in the transaction price as of December 31, 2020, as it is not considered probable that such payments will be received.
The Company determined that there was no discernable pattern in which the technology services would be provided during the
transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the
transfer service period. As of December 31, 2020, revenue allocated to this performance obligation has been fully recognized. No
revenue was recognized related to the Reneo License Agreement for the year ended December 31, 2020. For the years ended
December 31, 2019 and 2018, $1.7 million and $3.7 million of revenue was recognized related to this combined performance
obligation, respectively.
Huadong License Agreement
On December 21, 2017, the Company entered into a License Agreement with Huadong (the “Huadong License Agreement”),
under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like
peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China
and certain other Pacific Rim territories, including Australia and South Korea (collectively, the “Huadong License Territory”).
Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to
develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic
uses in humans or animals outside of the Huadong License Territory. As discussed further in Note 20, on January 14, 2021, the
Company entered into the First Amendment to the Huadong License Agreement (the “First Huadong Amendment”). Under the terms
of the Huadong License Agreement, as amended, Huadong paid the Company an initial license fee of $8.0 million and is obligated to
pay potential development and regulatory milestone payments totaling up to $22.0 million, with an additional potential regulatory
milestone of $20.0 million if Huadong receives regulatory approval for a central nervous system indication. In addition, the Company
is eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to
low-double digit rates, based on tiered sales of licensed products.
Prior to the First Huadong Amendment, the Company also had the obligation to conduct a Phase 2 multi-region clinical trial (the
“Phase 2 MRCT”), should Huadong require it to do so. If conducted, the Phase 2 MRCT was to include sites in both the United States
and Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes and was
to be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a
Phase 3 clinical trial in China. The Company was responsible for contributing up to $3.0 million in connection with the Phase 2
MRCT. The First Huadong Amendment eliminated this obligation from the Huadong License Agreement.
In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Huadong
License Agreement. The significant performance obligations were determined to be (i) the exclusive license to develop and
commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-
how for a defined period after the effective date (iii) the obligation to sponsor and conduct the Phase 2 MRCT, (iv) the Company’s
obligation to participate on a joint development committee, and (v) other obligations considered to be de minimis in nature.
The transaction price has been allocated to these performance obligations based on their relative standalone selling prices, which
were estimated using an expected cost plus margin approach. The remaining milestone payments that the Company is eligible to
receive have not been included in the transaction price as of December 31, 2020, as it is not considered probable that such payments
will be received.
The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-
how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also
determined that there was no discernable pattern in which the technology transfer services would be provided during the transfer
service period. As such, the Company determined that the straight-line method would be used to recognize revenue for this
performance obligation over the transfer service period. In November 2018, the Company received notification from Huadong that
the Company had satisfied its obligations related to the technology transfer services. As such, this performance obligation is
considered complete as of December 31, 2018 and all of revenue associated with it has been recognized. For the year ended
December 31, 2018, the Company recognized $6.8 million of revenue related to this combined performance obligation.
The Company also determined that the obligation to sponsor and conduct a portion of the Phase 2 MRCT should be treated as a
separate performance obligation. A portion of the total consideration received under the Huadong License Agreement was allocated
to this performance obligation based on its estimated standalone selling price. Since the Company has not begun the Phase 2 MRCT
trial, the entire amount remains deferred as of December 31, 2020 and revenue will be recognized using the proportional performance
model over the period during which the Company conducts the Phase 2 MRCT trial. The unrecognized amount of the transaction
price allocated to this performance obligation as of December 31, 2020 was $1.0 million. No revenue for this performance obligation
has been recognized as of December 31, 2020. As discussed above and further in Note 20, the obligation to conduct the Phase 2
MRCT was removed by the First Huadong Amendment.
F-14
The Company also determined that the obligation to participate in the joint development committee (the “JDC”) to oversee the
development of products and the Phase 2 MRCT in accordance with the development plan should be treated as a separate performance
obligation. A portion of the total consideration received under the Huadong License Agreement was allocated to this performance
obligation based on its estimated standalone selling price. A portion of this amount remains deferred as of December 31, 2020 and
revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC.
The unrecognized amount of the transaction price allocated to this performance obligation as of December 31, 2020 was $0.1 million.
An immaterial amount of revenue was recognized for this performance obligation for the years ended December 31, 2020, 2019 and
2018.
There have been no adjustments to the transaction price for the performance obligations under the Huadong License Agreement
during the years ended December 31, 2020, 2019 and 2018.
Newsoara License Agreement
On May 31, 2018, the Company entered into a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the
“Newsoara License Agreement”), under which Newsoara obtained an exclusive and sublicensable license to develop and
commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China and
other Pacific Rim territories (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement,
the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent
rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License
Territory. The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the
“First Newsoara Amendment”). Under the terms of the Newsoara License Agreement, Newsoara paid the Company an upfront cash
payment of $2.0 million. During the year ended December 31, 2019, the Company received an additional payment of $1.0 million
related to the satisfaction of a development milestone during the year. As amended, the Company is eligible to receive additional
potential development, regulatory and sales-based milestone payments totaling up to $58.5 million. In addition, Newsoara is obligated
to pay the Company royalty payments at high-single to low-double digit rates, based on tiers of annual net sales of licensed
products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of
expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product
in a country or a specified number of years after the first commercial sale of a licensed product in a country.
Pursuant to the terms of the Newsoara License Agreement, the Company is required to provide technology transfer services for a
defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations
at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the
technology transfer services. The Company has determined that the license and technology transfer services represent a single
performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to
this combined performance obligation. The remaining milestone payments that the Company is eligible to receive have not been
included in the transaction price as of December 31, 2020, as it is not considered probable that such payments will be received.
The Company determined that there was no discernable pattern in which the technology services would be provided during the
transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the
transfer service period. The $2.0 million of the transaction price related to the upfront payment allocated to this performance
obligation was recognized during the year ended December 31, 2018.
During the year ended December 31, 2019, the transaction price for this performance obligation was increased by $1.0 million
due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during
the year ended December 31, 2019, as the related performance obligation has been fully satisfied.
F-15
Anteris License Agreement
On December 11, 2020, we entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License
Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the
Company’s Nrf2 activator, HPP971.
Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The
Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0
million. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products.
Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents
covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number
of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received
preferred stock representing a minority ownership interest in Anteris.
Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for
a 30 day period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance
obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the
technology transfer services. The Company has determined that the license and technology transfer services represent a single
performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to
this combined performance obligation. As of December 31, 2020, the transaction price consists of the $2.0 million initial license
payment as well as the fair value of the equity interest received in Anteris of $4.2 million. The remaining milestone payments that the
Company is eligible to receive have not been included in the transaction price as of December 31, 2020, as it is not considered
probable that such payments will be received. The revenue related to this performance obligation has been fully recognized as of
December 31, 2020 as the technology transfer services are considered complete.
JDRF Agreement
In August 2017, the Company entered into the JDRF Agreement to support the funding of the Simplici-T1 Study, an adaptive
Phase 1b/2 study to explore the effects of TTP399 in type 1 diabetics. We initiated this study in the fourth quarter of 2017. According
to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.0 million based on the achievement of research
and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the
project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization,
licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes.
Payments that the Company receives from JDRF under this agreement are recorded as restricted cash and current liabilities and
recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the
restricted cash is utilized to fund such development activities. As of December 31, 2020, the Company had received funding under
this agreement of $3.0 million, and research and development costs were offset by $3.0 million.
Contract Liabilities
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
Current portion of contract liabilities ...................................................... $
Contract liabilities, net of current portion ...............................................
Total contract liabilities ........................................................................ $
31 $
1,009
1,040 $
31
1,033
1,064
December 31, 2020
December 31, 2019
The change in the Company’s contract liabilities for the year ended December 31, 2020 of an immaterial amount was due to the
recognition of amounts included in the contract liability at the beginning of the period. The Company also recognized an additional
$1.0 million of revenue related to changes in the estimated transaction prices for one of its customer contracts during the year ended
December 31, 2019 for which the related performance obligation had already been satisfied.
Note 4: Share-Based Compensation
In conjunction with the Company’s initial public offering (“IPO”), the board of directors of vTv Therapeutics Inc. (the “Board
of Directors”) and sole stockholder adopted a long-term equity incentive plan, the vTv Therapeutics Inc. 2015 Omnibus Equity
Incentive Plan (the “Plan”). The Plan provides for the grant of stock options, restricted stock, restricted stock units and other awards
based on our Class A Common Stock to management, other key employees, consultants and non-employee directors on terms and
subject to conditions as established by our Compensation Committee. In settlement of its obligations under this plan, the Company
F-16
will issue new shares of Class A Common Stock. Following an amendment to increase the number of shares available under the plan
in 2020, the maximum number of shares of the Company’s Class A Common Stock that has been approved and may be subject to
awards under the Plan is 7.0 million, subject to adjustment in accordance with terms of the Plan.
The Company has issued non-qualified stock option awards and restricted stock units to certain employees, consultants and non-
employee directors of the Company. These awards generally vest ratably over a three-year period and the option awards expire after a
term of ten years from the date of grant. For the years ended December 31, 2020, 2019 and 2018, the Company recognized $1.0
million, $1.5 million and $2.7 million of compensation expense related to share-based awards, respectively. Given that the Company
has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these
awards. As of December 31, 2020, the Company had total unrecognized stock-based compensation expense of approximately $3.6
million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.6 years. The weighted
average grant date fair value for all option grants during the years ended December 31, 2020, 2019 and 2018 was $1.81, $1.91 and
$2.28 per option, respectively.
The aggregate intrinsic value of the in-the-money awards outstanding as well as those exercisable as of December 31, 2020 was
an insignificant amount.
The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of
stock options granted was estimated using the following assumptions during the years ended December 31, 2020, 2019 and 2018:
Expected volatility ............................
Expected life of option, in years .......
Risk-free interest rate ........................
Expected dividend yield ....................
2020
120.37% - 121.43%
5.7 - 6.0
0.39% - 0.53%
0.00%
For the Year Ended December 31,
2019
115.29% - 120.15%
5.3 - 6.0
1.58% - 2.64%
0.00%
2018
71.15% - 99.23%
5.7 - 6.0
2.69% - 2.84%
0.00%
The following table summarizes the activity related to the stock option awards for the year ended December 31, 2020 (in
thousands, except per share amounts):
Number of Shares
Weighted-
Average Exercise Price
Awards outstanding at December 31, 2019 ..................
Granted ...................................................................
Forfeited ..................................................................
Awards outstanding at December 31, 2020 ..................
Options exercisable at December 31, 2020 ..................
Weighted average remaining contractual term........
Options vested and expected to vest at December 31,
2020 ..............................................................................
Weighted average remaining contractual term........
2,531,143 $
1,975,250
(53,036)
4,453,357 $
1,852,721 $
6.0 Years
4,166,666 $
7.9 Years
6.19
2.10
3.28
4.41
7.58
4.57
The following table summarizes the activity related to the awards of RSUs for the year ended December 31, 2020:
Awards outstanding at December 31, 2019 ...................
Vested ......................................................................
Awards outstanding at December 31, 2020 ...................
RSUs expected to vest at December 31, 2020 ...............
11,667 $
(11,667)
— $
— $
5.81
5.81
—
—
Number of Shares
Weighted-
Average Grant Date Fair
Value
F-17
As of December 31, 2020, the Company had no unrecognized stock-based compensation expense for its outstanding RSU
awards.
Compensation expense related to the grants of stock options is included in research and development and general and
administrative expense as follows (in thousands):
Research and development ............................. $
General and administrative .............................
Total share-based compensation expense .... $
348 $
661
1,009 $
522 $
996
1,518 $
994
1,682
2,676
2020
2019
2018
Note 5: Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following (in thousands):
Prepaid insurance ...................................................................... $
Prepaid taxes .............................................................................
Prepaid - other ..........................................................................
Total .................................................................................... $
December 31,
2020
2019
771 $
129
39
939 $
551
147
108
806
Note 6: Property and Equipment
Property and equipment consists of the following (in thousands):
Leasehold improvements ........................................................... $
Computers and hardware ...........................................................
Software .....................................................................................
Furniture and office equipment .................................................
Total property and equipment ..............................................
Less: accumulated depreciation and amortization .....................
Property and equipment, net ...................................................... $
December 31,
2020
2019
406 $
48
80
49
583
(216)
367 $
405
48
107
49
609
(148 )
461
Depreciation expense was $0.1 million and $0.2 million for the years ended December 31, 2020 and 2018, respectively and was
an insignificant amount for the year ended December 31, 2019.
Note 7: Investments
In connection with the Reneo and Anteris License Agreements, the Company has received equity interests representing a
minority equity interest in each investee. In each case, the Company’s investment is measured at cost less impairment, adjusted for
any changes in observable prices, because the Company owns less than 20% of the voting equity and does not have the ability to
exercise significant influence over the investees. The investments were initially recognized at fair value and are classified as long-
term investments in the Company’s Consolidated Balance Sheets.
F-18
As of December 31, 2020, the Company’s equity investments without readily determinable fair values assessed under the
measurement alternative consist of the following:
Reneo common stock ............................... $
Anteris preferred stock ............................
Total ...................................................... $
2,480 $
4,245
6,725 $
2,480
—
2,480
December 31,
2020
2019
The Company received its investment in Anteris preferred stock as consideration under the Anteris License Agreement entered
into on December 11, 2020. The fair value of the investment was derived from the transaction prices of other securities sold using a
market approach. The investment qualifies as Level 3 under the fair value hierarchy as it was valued using unobservable inputs
including volatility and risk-free rate assumptions which were 125.0% and 0.37%, respectively.
No adjustments have been made to the value of the Company’s investment in either Reneo or Anteris since their initial
measurement either due to impairment or based on observable price changes.
Note 8: Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consist of the following (in thousands):
Accounts payable ...................................................................... $
Accrued development costs ......................................................
Accrued compensation and related costs ..................................
Accrued other ...........................................................................
Total .................................................................................... $
December 31,
2020
2019
1,925 $
2,581
1,594
20
6,120 $
2,232
3,148
1,559
129
7,068
Note 9: Leases
The Company leased its former headquarters location under an operating lease that expired in December 2019. In connection
with its adoption of ASC Topic 842, the Company recognized a right of use asset and corresponding operating lease liability of $0.3
million related to this lease as of January 1, 2019. The Company elected to use the package of practical expedients in implementing
ASC Topic 842 under which the Company did not reassess the operating or finance lease classification of its previously existing
leases. Further, the Company did not reassess whether expired or existing contracts include leases.
In August 2019, the Company leased new office space for its headquarters location under an operating lease. This lease
commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option
to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its
related right of use assets or lease liabilities as their election is not considered reasonably certain. Further, this lease does not include
any material residual value guarantee or restrictive covenants.
At December 31, 2020, the weighted average incremental borrowing rate and remaining lease term for the operating leases held
by the Company were 13.1% and 4.1 years, respectively.
Maturities of lease liabilities for the Company’s operating leases as of December 31, 2020 were as follows (in thousands):
2021 ................................................................ $
2022 ................................................................
2023 ................................................................
2024 ................................................................
2025 ................................................................
Thereafter .......................................................
Total lease payments ......................................
Less: imputed interest ....................................
Present value of lease liabilities ................ $
255
261
268
275
23
—
1,082
(251 )
831
F-19
Operating lease cost was $0.2 million, $0.4 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018,
respectively. During the year ended December 31, 2020, cash paid for operating leases was $0.2 million.
The Company had recognized an asset retirement obligation for an obligation in its old facility lease that required the Company to
return the property to the same or similar condition at the end of the lease as existed when the Company began using the facility. As
no amounts were required to be paid upon exit of the lease, the asset retirement obligation was reversed during the year ended
December 31, 2020. Asset retirement obligations recorded as a component of other noncurrent liabilities in the Consolidated Balance
Sheets were $0.3 million at December 31, 2019. An immaterial amount of accretion and depreciation expense was recognized in the
years ended December 31, 2019 and 2018
Note 10: Notes Payable
Notes payable consist of the following (in thousands):
December 31,
2020
December 31,
2019
Notes payable under the Loan Agreement .............. $
Short-term financing ...............................................
Accreted final payment ...........................................
Total notes payable ..............................................
Less: Current portion .............................................
Total notes payable, net of current portion ............. $
— $
84
—
84
(84)
— $
4,896
144
1,132
6,172
(6,172 )
—
In October 2016, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation and Silicon
Valley Bank, under which the Company and vTv LLC borrowed $20.0 million. On April 1, 2020, the Company entered into an
amendment to the Loan Agreement (the “Second Amendment”) and on July 29, 2020, the Company entered into the Third
Amendment to the Loan Agreement. These amendments extended the maturity dates of the loans and adjusted the minimum cash
balance requirements and their impacts have been incorporated into these disclosures and are more fully described below.
Each loan tranche bore interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds
0.5%.
The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first
tranche required only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued
interest through the scheduled maturity date on May 1, 2020. In connection with the Third Amendment, the maturity date of the first
tranche was extended to September 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million originally due
on May 1, 2020 was extended to September 1, 2020 as part of the Third Amendment, or such earlier date specified in the Loan
Agreement. The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly
interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled
maturity date on October 1, 2020. In connection with the Second Amendment, the maturity date of the second tranche was extended
to January 1, 2021. In addition, a final payment for the second tranche loan equal to $0.5 million was originally due on October 1,
2020, or such earlier date specified in the Loan Agreement. In connection with the Second Amendment, the due date for this final
payment was extended to January 1, 2021, or such earlier date specified in the Loan Agreement. The total amount of the payment was
increased to $0.8 million as a result of the Second and Third Amendments. For each of the first and second tranches, the combined
Second and Third Amendment required only monthly interest payments on the outstanding principal balance for the amounts due from
April 1, 2020, through August 1, 2020. As amended, the remaining principal balance and final interest payment under the first tranche
was paid upon maturity. Further, the Second and Third Amendments require equal monthly principal payments plus accrued interest
for the second tranche beginning September 1, 2020 through the scheduled maturity on January 1, 2021. The full amount outstanding
under both the first and second tranches, including the related final interest payments were paid in accordance with the scheduled
maturities, with the final payment made prior to December 31, 2020.
F-20
In connection with the Loan Agreement, the Company has issued to the Lenders warrants to purchase shares of the
Company’s Class A Common Stock (the “Warrants”). On October 28, 2016, the Company issued Warrants to purchase 152,580
shares of its Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0%
of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the principal amount available under the
second tranche of the Loan Agreement. On March 24, 2017, in connection with the funding of the second tranche, the Company
issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which
aggregate exercise price represents 3.0% of the principal amount of the second tranche of the Loan Agreement. In each instance, the
Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A
Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading
days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on
the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.
The Company’s obligations under the Loan Agreement were secured by a first priority security interest in substantially all of
its assets. As a result of the termination of the STEADFAST Study, the Company granted the Lenders a first priority security interest
in all of the Company’s intellectual property, subject to certain limited exceptions. The Company agreed not to pledge or otherwise
encumber its intellectual property assets, subject to certain exceptions. Upon full repayment and termination of the Loan Agreement
in December 2020, these security interests and pledges have been extinguished.
The Loan Agreement included customary affirmative and restrictive covenants, including, but not limited to, restrictions on
the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its
subsidiaries. The Loan Agreement did not contain any financial maintenance covenants other than a requirement to maintain a
minimum cash balance from time-to-time in a deposit account pledged to secure the Loan Agreement and subject to an account
control agreement. The Loan Agreement included customary events of default, including payment defaults, covenant defaults, and
material adverse change default. Upon full repayment and termination of the Loan Agreement in December 2020, the associated
covenants terminated.
The Company incurred $0.7 million of costs in connection with the Loan Agreement in the year ended December 31, 2016.
These costs, along with the allocated fair value of the Warrants issued of $0.9 million, were treated as a debt discount, and are offset
against the carrying value of the notes payable in the Company’s Consolidated Balance Sheets as of December 31, 2020 and 2019.
These costs will be recognized as interest expense over the term of the first tranche using the effective interest method. The Second
and Third Amendments were considered modifications to the existing agreement for accounting purposes. As such, the Company
determined a new effective interest rate of 21.5% on the debt considering the remaining unamortized cost and the increases to the final
payment for the second tranche as a result of these amendments. The related costs were amortized and the final payments for the first
and second loan tranches were accrued as additional interest expense, using the effective interest method over the remaining term of
the Loan Agreement
The Company recorded interest expense related to the Loan Agreement of $0.7 million, $1.8 million and $3.1 million for the
years ended December 31, 2020, 2019 and 2018, respectively.
Note 11: Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific
contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount.
The Company is not currently a party to any material legal proceedings.
Columbia University Agreement
In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license
certain intellectual property from Columbia. Under the agreement, the Company was obligated to pay to Columbia (1) an annual fee of
$0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments
at a single digit royalty rate based on net sales of licensed products as defined in the agreement. In December 2018, the Company
notified Columbia of its intent to terminate this license agreement.
Novo Nordisk
In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S
(the “Novo License Agreement”) whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk
F-21
intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention,
treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company
obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as
TTP399. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas
of therapeutic use. Under the terms of the Novo License Agreement, the Company has additional potential developmental and
regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million
for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The
Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at
mid-single digit royalty rates, based on tiered sales of commercialized licensed products.
Huadong License Agreement
Under the terms of the Huadong License Agreement, prior to its amendment in January 2021, vTv LLC was obligated to act as
the sponsor of the Phase 2 MRCT should Huadong require it to do so. The Phase 2 MRCT was to include sites in both US and the
Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes and was to
be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a Phase 3
clinical trial in China. vTv LLC was responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT. In
connection with the First Huadong Amendment, discussed further in Note 20, the Company’s obligation to sponsor and contribute
funding to the Phase 2 MRCT was eliminated from the Huadong License Agreement.
Note 12: Stockholders’ Equity
On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A
Common Stock, 100,000,000 shares of Class B Common Stock and 50,000,000 shares of preferred stock, par value $0.01 per share.
Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters
submitted to stockholders for their vote or approval. The holders of Class A Common Stock and Class B Common Stock will vote
together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of
certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers,
preferences or special rights of the Class B Common Stock so as to affect them adversely, which amendments must be approved by a
majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as
otherwise required by applicable law. The voting power of the outstanding Class B Common Stock (expressed as a percentage of the
total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B
Common Stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation,
dissolution or winding up of the Company.
ATM Offering
In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company
may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an
aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4)
under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement
on Form S-3.
During the year ended December 31, 2020, the Company sold 5,480,941 shares of Class A common stock under the ATM
Offering at then-market prices for total gross proceeds of approximately $13.0 million, respectively. After offering costs and sales
commissions owed in connection with the ATM Offering, the Company’s aggregate net proceeds for the year ended December 31,
2020 were approximately $12.5 million.
As discussed further in Note 20, on January 14, 2021, the Company filed a prospectus supplement increasing the aggregate
offering price available under the ATM Offering by $5.5 million.
Lincoln Park Capital Transaction
On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the
“Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class
A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC
Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park. pursuant to the
F-22
Purchase Agreement. The Company filed a registration statement to register 5,331,306 shares which became effective on December
8, 2020.
As a result, on November 24, 2020, 425,725 newly issued shares of the Company’s common stock, equal to 1.5% percent of the
$47.0 million availability, were issued to Lincoln Park as consideration for Lincoln Park’s commitment to purchase shares of the
Company’s Class A common stock under the agreement. Upon effectiveness of the registration statement, 963,855 newly issued
shares of Class A common stock, valued at $2.08 per share, were sold to Lincoln Park in an initial purchase for an aggregate gross
purchase price of $2.0 million.
Over the 36-month term of the LPC Purchase Agreement, for up to an aggregate amount of $47,000,000 of shares of Class A
common stock (subject to certain limitations and conditions), the Company has the right, but not the obligation, from time to time, in
its sole discretion, to direct Lincoln Park to purchase up to 250,000 shares per day (the “Regular Purchase Share Limit”) of the Class
A common stock (each such purchase, a “Regular Purchase”). The Regular Purchase Share Limit will increase to 275,000 shares per
day if the closing price of the Class A common stock on the applicable purchase date is not below $4.00 per share and will further
increase to 300,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $5.00
per share. In any case, Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $2,000,000. The
purchase price for shares of Class A common stock to be purchased by Lincoln Park under a Regular Purchase will be equal to the
lower of (in each case, subject to the adjustments described in the LPC Purchase Agreement): (i) the lowest sale price for the Class A
common stock on the applicable purchase date and (ii) the arithmetic average of the three lowest closing sales prices for the Class A
common stock during the 10 consecutive trading days prior to the purchase date.
If the Company directs Lincoln Park to purchase the maximum number of shares of Class A common stock that the Company
may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the LPC
Purchase Agreement, the Company may direct Lincoln Park to make an “accelerated purchase” and an “additional accelerated
purchase”, each of an additional number of shares of Class A common stock which may not exceed the lesser of: (i) 300% of the
number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of the
Common Stock traded during a specified period on the applicable purchase date as set forth in the LPC Purchase Agreement. The
purchase price for such shares will be the lesser of (i) 97% of the volume weighted average price of the Class A common stock over a
certain portion of the date of sale as set forth in the LPC Purchase Agreement and (ii) the closing sale price of the Class A common
Stock on the date of sale (an “Accelerated Purchase”). Under certain circumstances and in accordance with the LPC Purchase
Agreement, the Company may direct Lincoln Park to purchase shares in multiple Accelerated Purchases on the same trading day.
The LPC Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of its Class A
common stock if those shares, when aggregated with all other shares of Class A common stock then beneficially owned by Lincoln
Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more
than 9.99% of the then total outstanding shares of Class A common stock as calculated pursuant to Section 13(d) of the Securities
Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.
Under applicable rules of the Nasdaq Global Select Market, the Company may not issue or sell to Lincoln Park under the LPC
Purchase Agreement more than 19.99% of the shares of the Class A common stock outstanding immediately prior to the execution of
the LPC Purchase Agreement (the “Exchange Cap”) (or 14,768,682 shares, based on 73,880,351 shares outstanding immediately prior
to the execution of the LPC Purchase Agreement), unless (i) stockholder approval is obtained or (ii) the issuances and sales of Class A
common stock pursuant to the LPC Purchase Agreement are not deemed to be “below market” in accordance with the applicable rules
of Nasdaq.
The LPC Purchase Agreement does not limit the Company’s ability to raise capital from other sources at its sole discretion,
except that, subject to certain exceptions, the Company may not enter into another “equity line” or similar transaction.
The LPC Purchase Agreement and Registration Rights Agreement each contain customary representations, warranties, and
agreements of the Company and Lincoln Park, indemnification rights and other obligations of the parties. The offering of Class A
common stock pursuant to the LPC Purchase Agreement will terminate on the date that all shares offered by the LPC Purchase
Agreement have been sold or, if earlier, the expiration or termination of the LPC Purchase Agreement. The Company has the right to
terminate the LPC Purchase Agreement at any time, without fee, penalty or cost to the Company.
The net proceeds under the LPC Purchase Agreement to the Company will depend on the frequency and prices at which shares
of Class A common stock are sold to Lincoln Park. Actual sales of shares of Class A common stock to Lincoln Park under the LPC
Purchase Agreement and the amount of such net proceeds will depend on a variety of factors to be determined by the Company from
time to time, including (among others) market conditions, the trading price of the Class A common stock and determinations by the
Company as to other available and appropriate sources of funding for the Company. Lincoln Park has covenanted not to cause or
engage in any manner whatsoever, any direct or indirect short selling or hedging of Class A common stock.
F-23
Letter Agreement Warrants
The Company has entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the
Company has or had the right to sell to MacAndrews shares of its Class A Common Stock at a specified price per share, and
MacAndrews has or had the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock
at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements,
the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s
Class A Common Stock. Certain terms of each of these Letter Agreements are set forth in Note 14.
The Letter Agreement Warrants were recorded as warrant liability, related party within the Company’s Consolidated Balance
Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a
reduction to additional paid-in capital. During the years ended December 31, 2020, 2019 and 2018 the Company recognized
income/(expense) of $0.3 million, $0.8 million and $(0.6) million, respectively, related to the change in fair value of the Letter
Agreement Warrants. These amounts were recognized as a component of other income (expense), related party in the Consolidated
Statements of Operations.
Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 19
using the following assumptions:
Expected volatility .........
Expected life of option, in
years ...............................
Risk-free interest rate ......
Expected dividend
yield ...............................
December 5,
2017
90.00%
July 30, 2018
December 11,
2018
September 26,
2019
December 23,
2019
95.29%
104.46%
110.35%
110.41%
7.0
2.80%
7.0
2.94%
7.0
2.77%
7.0
1.65%
7.0
1.84%
0.00%
0.00%
0.00%
0.00%
0.00%
Loan Agreement Warrants
On October 28, 2016, the Company entered into the Loan Agreement as discussed in Note 10. In connection with the Loan
Agreement, the Company issued to the Lenders Warrants to purchase a total of 152,580 shares of the Company’s Class A Common
Stock at an exercise price of $6.39 per share. Additionally, upon funding of the second tranche on March 24, 2017, the Company
issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which
aggregate exercise price represents 3.0% of the amount available under the second tranche of the Loan Agreement. The Warrants
will expire seven years from their date of issuance.
Note 13: Redeemable Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 29.9%
noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units
and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market
value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing
member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The
exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the
Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses
associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2020 and 2019,
the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $83.9 million and
$40.2 million, respectively.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are
accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The
following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
F-24
Net loss attributable to vTv Therapeutics Inc.
common shareholders ....................................................... $
Increase in vTv Therapeutics Inc. accumulated
deficit for purchase of LLC Units as a result
of common stock issuances ...............................................
Change from net loss attributable to
vTv Therapeutics Inc. common shareholders
and transfers to noncontrolling interest ....................... $
2020
December 31,
2019
2018
(8,499) $
(17,913 ) $
(8,650)
(8,943)
(17,971 )
(19,456)
(17,442) $
(35,884 ) $
(28,106)
Note 14: Related-Party Transactions
MacAndrews & Forbes Incorporated
MacAndrews directly or indirectly controls 23,084,267 shares of Class B Common Stock. Further, as of December 31, 2020,
MacAndrews directly or indirectly holds 36,606,212 shares of the Company’s Class A Common Stock. As a result, MacAndrews’
holdings represent approximately 77.4% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
Letter Agreements
The Company has entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the
Company has the right to sell to MacAndrews shares of its Class A Common Stock at a specified price per share, and MacAndrews
has the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock at the same price. In
addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also
issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A Common
Stock.
Certain terms of these Letter Agreements are set forth in the tables below:
December 5, 2017 Letter
Agreement
July 30, 2018 Letter
Agreement
December 11, 2018 Letter
Agreement
Aggregate dollar value to be
sold under agreement ................
Specified purchase price
per share .................................... $
Expiration date of letter
agreement ..................................
Shares available to be issued
under related warrants ...............
Exercise price of related
warrants ..................................... $
Expiration date of related
warrants .....................................
Total shares issued as of
December 31, 2020 ...................
Remaining shares to be issued
as of December 31, 2020 ...........
$10.0 million
$10.0 million
$10.0 million
4.38 $
1.33 $
1.84
December 5, 2018
July 30, 2019
December 11, 2019
198,267
518,654
5.04 $
1.53 $
340,534
2.12
December 5, 2024
July 30, 2025
December 11, 2025
2,283,105
7,518,797
5,434,783
—
—
—
F-25
Aggregate dollar value to be
sold under agreement ...............
Specified purchase price
per share ................................... $
Expiration date of letter
agreement .................................
Shares available to be issued
under related warrants ..............
Exercise price of related
warrants .................................... $
Expiration date of related
warrants ....................................
Total shares issued as of
December 31, 2020 ..................
Remaining shares to be issued
as of December 31, 2020 ..........
March 18, 2019 Letter
Agreement
September 26, 2019 Letter
Agreement
December 23, 2019 Letter
Agreement
$9.0 million
$10.0 million
$10.0 million
1.65 $
1.46 $
1.60
March 18, 2020
September 26, 2020
December 23, 2020
—
— $
400,990
1.68 $
365,472
1.84
September 26, 2026
December 23, 2026
5,454,546
6,849,316
6,250,000
—
—
—
Each of the December 5, 2017 and July 30, 2018 Letter Agreements resulted in a deemed capital contribution to the Company as
the fair value of the financial instrument received by the Company exceeded the fair value of those financial instruments issued to
MacAndrews. The December 11, 2018, March 18, 2019, September 26, 2019 and December 23, 2019 Letter Agreements resulted in a
deemed distribution to MacAndrews as the fair value of the financial instruments issued to MacAndrews exceeded the fair value of the
financial instrument received by the Company. This deemed distribution has been reflected as a reduction to the net loss attributable
to common shareholders of vTv Therapeutics Inc. for computing net loss per share.
Exchange Agreement
Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv
Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for
(i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A
Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv
Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any
decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire
Board of Directors. As of December 31, 2020, MacAndrews has not exchanged any shares under the provisions of this agreement.
Tax Receivable Agreement
The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv
Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its
transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax
that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of
Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock
(or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable
Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been
exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor
has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2020.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the
“Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration
rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the
size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a
majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.
F-26
Note 15: Employee Benefit Plan
The Company has a 401(k) retirement plan in which all of its full-time employees are eligible to participate. The plan provides
for the Company to make discretionary 50% matching contributions up to a maximum of 6% of employees’ eligible compensation.
The Company contributed $0.1 million, $0.1 million and $0.2 million to the plan for the years ended December 31, 2020, 2019 and
2018, respectively.
Note 16: Income Taxes
From August 1, 2015, vTv Therapeutics Inc. has been subject to U.S. federal income taxes as well as state taxes. The Company
did not record an income tax provision for the year ended December 31, 2020. The Company recorded an income tax provision
of $0.1 million and $0.2 million for the years ended December 31, 2019 and 2018, respectively, representing foreign withholding
taxes incurred in connection with payments received under license agreements with foreign entities.
As discussed in Note 14, the Company is party to a tax receivable agreement with a related party which provides for the
payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in
U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is
deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this
agreement, the Company has not recognized any liability related to this agreement as of December 31, 2020.
In December 2019, the FASB issued ASU 2019-12, which intended to simplify various aspects related to accounting for income
taxes. ASU 2019-12 removes certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance
to improve consistent application of ASC 740. This guidance is effective for fiscal years beginning after December 15, 2020,
including interim periods therein, and early adoption is permitted. Adoption of ASU 2019-12 in 2021 is not expected to have a
material effect on the Company’s consolidated financial statements.
On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was enacted in response to
COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new
legislation is enacted. The CARES Act made various tax law changes including among other things (i) increased the limitation under
IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacted a technical correction so that qualified
improvement property can be immediately expensed under IRC Section 168(k), (iii) made modifications to the federal net operating
loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding
taxable years in order to generate a refund of previously paid income taxes, and (iv) enhanced recoverability of AMT tax credits.
Given the Company’s full valuation allowance position, the CARES Act did not have a material impact on the financial statements.
A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):
December 31,
2020
2019
2018
U.S. statutory tax benefit ............................................... $ (2,688) $ (4,586 ) $ (4,966 )
Partnership income (federal) not subject to tax to the
Company........................................................................
Foreign withholding tax .................................................
State taxes (net of federal benefit) .................................
Research and development tax credit ............................
Other ..............................................................................
Change in valuation allowance ......................................
Provision for income taxes ....................................... $
Effective income tax rate ...............................................
1,868
79
134
(231 )
(81 )
2,917
100 $
-0.5 %
904
—
(13)
(138)
75
1,860
— $
0.0%
3,346
200
(224 )
(1,122 )
(168 )
3,134
200
-0.8 %
F-27
Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):
December 31,
2020
2019
Deferred tax assets:
Net operating loss carryforwards ................................................ $
R&D Tax Credit carryforwards ..................................................
Investment in partnerships ..........................................................
Charitable contributions ..............................................................
Total deferred tax assets ...........................................................
Valuation allowance ......................................................................
Net deferred tax assets ................................................................... $
17,338 $
1,587
(1,520 )
12
17,417
(17,417 )
— $
14,540
1,517
(511 )
11
15,557
(15,557 )
—
The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable
income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated
was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as
forecasts of profitability. Based on the weight of objective evidence, including cumulative pre-tax losses in recent years, the Company
concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance.
During the year ended December 31, 2020, the Company’s valuation allowance increased by $1.9 million.
The Company has federal net operating loss carryforwards of $79.1 million that will be available to offset future taxable
income. Approximately, $40.0 million of these carryforwards expire in varying amounts starting in 2035 to 2037, if not utilized and
are available to offset 100% of future taxable income. The remaining $39.1 million may be carried forward indefinitely but are only
available to offset 80% of future taxable income. The Company has federal research and development tax credits of $1.6 million
which expire in varying amounts starting in 2035 to 2040.
The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a
company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the
Company has taken or expects to take on a tax return. As of December 31, 2020, the Company had no uncertain tax positions. There
are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly
increase or decrease within twelve months of December 31, 2020.
The Company files U.S. federal, New York, North Carolina and Virginia tax returns. The earliest open tax years that are still
subject to examination by the IRS and the aforementioned state tax authorities are 2016 to 2019.
Note 17: Restructuring
In December 2018, the Company initiated a corporate restructuring to align with a strategic decision to continue the
development of its drug candidates using external resources rather than internal resources. The restructuring allowed the Company to
reduce costs while continuing to conduct clinical trials, to support existing partnerships that are advancing development of additional
assets, and to pursue new licensing and partnership opportunities. This restructuring included a significant reduction in its workforce.
The Company completed these restructuring activities in the second quarter of 2019.
As of and during the year ended December 31, 2018, the Company had recognized an accrual and related expense of $0.3
million related to these severance benefits. During the year ended December 31, 2019, the Company made cash payments of $0.3
million related to these severance benefits and recognized an immaterial amount of expense related to this plan. The related expense
has been recognized as a component of research and development and general and administrative expense within the Consolidated
Statements of Operations based on the responsibilities of the impacted employees. There were no accruals recorded for these actions
within the Consolidated Balance Sheet as of December 31, 2020 or 2019.
Note 18: Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of
shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially
dilutive shares. Diluted loss per share for the years ended December 31, 2020, 2019 and 2018 is the same as basic loss per share as the
inclusion of potentially issuable shares would be antidilutive.
F-28
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A
Common Stock is as follows (amounts in thousands, except per share amounts):
Numerator:
Net loss ........................................................................................... $
Less: Net loss attributable to noncontrolling interests .................
Net loss attributable to vTv Therapeutics Inc. ................................
Less: Deemed distribution to related party (Note 13) ..................
Net loss attributable to common shareholders of vTv Therapeutics
Inc.,
basic and diluted .......................................................................... $
Denominator:
2020
Year Ended December 31,
2019
2018
(12,802) $
(4,303)
(8,499)
—
(21,938 ) $
(8,894 )
(13,044 )
(4,869 )
(23,845)
(15,934)
(7,911)
(739)
(8,499) $
(17,913 ) $
(8,650)
Weighted-average vTv Therapeutics Inc. Class A Common
Stock, basic and diluted ...............................................................
Net loss per share of vTv Therapeutics Inc. Class A
Common Stock, basic and diluted ............................................... $
47,137,917
30,292,030 12,449,236
(0.18) $
(0.59 ) $
(0.69)
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
2020
Year Ended December 31,
2019
2018
Class B Common Stock (1) ................................................................... 23,094,221 23,094,221 23,094,221
1,767,503
Common stock options granted under the Plan ....................................
23,333
Restricted stock units ...........................................................................
4,619,566
Common stock options granted under the Letter Agreement ...............
1,248,041
Common stock warrants .......................................................................
Total ................................................................................................ 29,562,081 33,901,534 30,752,664
2,531,143
11,667
6,250,000
2,014,503
4,453,357
—
—
2,014,503
(1) Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly,
separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each
share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A
Common Stock.
Note 19: Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts
receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.
The fair value of the Company’s Loan Agreement was considered to approximate its carrying value because it bore interest at a
variable interest rate.
The Company measures the value of its investments in Reneo and Anteris at cost minus impairment, if any, plus or minus
changes resulting from observable price changes in orderly transactions for the identical or similar investment. Since acquiring the
Reneo and Anteris investments, there have been no observable price changes in identical or similar investments, nor were there any
indications of impairment. As such, the value of the Company’s investments in Reneo and Anteris has not been remeasured.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine
the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The
F-29
following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2020, 2019 and 2018 (in
thousands):
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Balance at
December 31,
2020
Warrant liability, related party (1) ..................................... $
Total .......................................................................... $
2,871 $
2,871 $
— $
— $
— $
— $
2,871
2,871
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Balance at
December 31,
2019
Warrant liability, related party (1) ..................................... $
Total .......................................................................... $
2,601 $
2,601 $
— $
— $
— $
— $
2,601
2,601
(1) Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected
stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 Instruments for the years ended December 31, 2020, 2019 and
2018
Net Change in
fair value
included in
earnings
Balance at
January 1
Purchases /
Issuance
Sales /
Repurchases
Balance at
December 31,
2020
Warrant liability, related party ........................................ $
Total .......................................................................... $
2,601 $
2,601 $
270 $
270 $
— $
— $
— $
— $
2,871
2,871
2019
Warrant liability, related party ........................................
Total .......................................................................... $
2,436
2,436 $
(827)
(827) $
992
992 $
—
— $
2,601
2,601
2018
Warrant liability, related party ........................................
Total .......................................................................... $
492
492 $
638
638 $
1,306
1,306 $
—
— $
2,436
2,436
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the years ended
December 31, 2020, 2019 and 2018. Gains and losses recognized due to the change in fair value of the warrant liability, related party
are recognized as a component of other (expense) income, related party in the Consolidated Statements of Operations
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing
models based on the Company’s current capitalization. Expected volatility is based on a portfolio of selected stocks of companies
believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve
in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants were:
December 31, 2020
December 31, 2019
Expected volatility ......................... 120.53% - 142.07%
Risk-free interest rate .....................
0.26% - 0.50%
Range
Weighted Average
128.16%
0.39%
Range
110.76% - 123.83%
1.69% - 1.83%
Weighted Average
115.20%
1.74%
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
F-30
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants.
For the Company’s warrants, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the
liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.
Note 20: Subsequent Events
On January 14, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of
the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent
or principal, shares of the Company’s Class A Common Stock, by an aggregate offering price of $5.5 million. No shares of Class A
Common Stock have been sold under the ATM Offering subsequent to December 31, 2020.
Subsequent to December 31, 2020, the Company exercised its right under the LPC Purchase Agreement to cause Lincoln Park
to purchase 3.5 million shares of its Class A Common Stock for total gross proceeds of $8.0 million.
On January 14, 2021, the Company entered into the First Huadong Amendment which eliminates the Company’s obligation to
sponsor the Phase 2 MRCT and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also
reduced the total potential development and regulatory milestone payments by $3.0 million.
F-31
vTv Therapeutics Inc.
Corporate Subsidiaries as of February 24, 2021
Exhibit 21.1
Subsidiary
vTv Therapeutics LLC
Jurisdiction of Incorporation
Delaware
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-206335) pertaining to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive
Plan;
Exhibit 23.1
(2) Registration Statement (Form S-3 No. 333-223269) of vTv Therapeutics Inc.;
(3) Registration Statement (Form S-3 No. 333-232571) of vTv Therapeutics Inc.;
(4) Registration Statement (Form S-8 No. 333-240304) of vTv Therapeutics Inc.; and
(5) Registration Statement (Form S-1 No. 333-250934) of vTv Therapeutics Inc.
of our report dated February 20, 2020 with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this
Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Raleigh, North Carolina
February 24, 2021
I, Stephen L. Holcombe, certify that:
SECTION 302 CERTIFICATION
EXHIBIT 31.1
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of vTv Therapeutics Inc. (the “registrant”);
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report
is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: February 24, 2021
By: /s/ Stephen L. Holcombe
Stephen L. Holcombe
President and Chief Executive Officer
I, Rudy C. Howard, certify that:
SECTION 302 CERTIFICATION
EXHIBIT 31.2
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of vTv Therapeutics Inc. (the “registrant”);
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report
is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: February 24, 2021
By: /s/ Rudy C. Howard
Rudy C. Howard
Chief Financial Officer
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
EXHIBIT 32.1
In connection with the Annual Report of vTv Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December
31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen L. Holcombe, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an
officer of the Company that, to my knowledge:
1.
2.
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act
of 1934; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: February 24, 2021
By: /s/ Stephen L. Holcombe
Stephen L. Holcombe
President and Chief Executive Officer
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
EXHIBIT 32.2
In connection with the Annual Report of vTv Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December
31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rudy C. Howard, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an
officer of the Company that, to my knowledge:
1.
2.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: February 24, 2021
By: /s/ Rudy C. Howard
Rudy C. Howard
Chief Financial Officer